<?xml version="1.0" encoding="utf-8"?>
<addis-data xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://drugis.org/files/addis-3.xsd">
   <indications>
      <indication name="Type II diabetes mellitus " code="190392008"/>
   </indications>
   <endpoints>
      <endpoint description="" name="2-h PPG change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="mmol/l"/>
      </endpoint>
      <endpoint description="" name="2-h PPG end" direction="LOWER_IS_BETTER">
         <continuous unitOfMeasurement="mmol/l"/>
      </endpoint>
      <endpoint description="" name="B-cell function index end" direction="LOWER_IS_BETTER">
         <continuous unitOfMeasurement="pmol/min per m2 per mmol/l"/>
      </endpoint>
      <endpoint description="" name="C-peptide change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="nmol/l"/>
      </endpoint>
      <endpoint description="" name="C-peptide end" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="nmol/l"/>
      </endpoint>
      <endpoint description="" name="FPG change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="mmol/l"/>
      </endpoint>
      <endpoint description="" name="FPG end" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="mmol/l"/>
      </endpoint>
      <endpoint description="" name="FSG change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="mmol/L"/>
      </endpoint>
      <endpoint description="" name="Fasting proinsulin level change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="pmol/l"/>
      </endpoint>
      <endpoint description="" name="HOMA-B change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement=""/>
      </endpoint>
      <endpoint description="" name="HOMA-B end" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement=""/>
      </endpoint>
      <endpoint description="" name="HOMA-IR change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement=""/>
      </endpoint>
      <endpoint description="" name="HOMA-IR end" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement=""/>
      </endpoint>
      <endpoint description="" name="HbA1c change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="%"/>
      </endpoint>
      <endpoint description="" name="HbA1c end" direction="LOWER_IS_BETTER">
         <continuous unitOfMeasurement="%"/>
      </endpoint>
      <endpoint description="" name="M-value change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement=""/>
      </endpoint>
      <endpoint description="" name="MDG change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="mg/dl"/>
      </endpoint>
      <endpoint description="" name="MDG end" direction="LOWER_IS_BETTER">
         <continuous unitOfMeasurement="mg/dl"/>
      </endpoint>
      <endpoint description="" name="Proinsulin-to-insulin ratio change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement=""/>
      </endpoint>
      <endpoint description="" name="Proinsulin-to-insulin ratio end" direction="LOWER_IS_BETTER">
         <continuous unitOfMeasurement=""/>
      </endpoint>
      <endpoint description="" name="QUICKI change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement=""/>
      </endpoint>
      <endpoint description="" name="QUICKI end" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement=""/>
      </endpoint>
      <endpoint description="" name="daily mean glucose change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="mmol/L"/>
      </endpoint>
      <endpoint description="" name="fasting proinsuline end" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="pmol/l"/>
      </endpoint>
      <endpoint description="" name="fasting serum insulin change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="uIU/ml"/>
      </endpoint>
      <endpoint description="" name="fasting serum insuline end" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="uIU/ml"/>
      </endpoint>
      <endpoint description="" name="insulin change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="pmol/l"/>
      </endpoint>
      <endpoint description="" name="insulin end" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="pmol/l"/>
      </endpoint>
      <endpoint description="" name="weight change" direction="HIGHER_IS_BETTER">
         <continuous unitOfMeasurement="kg"/>
      </endpoint>
      <endpoint description="" name="weight end" direction="LOWER_IS_BETTER">
         <continuous unitOfMeasurement="kg"/>
      </endpoint>
   </endpoints>
   <adverseEvents>
      <adverseEvent description="" name="Abdominal pain" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Angina pectoris" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Anorexia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Arthralgia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Asthenia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Back pain" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Blood CPK increased" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Blood CPK-MB increased" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Blood glucose increase" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Blood glucose increased" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Bronchitis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Bursitis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Cervicobrachial syndrome" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Clinical SAE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Constipation" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Cough" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Depression" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Diabetic neuropathy" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Diarrhea" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Discontinuation due to AE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Discontinuation due to SAE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Discontinuation due to drug-related AE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Discontinuation due to drug-related SAE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Dizziness" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Drug-related clinical AE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Drug-related clinical SAE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Dyspepsia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Eczema" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Edema" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Fatigue" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Feeling jittery" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Gastritis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Gastroenteritis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Gastrointestinal disorders" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Headache" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Hemoglobin decreased" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Hyperglycaemia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Hyperhidrosis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Hyperlipidemia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Hypertension" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Hypoglycemia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Influenza" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Insomnia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Joint sprain" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Musculoskeletal pain" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Nasopharyngitis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Nausea" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Neck pain" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Number of hypeoglycemic episodes" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Oedema peripheral" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="One or more clinical AE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Osteoarthritis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Overall gastrointestinal AE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Pain" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Pain in extremity" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Paraesthesia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Pharyngitis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Pharyngotonsillitis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Pruritus " direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Pyrexia" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Respiratory tract infection" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="SAE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Sciatica" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Seasonal allergy" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Sinusitis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Sweating increase" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Tinea pedis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Tremor" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Upper respiratory tract infection" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Upper respiratory tract inflammation" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Urinary tract infection" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Urine bacteria increased" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Vomiting" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Weakness" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Who died" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="Worsening hypertension" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="cough" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="diastolic blood pressure" direction="LOWER_IS_BETTER">
         <continuous unitOfMeasurement="mmHg"/>
      </adverseEvent>
      <adverseEvent description="" name="gastroenteritis" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="nervous system disorders" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="one or more AE" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="periphera oedema" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="r-Glutamyl transferase increased" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
      <adverseEvent description="" name="weight increase" direction="LOWER_IS_BETTER">
         <rate/>
      </adverseEvent>
   </adverseEvents>
   <drugs>
      <drug atcCode="A10BB07" name="Glipizide"/>
      <drug atcCode="A10AE04" name="Insulin glargine"/>
      <drug atcCode="A10BH01" name="Sitagliptin"/>
      <drug atcCode="A10BX04" name="exenatide"/>
      <drug atcCode="A10BB12" name="glimepiride"/>
      <drug atcCode="A10BX07" name="liraglutide"/>
      <drug atcCode="A10BA02" name="metformin"/>
      <drug atcCode="A10BG03" name="pioglitazone"/>
      <drug atcCode="" name="placebo"/>
      <drug atcCode="A10BG02" name="rosiglitazone"/>
      <drug atcCode="A10BH02" name="vildagliptin"/>
   </drugs>
   <populationCharacteristics>
      <populationCharacteristic description="2-h PPG at baseline" name="2-h PPG bas">
         <continuous unitOfMeasurement="mmol/l"/>
      </populationCharacteristic>
      <populationCharacteristic description="Age in years" name="Age">
         <continuous unitOfMeasurement="Years"/>
      </populationCharacteristic>
      <populationCharacteristic description="B-cell function index at baseline" name="B-cell function index bas">
         <continuous unitOfMeasurement="pmol/min per m2 per mmol/l"/>
      </populationCharacteristic>
      <populationCharacteristic description="body mass index" name="BMI">
         <continuous unitOfMeasurement="kg/m2"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="C-peptide">
         <continuous unitOfMeasurement="mmol/l"/>
      </populationCharacteristic>
      <populationCharacteristic description="Duration of diabetes" name="Duration of diabetes">
         <continuous unitOfMeasurement="years"/>
      </populationCharacteristic>
      <populationCharacteristic description="Duration of previous MET treatment" name="Duration of previous MET treatment">
         <continuous unitOfMeasurement="months"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="Duration of sulphonylurea">
         <continuous unitOfMeasurement="month"/>
      </populationCharacteristic>
      <populationCharacteristic description="FPG at baseline" name="FPG bas">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description="fasting plasma insulin at baseline" name="FPI bas">
         <continuous unitOfMeasurement="pmol/l"/>
      </populationCharacteristic>
      <populationCharacteristic description="fasting plasma proinsulin at baseline" name="FPP bas">
         <continuous unitOfMeasurement="pmol/l"/>
      </populationCharacteristic>
      <populationCharacteristic description="fasting serum glusoce at baseline" name="FSG bas">
         <continuous unitOfMeasurement="mmol/L"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="Fructosamine">
         <continuous unitOfMeasurement="mmol/l"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="Glucagon">
         <continuous unitOfMeasurement="mmol/l"/>
      </populationCharacteristic>
      <populationCharacteristic description="HOMA-B at baseline" name="HOMA-B bas">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description="HbA1c at baseline" name="HbA1c bas">
         <continuous unitOfMeasurement="%"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="Height">
         <continuous unitOfMeasurement="cm"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="Insulin">
         <continuous unitOfMeasurement="mmol/l"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="M-value bas">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description="Metformin daose at the baseline" name="Metformin dose bas">
         <continuous unitOfMeasurement="mg/day"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="Nationality">
         <categorical>
            <category>Chinese</category>
            <category>Indian</category>
            <category>Korean</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description="Proinsulin-to-insulin ratio at baseline" name="Proinsulin-to-insulin ratio bas">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="Sex">
         <categorical>
            <category>male</category>
            <category>female</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="Treated with MET and SU">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="antihypertensive agent">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description="baseline mean weight" name="baseline mean weight">
         <continuous unitOfMeasurement="kg"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="country">
         <categorical>
            <category>china</category>
            <category>india</category>
            <category>korea</category>
            <category>taiwan</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="daily mean glucose at baseline">
         <continuous unitOfMeasurement="mmol/L"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="daily mean glucose bas">
         <continuous unitOfMeasurement="mmol/L"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="diagstolic blood pressure bas">
         <continuous unitOfMeasurement="mmHg"/>
      </populationCharacteristic>
      <populationCharacteristic description="discontinued" name="discontinued">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="duration of TZD use">
         <continuous unitOfMeasurement="months"/>
      </populationCharacteristic>
      <populationCharacteristic description="hypertension" name="hypertension">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="on maximum TZD before study">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description="yes" name="prior use of OHAa">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description="race" name="race">
         <categorical>
            <category>caucasian</category>
            <category>hispanic or latino</category>
            <category>black</category>
            <category>other</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="race1">
         <categorical>
            <category>caucasian</category>
            <category>black</category>
            <category>asian</category>
            <category>native american</category>
            <category>hispanic</category>
            <category>other</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="race2">
         <categorical>
            <category>caucasian</category>
            <category>black</category>
            <category>asian</category>
            <category>hispanic or latino</category>
            <category>pacific islander</category>
            <category>other</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="race3">
         <categorical>
            <category>asian</category>
            <category>black</category>
            <category>hispanic</category>
            <category>white</category>
            <category>other</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="race4">
         <categorical>
            <category>white</category>
            <category>hispanic</category>
            <category>black</category>
            <category>other</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="race5">
         <categorical>
            <category>caucasian</category>
            <category>hispanic or latino</category>
            <category>asian (indian subcontinent)</category>
            <category>asian (non-indian subcontinent)</category>
            <category>black</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="race6">
         <categorical>
            <category>white</category>
            <category>hispanic</category>
            <category>black</category>
            <category>multiracial</category>
            <category>other</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="race7">
         <categorical>
            <category>caucasian</category>
            <category>other</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="race8">
         <categorical>
            <category>asian</category>
            <category>black</category>
            <category>multiracial</category>
            <category>white</category>
            <category>other</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="race9">
         <categorical>
            <category>white</category>
            <category>other</category>
         </categorical>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="serum fructosamine bas">
         <continuous unitOfMeasurement="(umol/l"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="systolic blood pressure">
         <continuous unitOfMeasurement="mmHg"/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="treated with MET">
         <continuous unitOfMeasurement=""/>
      </populationCharacteristic>
      <populationCharacteristic description=" " name="use of anti-hyperglycemic medication at screening">
         <categorical>
            <category>combination therapy</category>
            <category>monotherapy</category>
            <category>absence of therapy</category>
         </categorical>
      </populationCharacteristic>
   </populationCharacteristics>
   <studies>
      <study name="ahren04">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 (vildagliptin) versus placebo in patients with type 2 diabetes continuing metformin treatment.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Male or infertile female patients aged &gt;30 years diagnosed with type 2 diabetes at least 6 months before enrollment and treated with a stable dosage of metformin for &gt;3 months were included.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had a history of type 1 or secondary forms of diabetes, significant diabetes complications, clinically significant cardiovascular abnormalities, liver disease, acromegaly, asthma, major skin allergies, or major gastrointestinal surgery. Patients with fasting triglyceride levels &gt;5.1 mmol/l or fasting plasma glucose (FPG) &lt;6.1 or &gt;13.3 mmol/l were excluded, as were those treated with any drugs considered possibly able to affect results or their interpretation.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>15562200</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-15</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-cough">
               <adverseEvent name="cough"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Worsening hypertension">
               <adverseEvent name="Worsening hypertension"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Urinary tract infection">
               <adverseEvent name="Urinary tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastroenteritis">
               <adverseEvent name="Gastroenteritis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Bursitis">
               <adverseEvent name="Bursitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of previous MET treatment">
               <populationCharacteristic name="Duration of previous MET treatment"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-hypertension">
               <populationCharacteristic name="hypertension"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-discontinued">
               <populationCharacteristic name="discontinued"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="56" name="Vildagliptin">
               <notes/>
            </arm>
            <arm size="51" name="Placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Vildagliptin"/>
               <continuousMeasurement stdDev="0.3" sampleSize="50" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.3" sampleSize="47" mean="0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Vildagliptin"/>
               <continuousMeasurement stdDev="0.1" sampleSize="50" mean="-0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.1" sampleSize="47" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-cough"/>
               <arm name="Vildagliptin"/>
               <rateMeasurement sampleSize="56" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-cough"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="51" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Vildagliptin"/>
               <rateMeasurement sampleSize="56" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="51" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Worsening hypertension"/>
               <arm name="Vildagliptin"/>
               <rateMeasurement sampleSize="56" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Worsening hypertension"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="51" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Urinary tract infection"/>
               <arm name="Vildagliptin"/>
               <rateMeasurement sampleSize="56" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Urinary tract infection"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="51" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastroenteritis"/>
               <arm name="Vildagliptin"/>
               <rateMeasurement sampleSize="56" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastroenteritis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="51" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bursitis"/>
               <arm name="Vildagliptin"/>
               <rateMeasurement sampleSize="56" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bursitis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="51" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Vildagliptin"/>
               <rateMeasurement sampleSize="56" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Vildagliptin"/>
               <continuousMeasurement stdDev="3.6" sampleSize="56" mean="29.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="3.6" sampleSize="51" mean="30.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Vildagliptin"/>
               <continuousMeasurement stdDev="10.0" sampleSize="56" mean="57.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="11.0" sampleSize="51" mean="55.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Vildagliptin"/>
               <continuousMeasurement stdDev="4.2" sampleSize="56" mean="5.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="3.7" sampleSize="51" mean="5.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of previous MET treatment"/>
               <arm name="Vildagliptin"/>
               <continuousMeasurement stdDev="25.6" sampleSize="56" mean="28.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of previous MET treatment"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="36.1" sampleSize="51" mean="29.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-hypertension"/>
               <arm name="Vildagliptin"/>
               <rateMeasurement sampleSize="56" rate="28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-hypertension"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="51" rate="27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-discontinued"/>
               <arm name="Vildagliptin"/>
               <rateMeasurement sampleSize="56" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-discontinued"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="51" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Vildagliptin"/>
               <continuousMeasurement stdDev="2.0" sampleSize="56" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.0" sampleSize="51" mean="10.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Vildagliptin"/>
               <continuousMeasurement stdDev="0.6" sampleSize="56" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.7" sampleSize="51" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Vildagliptin"/>
               <categoricalMeasurement>
                  <category rate="17" name="female"/>
                  <category rate="39" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="17" name="female"/>
                  <category rate="34" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Run-in">
               <duration>P28D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P84D</duration>
               <notes/>
            </epoch>
            <epoch name="Extension">
               <duration>P280D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <usedBy arm="Vildagliptin" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Run-in"/>
               <usedBy arm="Vildagliptin" epoch="Run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Follow up">
               <activity>
                  <predefined>FOLLOW_UP</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Extension"/>
               <usedBy arm="Vildagliptin" epoch="Extension"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo +metformin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                     <drugTreatment>
                        <flexibleDose unit="MILLIGRAMS_A_DAY" maxDose="3000.0" minDose="1500.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin+metformin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <flexibleDose unit="MILLIGRAMS_A_DAY" maxDose="3000.0" minDose="1500.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Vildagliptin" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="aschner06">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To examine the efficacy and safety of once-daily oral sitagliptin as monotherapy in patients with type 2 diabetes.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients, 18-75 years of age, on and not on an OHA were eligible</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients with type 1 diabetes, unstable cardiac disease, significant renal impairment (creatinine clearance &lt;50 ml/min), or elevated (more than twofold the upper limit of normal) alanine aminotransferase, aspartate aminotransferase, or creatine phosphokinase were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17130196</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-17</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-Proinsulin-to-insulin ratio end">
               <endpoint name="Proinsulin-to-insulin ratio end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B end">
               <endpoint name="HOMA-B end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Clinical SAE">
               <adverseEvent name="Clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related SAE">
               <adverseEvent name="Discontinuation due to drug-related SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Overall gastrointestinal AE">
               <adverseEvent name="Overall gastrointestinal AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Proinsulin-to-insulin ratio bas">
               <populationCharacteristic name="Proinsulin-to-insulin ratio bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HOMA-B bas">
               <populationCharacteristic name="HOMA-B bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="253" name="Placebo">
               <notes/>
            </arm>
            <arm size="238" name="Sitagliptin low-dose">
               <notes/>
            </arm>
            <arm size="250" name="Sitagliptin high-dose">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="3.1" sampleSize="247" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="2.5" sampleSize="234" mean="8.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="2.6" sampleSize="244" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Proinsulin-to-insulin ratio end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.28" sampleSize="220" mean="0.44"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Proinsulin-to-insulin ratio end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.25" sampleSize="210" mean="0.37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Proinsulin-to-insulin ratio end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.22" sampleSize="217" mean="0.34"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="61.5" sampleSize="235" mean="56.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="91.8" sampleSize="218" mean="70.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="66.3" sampleSize="228" mean="68.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="3.18" sampleSize="253" mean="-1.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="3.09" sampleSize="238" mean="-0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="3.16" sampleSize="250" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.37" sampleSize="244" mean="8.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="1.15" sampleSize="229" mean="7.39"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="1.14" sampleSize="238" mean="7.31"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="167"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="250" rate="157"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="160"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="238" rate="23"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Clinical SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Clinical SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="238" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Clinical SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="250" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="250" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="238" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="250" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="238" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="250" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Overall gastrointestinal AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="29"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Overall gastrointestinal AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="238" rate="39"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Overall gastrointestinal AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="250" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="250" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="250" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="253" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="238" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="250" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="250" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Proinsulin-to-insulin ratio bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.3" sampleSize="220" mean="0.44"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Proinsulin-to-insulin ratio bas"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.82" sampleSize="210" mean="0.47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Proinsulin-to-insulin ratio bas"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.48" sampleSize="217" mean="0.44"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HOMA-B bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="52.1" sampleSize="235" mean="55.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HOMA-B bas"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="71.7" sampleSize="218" mean="57.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HOMA-B bas"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="53.4" sampleSize="228" mean="55.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.3" sampleSize="247" mean="9.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="234" mean="9.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="2.5" sampleSize="244" mean="9.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="18.1" sampleSize="253" mean="85.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="18.0" sampleSize="250" mean="85.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="19.2" sampleSize="250" mean="83.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.82" sampleSize="244" mean="8.03"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.88" sampleSize="229" mean="8.01"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.94" sampleSize="238" mean="8.08"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <usedBy arm="Sitagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="Sitagliptin low-dose" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Screening"/>
               <usedBy arm="Sitagliptin high-dose" epoch="Screening"/>
               <usedBy arm="Sitagliptin low-dose" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin high-dose" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin low-dose" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="200.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="bosi07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>109</value>
               <notes/>
            </centers>
            <objective>
               <value>We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>The study enrolled patients with type 2 diabetes who had been treated with metformin monotherapy for at least 3 months and who had been on a stable dose of &gt;= 1,500 mg daily for a minimum of 4 weeks before visit 1. Participants were required to have A1C in the range of 7.5–11.0% at the screening visit, and, if they were not at that time receiving their maximum-tolerated dose, they agreed to increase their metformin dose to 2,000 mg daily at visit 1. Male and female patients (nonfertile or of childbearing potential using a medically approved birth control method) aged 18–78 years, inclusive, with a BMI in the range of 22–45 kg/m2, inclusive, and with FPG �15
mmol/l were eligible to participate.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had a history of type 1 or secondary forms of diabetes, acute metabolic diabetes complications within the past 6 months, congestive heart failure requiring pharmacologic treatment, myocardial infarction, unstable angina, or coronary artery bypass surgery within the previous 6 months. Liver disease such as cirrhosis or chronic active hepatitis also precluded participation, as did renal disease or renal dysfunction as suggested by elevated serum creatinine levels &gt;= 132 umol/l for male and &gt;= 123 umol/l for female subjects.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17277036</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-17</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-2-h PPG end">
               <endpoint name="2-h PPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-B-cell function index end">
               <endpoint name="B-cell function index end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-diastolic blood pressure">
               <adverseEvent name="diastolic blood pressure"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race">
               <populationCharacteristic name="race"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of previous MET treatment">
               <populationCharacteristic name="Duration of previous MET treatment"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Metformin dose bas">
               <populationCharacteristic name="Metformin dose bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-2-h PPG bas">
               <populationCharacteristic name="2-h PPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-B-cell function index bas">
               <populationCharacteristic name="B-cell function index bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="177" name="Vildagliptin low-dose">
               <notes/>
            </arm>
            <arm size="185" name="Vildagliptin high-dose">
               <notes/>
            </arm>
            <arm size="182" name="Placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="1.33" sampleSize="143" mean="-0.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="1.36" sampleSize="143" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.35" sampleSize="130" mean="0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="3.99" sampleSize="143" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="4.08" sampleSize="143" mean="-1.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.7" sampleSize="130" mean="0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG end"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="7.98" sampleSize="143" mean="-1.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG end"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="8.16" sampleSize="143" mean="-2.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-B-cell function index end"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="15.96" sampleSize="143" mean="5.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-B-cell function index end"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="16.3" sampleSize="143" mean="5.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Vildagliptin low-dose"/>
               <rateMeasurement sampleSize="143" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Vildagliptin high-dose"/>
               <rateMeasurement sampleSize="143" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="130" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Vildagliptin low-dose"/>
               <rateMeasurement sampleSize="143" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Vildagliptin high-dose"/>
               <rateMeasurement sampleSize="143" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="130" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-diastolic blood pressure"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="8.16" sampleSize="143" mean="-2.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-diastolic blood pressure"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="8.09" sampleSize="130" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Vildagliptin low-dose"/>
               <rateMeasurement sampleSize="143" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="9.7" sampleSize="143" mean="54.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="9.5" sampleSize="143" mean="53.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="10.3" sampleSize="130" mean="54.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="Vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="4" name="other"/>
                  <category rate="24" name="hispanic or latino"/>
                  <category rate="9" name="black"/>
                  <category rate="106" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="Vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="5" name="other"/>
                  <category rate="19" name="hispanic or latino"/>
                  <category rate="13" name="black"/>
                  <category rate="106" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="2" name="other"/>
                  <category rate="24" name="hispanic or latino"/>
                  <category rate="9" name="black"/>
                  <category rate="95" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="5.3" sampleSize="143" mean="32.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="5.0" sampleSize="143" mean="32.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="6.1" sampleSize="130" mean="33.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="2.2" sampleSize="143" mean="9.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.6" sampleSize="143" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.4" sampleSize="130" mean="10.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="5.5" sampleSize="143" mean="6.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="4.7" sampleSize="143" mean="5.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="5.3" sampleSize="130" mean="6.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of previous MET treatment"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="23.2" sampleSize="143" mean="17.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of previous MET treatment"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="23.0" sampleSize="143" mean="17.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of previous MET treatment"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="16.7" sampleSize="130" mean="15.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Metformin dose bas"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="298.0" sampleSize="143" mean="2126.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Metformin dose bas"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="328.0" sampleSize="143" mean="2099.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Metformin dose bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="320.0" sampleSize="130" mean="2102.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-2-h PPG bas"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="5.32" sampleSize="143" mean="13.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-2-h PPG bas"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="6.8" sampleSize="143" mean="13.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-2-h PPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="6.75" sampleSize="130" mean="13.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="14.6" sampleSize="143" mean="18.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="13.6" sampleSize="143" mean="20.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="14.8" sampleSize="130" mean="20.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="61" name="female"/>
                  <category rate="82" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="55" name="female"/>
                  <category rate="88" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="61" name="female"/>
                  <category rate="69" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="143" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Vildagliptin high-dose"/>
               <continuousMeasurement stdDev="1.0" sampleSize="143" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.9" sampleSize="130" mean="8.3"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <usedBy arm="Vildagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="Vildagliptin low-dose" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Screening"/>
               <usedBy arm="Vildagliptin high-dose" epoch="Screening"/>
               <usedBy arm="Vildagliptin low-dose" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Vildagliptin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Vildagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="buse04">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>TRIPLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>101</value>
               <notes/>
            </centers>
            <objective>
               <value>This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>General inclusion criteria were a screening fasting plasma glucose concentration &lt;240 mg/dl, BMI 27-45 kg/m2, and HbA1c 7.1-11.0%, inclusive. In addition, subjects had stable weight (+-10%) for 3 months before screening and had no clinically relevant (for a type 2 diabetic population) abnormal laboratory test values (&gt;25% outside normal laboratory values). Female subjects were postmenopausal or surgically sterile or using contraceptives
for at least 3 months before screening and continuing throughout the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Subjects were excluded if they had used metformin, thiazolidinediones, meglitinides, a-glucosidase inhibitors, exogenous insulin therapy, or weight-loss drugs within the prior 3months. Further exclusion criteria included therapy with corticoste-roids, drugs known to affect gastrointestinal motility, transplantation medications, or
any investigational drug. Subjects were excluded if they had evidence of clinically significant comorbid conditions.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>15504997</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-17</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Feeling jittery">
               <adverseEvent name="Feeling jittery"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Sweating increase">
               <adverseEvent name="Sweating increase"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Weakness">
               <adverseEvent name="Weakness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race1">
               <populationCharacteristic name="race1"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPP bas">
               <populationCharacteristic name="FPP bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPI bas">
               <populationCharacteristic name="FPI bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="123" name="placebo">
               <notes/>
            </arm>
            <arm size="125" name="exenatide low-dose">
               <notes/>
            </arm>
            <arm size="129" name="exenatide high-dose">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.0" sampleSize="123" mean="0.12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="1.34" sampleSize="125" mean="-0.46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="1.25" sampleSize="129" mean="-0.86"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.33" sampleSize="123" mean="-0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="3.35" sampleSize="125" mean="-0.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="3.4" sampleSize="129" mean="-1.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.33" sampleSize="123" mean="0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="2.24" sampleSize="125" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="3.4" sampleSize="129" mean="-0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="18"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="46"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Feeling jittery"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Feeling jittery"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Feeling jittery"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating increase"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating increase"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sweating increase"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weakness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="123" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weakness"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Weakness"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="129" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="125" rate="64"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race1"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="12" name="black"/>
                  <category rate="26" name="hispanic"/>
                  <category rate="82" name="caucasian"/>
                  <category rate="2" name="asian"/>
                  <category rate="0" name="native american"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race1"/>
               <arm name="exenatide low-dose"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="21" name="black"/>
                  <category rate="23" name="hispanic"/>
                  <category rate="77" name="caucasian"/>
                  <category rate="2" name="asian"/>
                  <category rate="1" name="native american"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race1"/>
               <arm name="exenatide high-dose"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="21" name="black"/>
                  <category rate="28" name="hispanic"/>
                  <category rate="77" name="caucasian"/>
                  <category rate="2" name="asian"/>
                  <category rate="0" name="native american"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.0" sampleSize="123" mean="34.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="6.0" sampleSize="125" mean="33.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="6.0" sampleSize="129" mean="33.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.2" sampleSize="123" mean="10.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="2.5" sampleSize="125" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="2.8" sampleSize="129" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPP bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="54.0" sampleSize="123" mean="79.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPP bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="62.0" sampleSize="125" mean="77.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPP bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="60.0" sampleSize="129" mean="78.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPI bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="102.0" sampleSize="123" mean="139.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPI bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="118.0" sampleSize="125" mean="147.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPI bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="143.0" sampleSize="129" mean="148.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.7" sampleSize="123" mean="5.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="5.2" sampleSize="125" mean="6.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="6.6" sampleSize="129" mean="6.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="18.0" sampleSize="123" mean="99.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="22.0" sampleSize="125" mean="95.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="18.0" sampleSize="129" mean="95.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="11.0" sampleSize="123" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="10.0" sampleSize="125" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="11.0" sampleSize="129" mean="56.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="46" name="female"/>
                  <category rate="77" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide low-dose"/>
               <categoricalMeasurement>
                  <category rate="51" name="female"/>
                  <category rate="74" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide high-dose"/>
               <categoricalMeasurement>
                  <category rate="55" name="female"/>
                  <category rate="74" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.2" sampleSize="123" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="1.1" sampleSize="125" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="1.2" sampleSize="129" mean="8.6"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P28D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P210D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Randomization"/>
               <usedBy arm="exenatide low-dose" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Screening"/>
               <usedBy arm="exenatide low-dose" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Placebo run-in"/>
               <usedBy arm="exenatide low-dose" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.01"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.005"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="charbonnel06">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA1c [A1C] &gt;7 and &lt;10%) with metformin alone.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and women (aged 18-78 years) with type 2 diabetes and inadequate glycemic control (defined by an HbA1c [A1C] level &gt;7 and &lt;10%) while taking metformin monotherapy at a stable dose of at least 1,500 mg/day, either at entry into the study or after a metformin dose-stable run-in period, were eligible to be randomized. Patients who were not currently taking an oral antihyperglycemic agent (OHA), were taking any OHA in monotherapy, or were taking metformin in combination with another OHA were potentially eligible to participate in the study if their A1C level met the screening criteria.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had a history of type 1 diabetes, insulin use within 8 weeks of screening, renal function impairment inconsistent with the use of metformin, or a fasting plasma glucose (FPG) (or a fasting fingerstick glucose) at, or just before, randomization &gt;14.4 mmol/l (260 mg/dl). A history of hypoglycemia was not an exclusion criterion.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17130197</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-17</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-insulin end">
               <endpoint name="insulin end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-insulin change">
               <endpoint name="insulin change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-Proinsulin-to-insulin ratio end">
               <endpoint name="Proinsulin-to-insulin ratio end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-Proinsulin-to-insulin ratio change">
               <endpoint name="Proinsulin-to-insulin ratio change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-C-peptide end">
               <endpoint name="C-peptide end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-C-peptide change">
               <endpoint name="C-peptide change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B end">
               <endpoint name="HOMA-B end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B change">
               <endpoint name="HOMA-B change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-QUICKI end">
               <endpoint name="QUICKI end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-QUICKI change">
               <endpoint name="QUICKI change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-one or more AE">
               <adverseEvent name="one or more AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-gastroenteritis">
               <adverseEvent name="gastroenteritis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Bronchitis">
               <adverseEvent name="Bronchitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Influenza">
               <adverseEvent name="Influenza"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Cough">
               <adverseEvent name="Cough"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Urinary tract infection">
               <adverseEvent name="Urinary tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Arthralgia">
               <adverseEvent name="Arthralgia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hyperglycaemia">
               <adverseEvent name="Hyperglycaemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Back pain">
               <adverseEvent name="Back pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypertension">
               <adverseEvent name="Hypertension"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Blood glucose increase">
               <adverseEvent name="Blood glucose increase"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-use of anti-hyperglycemic medication at screening">
               <populationCharacteristic name="use of anti-hyperglycemic medication at screening"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="237" name="Placebo">
               <notes/>
            </arm>
            <arm size="464" name="Sitagliptin">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.1" sampleSize="224" mean="7.95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.97" sampleSize="453" mean="7.26"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.06" sampleSize="224" mean="-0.02"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.03" sampleSize="453" mean="-0.67"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.8" sampleSize="226" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="2.2" sampleSize="454" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.15" sampleSize="226" mean="0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.13" sampleSize="454" mean="-0.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-insulin end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="40.8" sampleSize="197" mean="72.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-insulin end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="76.2" sampleSize="419" mean="81.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-insulin change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="4.74" sampleSize="191" mean="-1.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-insulin change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="3.67" sampleSize="419" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Proinsulin-to-insulin ratio end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.21" sampleSize="169" mean="0.37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Proinsulin-to-insulin ratio end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.21" sampleSize="397" mean="0.33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Proinsulin-to-insulin ratio change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="169" mean="0.02"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Proinsulin-to-insulin ratio change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.0" sampleSize="397" mean="-0.03"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-C-peptide end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.4" sampleSize="186" mean="0.87"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-C-peptide end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.43" sampleSize="390" mean="0.93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-C-peptide change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="186" mean="0.03"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-C-peptide change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.0" sampleSize="390" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="37.5" sampleSize="196" mean="47.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="68.9" sampleSize="418" mean="65.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="196" mean="3.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.0" sampleSize="418" mean="19.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.028" sampleSize="196" mean="0.312"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.036" sampleSize="418" mean="0.318"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="196" mean="-0.002"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.0" sampleSize="418" mean="0.003"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-one or more AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="128"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-one or more AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="262"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="25"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-gastroenteritis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-gastroenteritis"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bronchitis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bronchitis"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="20"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="22"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="34"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Cough"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Cough"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Urinary tract infection"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Urinary tract infection"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperglycaemia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperglycaemia"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood glucose increase"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="237" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood glucose increase"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="464" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="9.7" sampleSize="237" mean="54.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="10.4" sampleSize="464" mean="54.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="17.5" sampleSize="237" mean="89.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="17.8" sampleSize="464" mean="86.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="4.9" sampleSize="237" mean="31.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="5.3" sampleSize="464" mean="30.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="5.5" sampleSize="237" mean="6.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="5.0" sampleSize="464" mean="6.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.82" sampleSize="224" mean="8.03"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.81" sampleSize="453" mean="7.96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.3" sampleSize="226" mean="9.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="2.3" sampleSize="454" mean="9.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-use of anti-hyperglycemic medication at screening"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="69" name="combination therapy"/>
                  <category rate="14" name="absence of therapy"/>
                  <category rate="154" name="monotherapy"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-use of anti-hyperglycemic medication at screening"/>
               <arm name="Sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="160" name="combination therapy"/>
                  <category rate="27" name="absence of therapy"/>
                  <category rate="277" name="monotherapy"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="96" name="female"/>
                  <category rate="141" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="205" name="female"/>
                  <category rate="259" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <usedBy arm="Sitagliptin" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Screening"/>
               <usedBy arm="Sitagliptin" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="defronzo05">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>TRIPLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>82</value>
               <notes/>
            </centers>
            <objective>
               <value>This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Subjects were 19-78 years of age with type 2 diabetes treated with metformin monotherapy. General inclusion criteria were screening fasting plasma glucose concentration of &lt;13.3 mmol/l (&lt;240 mg/dl), BMI of 27-45 kg/ m2, and HbA1c of 7.1-11.0%.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Exclusion criteria included use of sulfonylureas, meglitinides, thiazolidinediones, a-glucosidase inhibitors, exogenous
insulin therapy, weight loss drugs, corticosteroids, drugs known to affect gastrointestinal motility, transplantation
medications, or any investigational drug, or evidence of clinically significant comorbid conditions for 3 months before
screening.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>15855572</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-17</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Sinusitis">
               <adverseEvent name="Sinusitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hyperglycaemia">
               <adverseEvent name="Hyperglycaemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Back pain">
               <adverseEvent name="Back pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race">
               <populationCharacteristic name="race"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPI bas">
               <populationCharacteristic name="FPI bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPP bas">
               <populationCharacteristic name="FPP bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="113" name="placebo">
               <notes/>
            </arm>
            <arm size="110" name="exenatide low-dose">
               <notes/>
            </arm>
            <arm size="113" name="exenatide high-dose">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.06" sampleSize="113" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="1.05" sampleSize="110" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="1.06" sampleSize="113" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.09" sampleSize="113" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="4.2" sampleSize="110" mean="-1.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="5.32" sampleSize="113" mean="-2.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="113" rate="26"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="110" rate="40"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="113" rate="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="113" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="110" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="113" rate="18"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="113" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="110" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="113" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="113" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="110" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="113" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="113" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="110" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="113" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="113" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="110" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="113" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperglycaemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="113" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperglycaemia"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="110" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperglycaemia"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="113" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="113" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="110" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="113" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="110" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="4" name="other"/>
                  <category rate="12" name="hispanic or latino"/>
                  <category rate="15" name="black"/>
                  <category rate="82" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="exenatide low-dose"/>
               <categoricalMeasurement>
                  <category rate="5" name="other"/>
                  <category rate="8" name="hispanic or latino"/>
                  <category rate="12" name="black"/>
                  <category rate="85" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="exenatide high-dose"/>
               <categoricalMeasurement>
                  <category rate="4" name="other"/>
                  <category rate="9" name="hispanic or latino"/>
                  <category rate="10" name="black"/>
                  <category rate="90" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.0" sampleSize="113" mean="54.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="11.0" sampleSize="110" mean="53.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="11.0" sampleSize="113" mean="52.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="19.0" sampleSize="113" mean="100.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="22.0" sampleSize="110" mean="100.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="20.0" sampleSize="113" mean="101.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="6.0" sampleSize="113" mean="34.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="6.0" sampleSize="110" mean="34.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="6.0" sampleSize="113" mean="34.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.2" sampleSize="113" mean="9.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="110" mean="9.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="2.6" sampleSize="113" mean="9.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPI bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="31.0" sampleSize="113" mean="135.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPI bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="83.0" sampleSize="110" mean="129.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPI bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="91.0" sampleSize="113" mean="119.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPP bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="48.0" sampleSize="113" mean="58.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPP bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="58.0" sampleSize="110" mean="64.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPP bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="55.0" sampleSize="113" mean="58.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="6.1" sampleSize="113" mean="6.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="5.9" sampleSize="110" mean="6.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="4.7" sampleSize="113" mean="4.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="46" name="female"/>
                  <category rate="67" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide low-dose"/>
               <categoricalMeasurement>
                  <category rate="53" name="female"/>
                  <category rate="57" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide high-dose"/>
               <categoricalMeasurement>
                  <category rate="45" name="female"/>
                  <category rate="68" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.0" sampleSize="113" mean="8.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="1.1" sampleSize="110" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="1.1" sampleSize="113" mean="8.2"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P210D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Randomization"/>
               <usedBy arm="exenatide low-dose" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.005"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.01"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="dejager07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Vildagliptin in Drug-naive Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>This study aimed to conduct larger and longer-term studies in order to ascertain the efficacy and safety of vildagliptin monotherapy for use in the treatment of T2DM.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Male and female (non-fertile or of childbearing potential using a medically approved birth-control method) patients aged 18 - 80 years, inclusive, with a BMI of 22 - 45 kg/ m 2 , inclusive, and with a fasting plasma glucose (FPG) of &lt; 15 mmol/l were eligible to participate.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had a history of type 1 or secondary forms of diabetes, acute metabolic diabetic complications within the past 6 months, myocardial infarction, unstable angina, or coronary artery bypass surgery within the previous 6 months. Congestive heart failure, NYHA Class III or IV, and liver disease such as cirrhosis or chronic active hepatitis also precluded participation. Patients with any of the following laboratory abnormalities were also excluded: ALT or AST greater than 3 times the upper limit of normal (ULN), direct bilirubin &gt;1.3 times the ULN, serum creatinine levels &gt;2.5 mg/dl, clinically signifi cant abnormal TSH, or fasting triglycerides &gt;700 mg/dl.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17373638</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-22</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Clinical SAE">
               <adverseEvent name="Clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race">
               <populationCharacteristic name="race"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="163" name="vildagliptin low-dose">
               <notes/>
            </arm>
            <arm size="152" name="vildagliptin low-dose twice/day">
               <notes/>
            </arm>
            <arm size="157" name="vildagliptin high-dose">
               <notes/>
            </arm>
            <arm size="160" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="1.3" sampleSize="104" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <continuousMeasurement stdDev="1.2" sampleSize="90" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="1.3" sampleSize="92" mean="-0.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.3" sampleSize="94" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.4" sampleSize="104" mean="1.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <continuousMeasurement stdDev="0.4" sampleSize="90" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.4" sampleSize="92" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.4" sampleSize="94" mean="-1.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="109"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <rateMeasurement sampleSize="90" rate="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="92" rate="119"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="99"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <rateMeasurement sampleSize="90" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="92" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <rateMeasurement sampleSize="90" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="92" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <rateMeasurement sampleSize="90" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="92" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <rateMeasurement sampleSize="90" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="92" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <rateMeasurement sampleSize="90" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="92" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <rateMeasurement sampleSize="90" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="92" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Clinical SAE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Clinical SAE"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <rateMeasurement sampleSize="90" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Clinical SAE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="92" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Clinical SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <rateMeasurement sampleSize="90" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="92" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="104" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="11.4" sampleSize="104" mean="55.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <continuousMeasurement stdDev="9.6" sampleSize="90" mean="52.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="10.8" sampleSize="92" mean="53.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="94" mean="11.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="4" name="other"/>
                  <category rate="14" name="hispanic or latino"/>
                  <category rate="10" name="black"/>
                  <category rate="76" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <categoricalMeasurement>
                  <category rate="3" name="other"/>
                  <category rate="12" name="hispanic or latino"/>
                  <category rate="9" name="black"/>
                  <category rate="66" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="4" name="other"/>
                  <category rate="14" name="hispanic or latino"/>
                  <category rate="4" name="black"/>
                  <category rate="70" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="6" name="other"/>
                  <category rate="11" name="hispanic or latino"/>
                  <category rate="12" name="black"/>
                  <category rate="65" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="6.0" sampleSize="104" mean="32.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <continuousMeasurement stdDev="4.8" sampleSize="90" mean="33.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="6.1" sampleSize="92" mean="32.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.6" sampleSize="94" mean="32.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.8" sampleSize="104" mean="8.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <continuousMeasurement stdDev="0.8" sampleSize="90" mean="8.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.8" sampleSize="92" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.8" sampleSize="94" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="104" mean="9.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <continuousMeasurement stdDev="2.2" sampleSize="90" mean="10.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.3" sampleSize="92" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.5" sampleSize="94" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="3.6" sampleSize="104" mean="2.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <continuousMeasurement stdDev="3.3" sampleSize="90" mean="2.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="4.2" sampleSize="92" mean="2.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.5" sampleSize="94" mean="1.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="61" name="female"/>
                  <category rate="43" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin low-dose twice/day"/>
               <categoricalMeasurement>
                  <category rate="48" name="female"/>
                  <category rate="42" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="43" name="female"/>
                  <category rate="49" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="49" name="female"/>
                  <category rate="45" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="vildagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose twice/day" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Screening"/>
               <usedBy arm="vildagliptin high-dose" epoch="Screening"/>
               <usedBy arm="vildagliptin low-dose" epoch="Screening"/>
               <usedBy arm="vildagliptin low-dose twice/day" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin low-dose" epoch="Main phase"/>
               <usedBy arm="vildagliptin low-dose twice/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="fineman03">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>TRIPLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>AC2993 (synthetic exendin-4; exenatide) is a peptide that enhances glucosedependent insulin secretion, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. AC2993 also promotes B-cell proliferation and neogenesis in vitro and in animal models. This study examines the activity and safety of subcutaneously injected AC2993 in patients with type 2 diabetes currently treated with diet and/or oral antidiabetic agents (OAAs).</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <notes/>
            </inclusion>
            <exclusion>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>12882864</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-22</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race4">
               <populationCharacteristic name="race4"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-serum fructosamine bas">
               <populationCharacteristic name="serum fructosamine bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-antihypertensive agent">
               <populationCharacteristic name="antihypertensive agent"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="26" name="exenatide bd">
               <notes>
                  <note source="MANUAL">bd: breakfast and dinner</note>
               </notes>
            </arm>
            <arm size="27" name="exenatide  bs">
               <notes>
                  <note source="MANUAL">bs: breakfast and sleep time</note>
               </notes>
            </arm>
            <arm size="28" name="exenatide bds">
               <notes>
                  <note source="MANUAL">bds: breakfast, dinner and sleep time</note>
               </notes>
            </arm>
            <arm size="28" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide bd"/>
               <continuousMeasurement stdDev="0.36" sampleSize="26" mean="-1.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide  bs"/>
               <continuousMeasurement stdDev="0.62" sampleSize="27" mean="-0.71"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide bds"/>
               <continuousMeasurement stdDev="0.58" sampleSize="28" mean="-1.02"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.58" sampleSize="28" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race4"/>
               <arm name="exenatide bd"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="14" name="white"/>
                  <category rate="7" name="hispanic"/>
                  <category rate="15" name="black"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race4"/>
               <arm name="exenatide  bs"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="12" name="white"/>
                  <category rate="8" name="hispanic"/>
                  <category rate="6" name="black"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race4"/>
               <arm name="exenatide bds"/>
               <categoricalMeasurement>
                  <category rate="2" name="other"/>
                  <category rate="15" name="white"/>
                  <category rate="6" name="hispanic"/>
                  <category rate="5" name="black"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race4"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="0" name="other"/>
                  <category rate="19" name="white"/>
                  <category rate="7" name="hispanic"/>
                  <category rate="2" name="black"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide bd"/>
               <continuousMeasurement stdDev="8.0" sampleSize="26" mean="54.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide  bs"/>
               <continuousMeasurement stdDev="9.0" sampleSize="27" mean="51.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide bds"/>
               <continuousMeasurement stdDev="9.0" sampleSize="28" mean="50.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.0" sampleSize="28" mean="53.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide bd"/>
               <continuousMeasurement stdDev="16.7" sampleSize="26" mean="97.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide  bs"/>
               <continuousMeasurement stdDev="16.0" sampleSize="27" mean="98.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide bds"/>
               <continuousMeasurement stdDev="17.5" sampleSize="28" mean="96.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="16.7" sampleSize="28" mean="97.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide bd"/>
               <continuousMeasurement stdDev="3.8" sampleSize="26" mean="32.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide  bs"/>
               <continuousMeasurement stdDev="4.7" sampleSize="27" mean="33.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide bds"/>
               <continuousMeasurement stdDev="4.8" sampleSize="28" mean="33.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.1" sampleSize="28" mean="32.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide bd"/>
               <continuousMeasurement stdDev="2.8" sampleSize="26" mean="11.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide  bs"/>
               <continuousMeasurement stdDev="3.3" sampleSize="27" mean="11.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide bds"/>
               <continuousMeasurement stdDev="2.4" sampleSize="28" mean="10.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.6" sampleSize="28" mean="12.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-serum fructosamine bas"/>
               <arm name="exenatide bd"/>
               <continuousMeasurement stdDev="74.0" sampleSize="26" mean="344.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-serum fructosamine bas"/>
               <arm name="exenatide  bs"/>
               <continuousMeasurement stdDev="71.0" sampleSize="27" mean="340.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-serum fructosamine bas"/>
               <arm name="exenatide bds"/>
               <continuousMeasurement stdDev="0.0" sampleSize="28" mean="59.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-serum fructosamine bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="56.0" sampleSize="28" mean="346.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide bd"/>
               <continuousMeasurement stdDev="1.2" sampleSize="26" mean="9.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide  bs"/>
               <continuousMeasurement stdDev="1.0" sampleSize="27" mean="9.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide bds"/>
               <continuousMeasurement stdDev="1.1" sampleSize="28" mean="9.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.3" sampleSize="28" mean="9.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-antihypertensive agent"/>
               <arm name="exenatide bd"/>
               <rateMeasurement sampleSize="26" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-antihypertensive agent"/>
               <arm name="exenatide  bs"/>
               <rateMeasurement sampleSize="27" rate="17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-antihypertensive agent"/>
               <arm name="exenatide bds"/>
               <rateMeasurement sampleSize="28" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-antihypertensive agent"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="28" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide bd"/>
               <categoricalMeasurement>
                  <category rate="10" name="female"/>
                  <category rate="16" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide  bs"/>
               <categoricalMeasurement>
                  <category rate="10" name="female"/>
                  <category rate="17" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide bds"/>
               <categoricalMeasurement>
                  <category rate="12" name="female"/>
                  <category rate="16" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="7" name="female"/>
                  <category rate="21" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P28D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="exenatide  bs" epoch="Randomization"/>
               <usedBy arm="exenatide bd" epoch="Randomization"/>
               <usedBy arm="exenatide bds" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="exenatide  bs" epoch="Placebo run-in"/>
               <usedBy arm="exenatide bd" epoch="Placebo run-in"/>
               <usedBy arm="exenatide bds" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="8.0E-5"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide bd">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="8.0E-5"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide bd" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide bs">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="8.0E-5"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide  bs" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide bds">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="8.0E-5"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide bds" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="gao09">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To evaluate the efficacy of exenatide in Asian patients with type 2 diabetes (T2D) inadequately controlled with oral agents.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Eligible patients, male or female, were between 21 and 75 years of age (inclusive), met the World Health Organization criteria for type 2 diabetes, had been treated with a stable dose of MET and/or SU for at least 3 months prior to screening, and had inadequate glycaemic control (HbA1c &gt;7.0% and &lt;11.0%). Treated with a stable dose of one of the following for at least 3 months prior to screening: * &gt;=1000 mg/day immediate-release metformin; or metformin &gt;=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy.  HbA1c between 7.1% and 11.0%, inclusive.  Body Mass Index (BMI) &gt;21 kg/m^2 and &lt;35 kg/m^2. 
</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Have participated in this study previously, or any other study using exenatide or GLP-1 analogs. 
Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening. 
Have characteristics contraindicating metformin or sulfonylurea use. 
Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening. 
Have used drugs for weight loss within 1 month of screening. 
</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>19019476</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-22</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FSG change">
               <endpoint name="FSG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-daily mean glucose change">
               <endpoint name="daily mean glucose change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-M-value change">
               <endpoint name="M-value change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Anorexia">
               <adverseEvent name="Anorexia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pyrexia">
               <adverseEvent name="Pyrexia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Arthralgia">
               <adverseEvent name="Arthralgia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-country">
               <populationCharacteristic name="country"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-treated with MET">
               <populationCharacteristic name="treated with MET"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Treated with MET and SU">
               <populationCharacteristic name="Treated with MET and SU"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FSG bas">
               <populationCharacteristic name="FSG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-daily mean glucose bas">
               <populationCharacteristic name="daily mean glucose bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-M-value bas">
               <populationCharacteristic name="M-value bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="234" name="exenatide">
               <notes>
                  <note source="MANUAL">10ug twice/day</note>
               </notes>
            </arm>
            <arm size="232" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="0.05" sampleSize="234" mean="-1.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.08" sampleSize="232" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FSG change"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="0.18" sampleSize="234" mean="-1.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FSG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.2" sampleSize="232" mean="-0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="2.34" sampleSize="234" mean="-1.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.94" sampleSize="232" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-daily mean glucose change"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="3.1" sampleSize="234" mean="-2.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-daily mean glucose change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.5" sampleSize="232" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-M-value change"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="27.5" sampleSize="234" mean="19.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-M-value change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="27.4" sampleSize="232" mean="43.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="134"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="84"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="59"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Anorexia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pyrexia"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pyrexia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="9.0" sampleSize="234" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.0" sampleSize="232" mean="54.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-country"/>
               <arm name="exenatide"/>
               <categoricalMeasurement>
                  <category rate="26" name="taiwan"/>
                  <category rate="50" name="india"/>
                  <category rate="42" name="korea"/>
                  <category rate="116" name="china"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-country"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="24" name="taiwan"/>
                  <category rate="47" name="india"/>
                  <category rate="38" name="korea"/>
                  <category rate="123" name="china"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="6.0" sampleSize="234" mean="8.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.0" sampleSize="232" mean="8.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="3.2" sampleSize="234" mean="26.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.4" sampleSize="232" mean="26.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-treated with MET"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-treated with MET"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="56"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Treated with MET and SU"/>
               <arm name="exenatide"/>
               <rateMeasurement sampleSize="234" rate="189"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Treated with MET and SU"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="232" rate="186"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="1.0" sampleSize="234" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.0" sampleSize="232" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FSG bas"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="2.6" sampleSize="234" mean="9.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FSG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.5" sampleSize="232" mean="9.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="11.2" sampleSize="234" mean="69.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="11.1" sampleSize="232" mean="67.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-daily mean glucose bas"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="2.6" sampleSize="234" mean="10.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-daily mean glucose bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.5" sampleSize="232" mean="10.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-M-value bas"/>
               <arm name="exenatide"/>
               <continuousMeasurement stdDev="38.2" sampleSize="234" mean="52.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-M-value bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="39.0" sampleSize="232" mean="50.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide"/>
               <categoricalMeasurement>
                  <category rate="122" name="female"/>
                  <category rate="112" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="137" name="female"/>
                  <category rate="95" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo un-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P112D</duration>
               <notes>
                  <note source="MANUAL">Titration at week 4</note>
               </notes>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="exenatide" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="exenatide" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="exenatide" epoch="Placebo un-in"/>
               <usedBy arm="placebo" epoch="Placebo un-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide ">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.02"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="garber07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>The purpose of this study was to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor vildagliptin in combination with the thiazolidinedione (TZD) pioglitazone in patients with type 2 diabetes (T2DM).</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Eligibility criteria were age 18-80 years, body mass index 22-45 kg/m2, HbA1c 7.5-11% and fasting plasma glucose (FPG) &lt;15 mmol/l.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had a history of type 1 or secondary forms of diabetes,myocardial infarction, unstable angina or coronary artery bypass surgery within the previous 6 months.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17300592</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <value>2011-02-22</value>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-Fasting proinsulin level change">
               <endpoint name="Fasting proinsulin level change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-periphera oedema">
               <adverseEvent name="periphera oedema"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Arthralgia">
               <adverseEvent name="Arthralgia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Urinary tract infection">
               <adverseEvent name="Urinary tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-weight increase">
               <adverseEvent name="weight increase"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race">
               <populationCharacteristic name="race"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-duration of TZD use">
               <populationCharacteristic name="duration of TZD use"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-on maximum TZD before study">
               <populationCharacteristic name="on maximum TZD before study"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="147" name="vildagliptin low-dose">
               <notes/>
            </arm>
            <arm size="158" name="vildagliptin high-dose">
               <notes/>
            </arm>
            <arm size="158" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.1" sampleSize="107" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.1" sampleSize="112" mean="7.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.1" sampleSize="111" mean="8.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="2.9" sampleSize="107" mean="-7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.9" sampleSize="112" mean="-8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.0" sampleSize="111" mean="3.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.2" sampleSize="107" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.2" sampleSize="112" mean="-1.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.2" sampleSize="111" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-periphera oedema"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="147" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-periphera oedema"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="158" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-periphera oedema"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="158" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="147" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="158" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="158" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Urinary tract infection"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="147" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Urinary tract infection"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="158" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Urinary tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="158" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-weight increase"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="147" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-weight increase"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="158" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-weight increase"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="158" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="147" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="158" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="158" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="147" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="158" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="158" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="147" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="158" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="158" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="147" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="8.2" sampleSize="124" mean="54.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="9.2" sampleSize="136" mean="54.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="10.6" sampleSize="138" mean="54.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="2" name="other"/>
                  <category rate="12" name="hispanic or latino"/>
                  <category rate="6" name="black"/>
                  <category rate="104" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="5" name="other"/>
                  <category rate="12" name="hispanic or latino"/>
                  <category rate="11" name="black"/>
                  <category rate="108" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="7" name="other"/>
                  <category rate="10" name="hispanic or latino"/>
                  <category rate="13" name="black"/>
                  <category rate="108" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="5.0" sampleSize="124" mean="32.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="5.8" sampleSize="136" mean="32.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.8" sampleSize="138" mean="32.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="1.0" sampleSize="124" mean="8.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="1.2" sampleSize="136" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.2" sampleSize="138" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="2.9" sampleSize="124" mean="10.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="3.3" sampleSize="136" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.0" sampleSize="138" mean="10.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="4.3" sampleSize="124" mean="4.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="4.8" sampleSize="136" mean="4.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.6" sampleSize="138" mean="4.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-duration of TZD use"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="20.8" sampleSize="124" mean="17.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-duration of TZD use"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="17.6" sampleSize="136" mean="14.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-duration of TZD use"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="16.1" sampleSize="138" mean="14.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-on maximum TZD before study"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="124" rate="39"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-on maximum TZD before study"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="136" rate="38"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-on maximum TZD before study"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="138" rate="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="56" name="female"/>
                  <category rate="68" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="75" name="female"/>
                  <category rate="61" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="68" name="female"/>
                  <category rate="70" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Pre-medication administration">
               <duration>P28D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="vildagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Screening"/>
               <usedBy arm="vildagliptin high-dose" epoch="Screening"/>
               <usedBy arm="vildagliptin low-dose" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Pre-medication administration"/>
               <usedBy arm="vildagliptin high-dose" epoch="Pre-medication administration"/>
               <usedBy arm="vildagliptin low-dose" epoch="Pre-medication administration"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="45.0"/>
                        <drug name="pioglitazone"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="45.0"/>
                        <drug name="pioglitazone"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="45.0"/>
                        <drug name="pioglitazone"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="garber08">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To compare the efficacy and tolerability of vildagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled [haemoglobin A1c (HbA1c) 7.5 to 11%] with prior sulphonylurea (SU) monotherapy.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients were required to have been treated with an SU for &gt;3 months and with a stable
dose for &gt;4 weeks before the screening visit. Male or female patients (females of childbearing potential were required to use a medically approved contraceptive method), 18–80 years of age, with a body mass index (BMI) of 22–45 kg/m2 and fasting plasma glucose (FPG) &lt; 15 mmol/l were eligible to participate.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had a history of type 1 or secondary forms of diabetes, myocardial infarction, unstable angina or coronary artery bypass surgery within the previous 6 months. Congestive heart failure (New York Heart Association class III or IV), liver disease such as cirrhosis or chronic active hepatitis or use of any oral antidiabetic drug other than an SU within the past 2 months also precluded participation. Patients with any of the following laboratory abnormalities were also excluded: alanine aminotransferase (ALT) or aspartate
aminotransferase (AST) greater than three times the upper limit of normal (ULN), direct bilirubin &gt;1.3 times the ULN, serum creatinine levels &gt;220 mmol/l, thyroidstimulating hormone outside the normal range or fasting triglycerides (TGs) &gt;7.9 mmol/l.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>18284434</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Asthenia">
               <adverseEvent name="Asthenia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Influenza">
               <adverseEvent name="Influenza"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hyperhidrosis">
               <adverseEvent name="Hyperhidrosis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Sinusitis">
               <adverseEvent name="Sinusitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Back pain">
               <adverseEvent name="Back pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pain in extremity">
               <adverseEvent name="Pain in extremity"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Insomnia">
               <adverseEvent name="Insomnia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Paraesthesia">
               <adverseEvent name="Paraesthesia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Fatigue">
               <adverseEvent name="Fatigue"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hyperlipidemia">
               <adverseEvent name="Hyperlipidemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race">
               <populationCharacteristic name="race"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of sulphonylurea">
               <populationCharacteristic name="Duration of sulphonylurea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="170" name="vildagliptin low-dose">
               <notes/>
            </arm>
            <arm size="169" name="vildagliptin high-dose">
               <notes/>
            </arm>
            <arm size="176" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.1" sampleSize="132" mean="-0.58"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.09" sampleSize="132" mean="-0.63"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.09" sampleSize="144" mean="-0.07"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.3" sampleSize="132" mean="1.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.3" sampleSize="132" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.3" sampleSize="144" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.2" sampleSize="132" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.2" sampleSize="132" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.2" sampleSize="144" mean="0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="144"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="112"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="113"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Asthenia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperhidrosis"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperhidrosis"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperhidrosis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Insomnia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Paraesthesia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Paraesthesia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Paraesthesia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperlipidemia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperlipidemia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperlipidemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="169" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="170" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="10.6" sampleSize="132" mean="58.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="11.1" sampleSize="132" mean="58.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="10.5" sampleSize="144" mean="57.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="3" name="other"/>
                  <category rate="24" name="hispanic or latino"/>
                  <category rate="14" name="black"/>
                  <category rate="91" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="4" name="other"/>
                  <category rate="24" name="hispanic or latino"/>
                  <category rate="11" name="black"/>
                  <category rate="93" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="5" name="other"/>
                  <category rate="27" name="hispanic or latino"/>
                  <category rate="15" name="black"/>
                  <category rate="97" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="4.9" sampleSize="132" mean="32.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="5.3" sampleSize="132" mean="30.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.5" sampleSize="144" mean="31.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="132" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="1.0" sampleSize="132" mean="8.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.0" sampleSize="144" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="3.0" sampleSize="132" mean="10.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.7" sampleSize="132" mean="10.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.9" sampleSize="144" mean="10.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="5.2" sampleSize="132" mean="6.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="5.3" sampleSize="132" mean="6.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.8" sampleSize="144" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of sulphonylurea"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="42.7" sampleSize="132" mean="47.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of sulphonylurea"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="44.4" sampleSize="132" mean="45.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of sulphonylurea"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="56.0" sampleSize="144" mean="52.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="54" name="female"/>
                  <category rate="78" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="35" name="female"/>
                  <category rate="97" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="38" name="female"/>
                  <category rate="106" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="vildagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Screening"/>
               <usedBy arm="vildagliptin high-dose" epoch="Screening"/>
               <usedBy arm="vildagliptin low-dose" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo+glimepiride">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="4.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin high + glimepiride">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="4.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin low + glimepiride">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="4.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="goldstein07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To assess the efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes and inadequate glycemic control on diet and exercise.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients with type 2 diabetes, 18–78 years of age, who were either on or not on an OHA at the screening visit were eligible to participate.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Those with type 1 diabetes, unstable cardiac disease, significant renal impairment (estimated
creatinine clearance &lt;60 ml/min), or elevated (more than twofold the upper limit of normal) alanine aminotransferase or aspartate aminotransferase were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17485570</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555
SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-fasting proinsuline end">
               <endpoint name="fasting proinsuline end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-Fasting proinsulin level change">
               <endpoint name="Fasting proinsulin level change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B end">
               <endpoint name="HOMA-B end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B change">
               <endpoint name="HOMA-B change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-IR end">
               <endpoint name="HOMA-IR end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-IR change">
               <endpoint name="HOMA-IR change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Who died">
               <adverseEvent name="Who died"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related SAE">
               <adverseEvent name="Discontinuation due to drug-related SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="176" name="placebo">
               <notes/>
            </arm>
            <arm size="179" name="Sitagliptin ">
               <notes/>
            </arm>
            <arm size="182" name="metformin low-dose">
               <notes/>
            </arm>
            <arm size="182" name="metformin high-dose">
               <notes/>
            </arm>
            <arm size="190" name="sitagliptin + metformin low-dose">
               <notes/>
            </arm>
            <arm size="182" name="sitagliptin + metformin high-dose">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.47" sampleSize="176" mean="8.88"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="1.45" sampleSize="179" mean="8.18"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="1.36" sampleSize="182" mean="8.04"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="1.27" sampleSize="182" mean="7.58"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="1.2" sampleSize="190" mean="7.37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="1.09" sampleSize="182" mean="6.87"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.08" sampleSize="176" mean="0.17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="0.08" sampleSize="179" mean="-0.66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="0.08" sampleSize="182" mean="-0.82"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="0.17" sampleSize="182" mean="-1.13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="0.08" sampleSize="190" mean="-1.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="0.08" sampleSize="182" mean="-1.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.4" sampleSize="176" mean="11.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="3.0" sampleSize="179" mean="10.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="3.1" sampleSize="182" mean="9.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="3.6" sampleSize="182" mean="9.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="2.6" sampleSize="190" mean="8.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="2.0" sampleSize="182" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.19" sampleSize="176" mean="0.32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="0.19" sampleSize="179" mean="-0.97"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="0.03" sampleSize="182" mean="-1.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="0.19" sampleSize="182" mean="-1.63"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="0.19" sampleSize="190" mean="-2.61"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="0.19" sampleSize="182" mean="-3.55"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting proinsuline end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="30.7" sampleSize="176" mean="33.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting proinsuline end"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="30.2" sampleSize="179" mean="31.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting proinsuline end"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="25.8" sampleSize="182" mean="30.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting proinsuline end"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="29.1" sampleSize="182" mean="27.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting proinsuline end"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="35.0" sampleSize="190" mean="30.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting proinsuline end"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="19.1" sampleSize="182" mean="20.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.3" sampleSize="176" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="1.9" sampleSize="179" mean="-1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="1.8" sampleSize="182" mean="-5.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="1.7" sampleSize="182" mean="-9.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="1.66" sampleSize="190" mean="-6.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="1.6" sampleSize="182" mean="-15.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="49.8" sampleSize="176" mean="44.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="43.5" sampleSize="179" mean="48.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="45.1" sampleSize="182" mean="54.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="50.6" sampleSize="182" mean="59.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="61.1" sampleSize="190" mean="72.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="56.8" sampleSize="182" mean="74.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.2" sampleSize="176" mean="3.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="3.1" sampleSize="179" mean="10.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="3.0" sampleSize="182" mean="11.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="3.0" sampleSize="182" mean="14.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="8.0" sampleSize="190" mean="31.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="3.0" sampleSize="182" mean="33.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.7" sampleSize="176" mean="6.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="4.7" sampleSize="179" mean="5.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="4.7" sampleSize="182" mean="5.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="4.3" sampleSize="182" mean="5.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="5.6" sampleSize="190" mean="6.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="3.3" sampleSize="182" mean="4.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.33" sampleSize="176" mean="0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="0.3" sampleSize="179" mean="-0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="metformin low-dose"/>
               <continuousMeasurement stdDev="0.08" sampleSize="182" mean="-0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="metformin high-dose"/>
               <continuousMeasurement stdDev="0.3" sampleSize="182" mean="-1.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <continuousMeasurement stdDev="0.3" sampleSize="190" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <continuousMeasurement stdDev="0.28" sampleSize="182" mean="-2.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="89"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="101"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="113"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="110"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="105"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="30"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="24"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="179" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="metformin low-dose"/>
               <rateMeasurement sampleSize="182" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="sitagliptin + metformin low-dose"/>
               <rateMeasurement sampleSize="190" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="sitagliptin + metformin high-dose"/>
               <rateMeasurement sampleSize="182" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="176" rate="7"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Sitagliptin " epoch="Randomization"/>
               <usedBy arm="metformin high-dose" epoch="Randomization"/>
               <usedBy arm="metformin low-dose" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="sitagliptin + metformin high-dose" epoch="Randomization"/>
               <usedBy arm="sitagliptin + metformin low-dose" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Sitagliptin " epoch="Screening"/>
               <usedBy arm="metformin high-dose" epoch="Screening"/>
               <usedBy arm="metformin low-dose" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <usedBy arm="sitagliptin + metformin high-dose" epoch="Screening"/>
               <usedBy arm="sitagliptin + metformin low-dose" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Sitagliptin " epoch="Placebo run-in"/>
               <usedBy arm="metformin high-dose" epoch="Placebo run-in"/>
               <usedBy arm="metformin low-dose" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <usedBy arm="sitagliptin + metformin high-dose" epoch="Placebo run-in"/>
               <usedBy arm="sitagliptin + metformin low-dose" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="metformin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="500.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="metformin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="metformin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1000.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="metformin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="sitagliptin  + metformin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="500.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="sitagliptin + metformin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="sitagliptin  + metformin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1000.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="sitagliptin + metformin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin " epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="goodman09">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>67</value>
               <notes/>
            </centers>
            <objective>
               <value>The aim of the study was to evaluate the effi cacy and safety of vildagliptin added to metformin in patients with type 2 diabetes mellitus.
The primary objective was to demonstrate that HbA 1c reduction with once-daily vildagliptin 100 mg AM dosing is superior to placebo.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients with T2DM and a baseline HbA 1c of 7.5 – 11 % who were receiving a stable dose of
metformin ≥ 1 500 mg / day for at least 3 months were assessed for eligibility. Male and female patients (nonfertile or of childbearing potential using a medically approved birth control
method) aged 18 – 78 years, with a body mass index (BMI) of 22– 40 kg/ m 2 and a fasting plasma glucose (FPG) &lt; 270 mg / dl ( &lt; 15 mmol/ l) who agreed to maintain the same dose of metformin throughout the study were eligible.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they were pregnant or lactating; had a history of type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes; had acute metabolic diabetic complications within the past 6 months, evidence of signifi cant diabetic complications, liver disease, signifi cant renal dysfunction, treatment with any oral antidiabetic other than metformin within 3 months of study entry, chronic insulin treatment within the past 6 months, or any of the following signifi - cant laboratory abnormalities: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2 times the upper limit of the normal (ULN) range, total bilirubin &gt; 2 times ULN, direct bilirubin &gt; ULN, serum creatinine levels ≥ 1.5 mg / dl (males) or ≥ 1.4 mg / dl (females) or a history of abnormal creatinine clearance.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>19221978</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Fatigue">
               <adverseEvent name="Fatigue"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Tremor">
               <adverseEvent name="Tremor"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pain in extremity">
               <adverseEvent name="Pain in extremity"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypertension">
               <adverseEvent name="Hypertension"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Bronchitis">
               <adverseEvent name="Bronchitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Sinusitis">
               <adverseEvent name="Sinusitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race2">
               <populationCharacteristic name="race2"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Metformin dose bas">
               <populationCharacteristic name="Metformin dose bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="125" name="vildagliptin am">
               <notes/>
            </arm>
            <arm size="123" name="vildagliptin pm">
               <notes/>
            </arm>
            <arm size="122" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin am"/>
               <continuousMeasurement stdDev="1.1" sampleSize="119" mean="-0.66"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin pm"/>
               <continuousMeasurement stdDev="1.1" sampleSize="119" mean="-0.53"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.08" sampleSize="117" mean="0.17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="38"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="42"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Fatigue"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tremor"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bronchitis"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bronchitis"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bronchitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin pm"/>
               <rateMeasurement sampleSize="123" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="vildagliptin am"/>
               <rateMeasurement sampleSize="125" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin am"/>
               <continuousMeasurement stdDev="10.3" sampleSize="125" mean="54.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin pm"/>
               <continuousMeasurement stdDev="11.4" sampleSize="123" mean="55.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.7" sampleSize="122" mean="54.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="vildagliptin am"/>
               <categoricalMeasurement>
                  <category rate="2" name="other"/>
                  <category rate="31" name="hispanic or latino"/>
                  <category rate="1" name="pacific islander"/>
                  <category rate="11" name="black"/>
                  <category rate="79" name="caucasian"/>
                  <category rate="1" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="vildagliptin pm"/>
               <categoricalMeasurement>
                  <category rate="0" name="other"/>
                  <category rate="28" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="9" name="black"/>
                  <category rate="84" name="caucasian"/>
                  <category rate="2" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="0" name="other"/>
                  <category rate="32" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="7" name="black"/>
                  <category rate="83" name="caucasian"/>
                  <category rate="0" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin am"/>
               <continuousMeasurement stdDev="4.6" sampleSize="125" mean="31.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin pm"/>
               <continuousMeasurement stdDev="4.8" sampleSize="123" mean="31.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.3" sampleSize="122" mean="31.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin am"/>
               <continuousMeasurement stdDev="1.0" sampleSize="125" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin pm"/>
               <continuousMeasurement stdDev="0.9" sampleSize="123" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.1" sampleSize="122" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin am"/>
               <continuousMeasurement stdDev="2.9" sampleSize="125" mean="10.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin pm"/>
               <continuousMeasurement stdDev="2.7" sampleSize="123" mean="10.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.8" sampleSize="122" mean="11.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Metformin dose bas"/>
               <arm name="vildagliptin am"/>
               <continuousMeasurement stdDev="373.4" sampleSize="125" mean="1889.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Metformin dose bas"/>
               <arm name="vildagliptin pm"/>
               <continuousMeasurement stdDev="389.1" sampleSize="123" mean="1869.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Metformin dose bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="410.7" sampleSize="122" mean="1932.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin am"/>
               <categoricalMeasurement>
                  <category rate="59" name="female"/>
                  <category rate="66" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin pm"/>
               <categoricalMeasurement>
                  <category rate="58" name="female"/>
                  <category rate="65" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="40" name="female"/>
                  <category rate="82" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P28D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="vildagliptin am" epoch="Randomization"/>
               <usedBy arm="vildagliptin pm" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Screening"/>
               <usedBy arm="vildagliptin am" epoch="Screening"/>
               <usedBy arm="vildagliptin pm" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <usedBy arm="vildagliptin am" epoch="Placebo run-in"/>
               <usedBy arm="vildagliptin pm" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin am" epoch="Main phase"/>
               <usedBy arm="vildagliptin pm" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="hanefeld07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To evaluate sitagliptin once daily monotherapy in a dose-ranging study.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Male and female patients, 21–75 years of age, with type 2 diabetes, either currently on OHA monotherapy (except thiazolidinediones) with glycosylated hemoglobin (HbA1c) ≥ 6% and ≤ 9% or not currently on an OHA with HbA1c ≥ 6.5% and &lt; 10%, were eligible to participate if they met screening criteria.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients with type 1 diabetes, unstable cardiac disease, or elevated (&gt; 2-fold the upper limit of normal (ULN)) alanine aminotransferase (ALT), aspartate aminotransferase (AST) or creatine phosphokinase (CPK) were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17559733</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-MDG end">
               <endpoint name="MDG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-MDG change">
               <endpoint name="MDG change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-fasting serum insuline end">
               <endpoint name="fasting serum insuline end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-fasting serum insulin change">
               <endpoint name="fasting serum insulin change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95% CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B end">
               <endpoint name="HOMA-B end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B change">
               <endpoint name="HOMA-B change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-IR end">
               <endpoint name="HOMA-IR end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-IR change">
               <endpoint name="HOMA-IR change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-QUICKI end">
               <endpoint name="QUICKI end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-QUICKI change">
               <endpoint name="QUICKI change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Who died">
               <adverseEvent name="Who died"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related SAE">
               <adverseEvent name="Discontinuation due to drug-related SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race3">
               <populationCharacteristic name="race3"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-prior use of OHAa">
               <populationCharacteristic name="prior use of OHAa"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="111" name="placebo">
               <notes/>
            </arm>
            <arm size="111" name="Sitagliptin low-dose">
               <notes/>
            </arm>
            <arm size="112" name="Sitagliptin mid-dose">
               <notes/>
            </arm>
            <arm size="110" name="Sitagliptin high-dose">
               <notes/>
            </arm>
            <arm size="111" name="Sitagliptin mid-dose twice-perday">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.11" sampleSize="111" mean="7.76"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="1.3" sampleSize="111" mean="7.47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="1.11" sampleSize="110" mean="7.38"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="1.02" sampleSize="112" mean="7.22"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.07" sampleSize="111" mean="0.12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.07" sampleSize="111" mean="-0.28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.07" sampleSize="110" mean="-0.44"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="0.07" sampleSize="112" mean="-0.44"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.6" sampleSize="111" mean="9.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="2.8" sampleSize="111" mean="9.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin mid-dose"/>
               <continuousMeasurement stdDev="2.1" sampleSize="111" mean="8.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="2.3" sampleSize="110" mean="8.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.12" sampleSize="111" mean="0.01"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.18" sampleSize="111" mean="-0.59"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.18" sampleSize="111" mean="-0.76"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.18" sampleSize="110" mean="-0.94"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MDG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="52.4" sampleSize="111" mean="188.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MDG end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="51.5" sampleSize="111" mean="179.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MDG end"/>
               <arm name="Sitagliptin mid-dose"/>
               <continuousMeasurement stdDev="48.6" sampleSize="111" mean="172.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MDG end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="50.0" sampleSize="110" mean="169.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MDG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.5" sampleSize="111" mean="-0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MDG change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="3.5" sampleSize="111" mean="-14.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MDG change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="3.4" sampleSize="110" mean="-22.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-MDG change"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="3.4" sampleSize="112" mean="-23.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insuline end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="11.5" sampleSize="111" mean="16.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insuline end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="11.3" sampleSize="111" mean="16.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insuline end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="12.3" sampleSize="110" mean="16.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insuline end"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="13.0" sampleSize="112" mean="15.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insulin change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.87" sampleSize="111" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insulin change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.84" sampleSize="111" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insulin change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.87" sampleSize="110" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insulin change"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="0.87" sampleSize="112" mean="0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="42.7" sampleSize="111" mean="58.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="52.1" sampleSize="111" mean="70.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="57.5" sampleSize="110" mean="73.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="59.3" sampleSize="112" mean="68.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.1" sampleSize="111" mean="-1.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="3.9" sampleSize="111" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin mid-dose"/>
               <continuousMeasurement stdDev="4.0" sampleSize="111" mean="13.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="4.0" sampleSize="110" mean="11.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="7.0" sampleSize="111" mean="7.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="7.0" sampleSize="111" mean="7.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="5.4" sampleSize="110" mean="6.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="5.9" sampleSize="112" mean="6.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.5" sampleSize="111" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.5" sampleSize="111" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.5" sampleSize="110" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="0.5" sampleSize="112" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.03" sampleSize="111" mean="0.303"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.03" sampleSize="111" mean="0.302"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.028" sampleSize="110" mean="0.305"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI end"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="0.031" sampleSize="112" mean="0.309"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.002" sampleSize="111" mean="0.004"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.002" sampleSize="111" mean="0.003"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI change"/>
               <arm name="Sitagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.002" sampleSize="111" mean="0.002"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.002" sampleSize="110" mean="0.006"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="38"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin mid-dose"/>
               <rateMeasurement sampleSize="111" rate="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin mid-dose"/>
               <rateMeasurement sampleSize="111" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <rateMeasurement sampleSize="112" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <rateMeasurement sampleSize="112" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="Sitagliptin mid-dose"/>
               <rateMeasurement sampleSize="111" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin mid-dose"/>
               <rateMeasurement sampleSize="111" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin mid-dose"/>
               <rateMeasurement sampleSize="111" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <rateMeasurement sampleSize="112" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <rateMeasurement sampleSize="112" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin mid-dose"/>
               <rateMeasurement sampleSize="111" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin mid-dose"/>
               <rateMeasurement sampleSize="111" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.3" sampleSize="111" mean="55.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="9.6" sampleSize="111" mean="55.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="7.9" sampleSize="110" mean="56.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="10.3" sampleSize="112" mean="55.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race3"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="15" name="other"/>
                  <category rate="87" name="white"/>
                  <category rate="8" name="black"/>
                  <category rate="0" name="hispanic"/>
                  <category rate="1" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race3"/>
               <arm name="Sitagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="8" name="other"/>
                  <category rate="98" name="white"/>
                  <category rate="4" name="black"/>
                  <category rate="0" name="hispanic"/>
                  <category rate="1" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race3"/>
               <arm name="Sitagliptin mid-dose"/>
               <categoricalMeasurement>
                  <category rate="13" name="other"/>
                  <category rate="90" name="white"/>
                  <category rate="7" name="black"/>
                  <category rate="0" name="hispanic"/>
                  <category rate="1" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race3"/>
               <arm name="Sitagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="7" name="other"/>
                  <category rate="97" name="white"/>
                  <category rate="6" name="black"/>
                  <category rate="0" name="hispanic"/>
                  <category rate="0" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.1" sampleSize="111" mean="31.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="4.8" sampleSize="111" mean="31.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin mid-dose"/>
               <continuousMeasurement stdDev="4.8" sampleSize="111" mean="32.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="5.8" sampleSize="110" mean="31.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.4" sampleSize="111" mean="3.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="3.4" sampleSize="111" mean="3.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin mid-dose"/>
               <continuousMeasurement stdDev="5.9" sampleSize="111" mean="4.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="3.9" sampleSize="110" mean="3.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="111" rate="72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="111" rate="70"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="110" rate="69"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <rateMeasurement sampleSize="112" rate="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.9" sampleSize="111" mean="7.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="111" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="111" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="110" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.4" sampleSize="111" mean="9.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="2.6" sampleSize="111" mean="9.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="2.3" sampleSize="110" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin mid-dose twice-perday"/>
               <continuousMeasurement stdDev="2.1" sampleSize="112" mean="9.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="41" name="female"/>
                  <category rate="70" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="54" name="female"/>
                  <category rate="57" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin mid-dose"/>
               <categoricalMeasurement>
                  <category rate="62" name="female"/>
                  <category rate="49" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="49" name="female"/>
                  <category rate="61" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="diet, exercise run-in">
               <duration>P42D</duration>
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P84D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Sitagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="Sitagliptin low-dose" epoch="Randomization"/>
               <usedBy arm="Sitagliptin mid-dose" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Sitagliptin high-dose" epoch="Screening"/>
               <usedBy arm="Sitagliptin low-dose" epoch="Screening"/>
               <usedBy arm="Sitagliptin mid-dose" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Sitagliptin high-dose" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin high-dose" epoch="diet, exercise run-in"/>
               <usedBy arm="Sitagliptin low-dose" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin low-dose" epoch="diet, exercise run-in"/>
               <usedBy arm="Sitagliptin mid-dose twice-perday" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin mid-dose twice-perday" epoch="diet, exercise run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="diet, exercise run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="25.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin mid">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin mid-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin mid twice/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin mid-dose twice-perday" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="hermansen07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA1c) &gt;7.5% and &lt;10.5%] while on glimepiride alone or in combination with metformin.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and women, &gt;18 and &lt;75 years of age, with type 2 diabetes were recruited for this study. Only the following patients were eligible to be screened: (i) already taking glimepiride alone (at any dose) or in combination with metformin (at any dose), (ii) taking anotherOHAin monotherapy or in dual- or triple-combination therapy or (iii) patients not taking any OHAs over the prior 8 weeks.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>At the screening visit, patients were excluded if they had a history of type 1 diabetes; were treated with insulin within 8 weeks of the screening visit; had renal dysfunction (creatinine clearance &lt;45 ml/min or &lt;60 ml/min if on metformin); or had a history of hypersensitivity, intolerance or a contraindication to the use of glimepiride, sulphonylurea agents, metformin or pioglitazone (which was included in this study as rescue therapy).</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17593236</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes>
                  <note source="MANUAL">SD not reported</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555
SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-fasting serum insuline end">
               <endpoint name="fasting serum insuline end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B end">
               <endpoint name="HOMA-B end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Who died">
               <adverseEvent name="Who died"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related SAE">
               <adverseEvent name="Discontinuation due to drug-related SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race2">
               <populationCharacteristic name="race2"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-prior use of OHAa">
               <populationCharacteristic name="prior use of OHAa"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="222" name="Sitagliptin">
               <notes/>
            </arm>
            <arm size="106" name="sitagliptin+glimepiride">
               <notes/>
            </arm>
            <arm size="116" name="sitagliptin+glimepiride+metformin">
               <notes/>
            </arm>
            <arm size="219" name="placebo">
               <notes/>
            </arm>
            <arm size="106" name="placebo+glimepiride">
               <notes/>
            </arm>
            <arm size="113" name="placebo+glimepiride+metformin">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.06" sampleSize="222" mean="-0.45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="sitagliptin+glimepiride"/>
               <continuousMeasurement stdDev="0.09" sampleSize="106" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <continuousMeasurement stdDev="0.08" sampleSize="116" mean="-0.59"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.06" sampleSize="219" mean="0.28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo+glimepiride"/>
               <continuousMeasurement stdDev="0.09" sampleSize="106" mean="0.27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo+glimepiride+metformin"/>
               <continuousMeasurement stdDev="0.08" sampleSize="113" mean="0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.0" sampleSize="222" mean="0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="sitagliptin+glimepiride"/>
               <continuousMeasurement stdDev="0.0" sampleSize="106" mean="1.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.16" sampleSize="222" mean="-0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="sitagliptin+glimepiride"/>
               <continuousMeasurement stdDev="0.25" sampleSize="106" mean="-0.04"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <continuousMeasurement stdDev="0.2" sampleSize="116" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.17" sampleSize="219" mean="0.87"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo+glimepiride"/>
               <continuousMeasurement stdDev="0.25" sampleSize="106" mean="1.02"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo+glimepiride+metformin"/>
               <continuousMeasurement stdDev="0.22" sampleSize="113" mean="0.72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insuline end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="12.9" sampleSize="222" mean="16.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insuline end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.1" sampleSize="219" mean="12.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="57.3" sampleSize="222" mean="61.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="55.2" sampleSize="219" mean="47.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="132"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="59"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="103"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="60"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="9.6" sampleSize="222" mean="55.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="sitagliptin+glimepiride"/>
               <continuousMeasurement stdDev="10.3" sampleSize="106" mean="54.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <continuousMeasurement stdDev="8.8" sampleSize="116" mean="56.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.6" sampleSize="219" mean="56.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo+glimepiride"/>
               <continuousMeasurement stdDev="10.2" sampleSize="106" mean="55.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo+glimepiride+metformin"/>
               <continuousMeasurement stdDev="8.9" sampleSize="113" mean="57.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="Sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="15" name="other"/>
                  <category rate="39" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="10" name="black"/>
                  <category rate="136" name="caucasian"/>
                  <category rate="22" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="sitagliptin+glimepiride"/>
               <categoricalMeasurement>
                  <category rate="6" name="other"/>
                  <category rate="26" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="7" name="black"/>
                  <category rate="61" name="caucasian"/>
                  <category rate="6" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <categoricalMeasurement>
                  <category rate="9" name="other"/>
                  <category rate="13" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="3" name="black"/>
                  <category rate="75" name="caucasian"/>
                  <category rate="16" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="10" name="other"/>
                  <category rate="32" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="12" name="black"/>
                  <category rate="140" name="caucasian"/>
                  <category rate="25" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="placebo+glimepiride"/>
               <categoricalMeasurement>
                  <category rate="7" name="other"/>
                  <category rate="25" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="3" name="black"/>
                  <category rate="59" name="caucasian"/>
                  <category rate="12" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="placebo+glimepiride+metformin"/>
               <categoricalMeasurement>
                  <category rate="3" name="other"/>
                  <category rate="7" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="9" name="black"/>
                  <category rate="81" name="caucasian"/>
                  <category rate="13" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="21.1" sampleSize="222" mean="86.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="sitagliptin+glimepiride"/>
               <continuousMeasurement stdDev="22.5" sampleSize="106" mean="85.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <continuousMeasurement stdDev="19.7" sampleSize="116" mean="87.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="21.8" sampleSize="219" mean="85.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo+glimepiride"/>
               <continuousMeasurement stdDev="22.6" sampleSize="106" mean="85.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo+glimepiride+metformin"/>
               <continuousMeasurement stdDev="21.1" sampleSize="113" mean="86.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="6.3" sampleSize="222" mean="31.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="sitagliptin+glimepiride"/>
               <continuousMeasurement stdDev="6.7" sampleSize="106" mean="31.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <continuousMeasurement stdDev="5.9" sampleSize="116" mean="31.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="6.3" sampleSize="219" mean="30.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo+glimepiride"/>
               <continuousMeasurement stdDev="6.4" sampleSize="106" mean="30.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo+glimepiride+metformin"/>
               <continuousMeasurement stdDev="6.2" sampleSize="113" mean="30.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="5.5" sampleSize="222" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="sitagliptin+glimepiride"/>
               <continuousMeasurement stdDev="5.0" sampleSize="106" mean="7.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <continuousMeasurement stdDev="5.7" sampleSize="116" mean="9.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="6.8" sampleSize="219" mean="9.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo+glimepiride"/>
               <continuousMeasurement stdDev="6.5" sampleSize="106" mean="8.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo+glimepiride+metformin"/>
               <continuousMeasurement stdDev="6.8" sampleSize="113" mean="10.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="222" rate="211"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="sitagliptin+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <rateMeasurement sampleSize="116" rate="116"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="219" rate="208"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="placebo+glimepiride"/>
               <rateMeasurement sampleSize="106" rate="98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-prior use of OHAa"/>
               <arm name="placebo+glimepiride+metformin"/>
               <rateMeasurement sampleSize="113" rate="110"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.76" sampleSize="222" mean="8.34"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="sitagliptin+glimepiride"/>
               <continuousMeasurement stdDev="0.79" sampleSize="106" mean="8.42"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <continuousMeasurement stdDev="0.73" sampleSize="116" mean="8.27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.74" sampleSize="219" mean="8.34"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo+glimepiride"/>
               <continuousMeasurement stdDev="0.8" sampleSize="106" mean="8.43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo+glimepiride+metformin"/>
               <continuousMeasurement stdDev="0.68" sampleSize="113" mean="8.26"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="2.1" sampleSize="222" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="sitagliptin+glimepiride"/>
               <continuousMeasurement stdDev="1.8" sampleSize="106" mean="10.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <continuousMeasurement stdDev="2.3" sampleSize="116" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.4" sampleSize="219" mean="10.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo+glimepiride"/>
               <continuousMeasurement stdDev="2.3" sampleSize="106" mean="10.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo+glimepiride+metformin"/>
               <continuousMeasurement stdDev="2.4" sampleSize="113" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="105" name="female"/>
                  <category rate="117" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="sitagliptin+glimepiride"/>
               <categoricalMeasurement>
                  <category rate="50" name="female"/>
                  <category rate="56" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="sitagliptin+glimepiride+metformin"/>
               <categoricalMeasurement>
                  <category rate="56" name="female"/>
                  <category rate="61" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="102" name="female"/>
                  <category rate="117" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo+glimepiride"/>
               <categoricalMeasurement>
                  <category rate="48" name="female"/>
                  <category rate="58" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo+glimepiride+metformin"/>
               <categoricalMeasurement>
                  <category rate="54" name="female"/>
                  <category rate="59" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="placebo+glimepiride" epoch="Randomization"/>
               <usedBy arm="placebo+glimepiride+metformin" epoch="Randomization"/>
               <usedBy arm="sitagliptin+glimepiride" epoch="Randomization"/>
               <usedBy arm="sitagliptin+glimepiride+metformin" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <usedBy arm="placebo+glimepiride" epoch="Screening"/>
               <usedBy arm="placebo+glimepiride+metformin" epoch="Screening"/>
               <usedBy arm="sitagliptin+glimepiride" epoch="Screening"/>
               <usedBy arm="sitagliptin+glimepiride+metformin" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <usedBy arm="placebo+glimepiride" epoch="Placebo run-in"/>
               <usedBy arm="placebo+glimepiride+metformin" epoch="Placebo run-in"/>
               <usedBy arm="sitagliptin+glimepiride" epoch="Placebo run-in"/>
               <usedBy arm="sitagliptin+glimepiride+metformin" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="sitagliptin+glimepiride">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="sitagliptin+glimepiride" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="sitagliptin+glimepiride+metformin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="sitagliptin+glimepiride+metformin" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo+glimepiride">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo+glimepiride" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo+glimepiride+metformin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo+glimepiride+metformin" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="kendall05">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with metforminsulfonylurea combination therapy.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>General inclusion criteria were a screening fasting plasma glucose concentration &lt;13.3 mmol/l, BMI 27–45 kg/m2, inclusive, and an A1C value of 7.5–11.0%. The metformin dose was&gt;1,500 mg/day, and the sulfonylurea dose was at least the maximally effective dose for 3 months before screening. In addition, subjects were weight stable (+-10%) for 3 months before screening and had no clinically relevant (for a type 2 diabetes population) abnormal laboratory test values (&gt;25% outside normal laboratory values). Female subjects were postmenopausal, surgically sterile, or using contraceptives for at least 3 months before screening and continuing throughout the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Subjects were excluded if they had evidence of other clinically significant medical conditions
or had used thiazolidinediones, meglitinides, a-glucosidase inhibitors, exogenous insulin, or weight loss drugs within the prior 3 months. Further exclusion criteria included therapy with
corticosteroids, drugs known to affect gastrointestinal motility, transplantation
medications, or any investigational drug.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>15855571</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Feeling jittery">
               <adverseEvent name="Feeling jittery"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race1">
               <populationCharacteristic name="race1"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="247" name="placebo">
               <notes/>
            </arm>
            <arm size="245" name="exenatide low-dose">
               <notes/>
            </arm>
            <arm size="241" name="exenatide high-dose">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.1" sampleSize="247" mean="0.23"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="1.1" sampleSize="245" mean="-0.55"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="1.24" sampleSize="241" mean="-0.77"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.14" sampleSize="247" mean="-0.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="3.13" sampleSize="245" mean="-1.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="3.1" sampleSize="241" mean="-1.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.14" sampleSize="247" mean="0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="3.13" sampleSize="245" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="3.1" sampleSize="241" mean="-0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="247" rate="51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="245" rate="96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="241" rate="117"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="247" rate="31"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="245" rate="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="241" rate="67"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="247" rate="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="245" rate="28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="241" rate="42"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="247" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="245" rate="36"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="241" rate="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="247" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="245" rate="25"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="241" rate="42"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Feeling jittery"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="247" rate="17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Feeling jittery"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="245" rate="21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Feeling jittery"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="241" rate="28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="247" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="245" rate="27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="241" rate="18"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="247" rate="114"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race1"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="4" name="other"/>
                  <category rate="30" name="black"/>
                  <category rate="39" name="hispanic"/>
                  <category rate="169" name="caucasian"/>
                  <category rate="4" name="asian"/>
                  <category rate="1" name="native american"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race1"/>
               <arm name="exenatide low-dose"/>
               <categoricalMeasurement>
                  <category rate="5" name="other"/>
                  <category rate="25" name="black"/>
                  <category rate="39" name="hispanic"/>
                  <category rate="169" name="caucasian"/>
                  <category rate="7" name="asian"/>
                  <category rate="0" name="native american"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race1"/>
               <arm name="exenatide high-dose"/>
               <categoricalMeasurement>
                  <category rate="4" name="other"/>
                  <category rate="28" name="black"/>
                  <category rate="40" name="hispanic"/>
                  <category rate="160" name="caucasian"/>
                  <category rate="7" name="asian"/>
                  <category rate="2" name="native american"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="10.0" sampleSize="247" mean="56.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="9.0" sampleSize="245" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="10.0" sampleSize="241" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="19.0" sampleSize="247" mean="99.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="19.0" sampleSize="245" mean="97.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="21.0" sampleSize="241" mean="98.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.0" sampleSize="247" mean="34.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="6.0" sampleSize="245" mean="33.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="6.0" sampleSize="241" mean="34.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.0" sampleSize="247" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="1.0" sampleSize="245" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="1.1" sampleSize="241" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.7" sampleSize="247" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="2.9" sampleSize="245" mean="10.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="241" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="6.2" sampleSize="247" mean="9.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="5.9" sampleSize="245" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="6.4" sampleSize="241" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="109" name="female"/>
                  <category rate="138" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide low-dose"/>
               <categoricalMeasurement>
                  <category rate="100" name="female"/>
                  <category rate="145" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide high-dose"/>
               <categoricalMeasurement>
                  <category rate="98" name="female"/>
                  <category rate="143" name="male"/>
               </categoricalMeasurement>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P28D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P210D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Randomization"/>
               <usedBy arm="exenatide low-dose" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Screening"/>
               <usedBy arm="exenatide low-dose" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Placebo run-in"/>
               <usedBy arm="exenatide low-dose" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.005"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.01"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="kikuchi09">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To assess the efficacy and tolerability of vildagliptin (10, 25 or 50 mg bid) in
Japanese patients with type 2 diabetes mellitus (T2DM).</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Male and female outpatients (aged 20–75 years) with a BMI of 20–35 kg/m2, HbA1c values of 6.5–10.0% and fasting plasma glucose (FPG) &lt; 270 mg/dL were eligible to participate in the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients with any of the following laboratory abnormalities were also excluded: alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin greater than two times the upper limit of normal (ULN), serum creatinine levels &gt;2.0 mg/dL, clinically significant abnormal thyroid stimulating hormone (TSH) levels or fasting triglycerides
(TG) &gt;700 mg/dL.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>19118913</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="false" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Blood CPK increased">
               <adverseEvent name="Blood CPK increased"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Blood CPK-MB increased">
               <adverseEvent name="Blood CPK-MB increased"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Seasonal allergy">
               <adverseEvent name="Seasonal allergy"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-r-Glutamyl transferase increased">
               <adverseEvent name="r-Glutamyl transferase increased"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract inflammation">
               <adverseEvent name="Upper respiratory tract inflammation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pruritus ">
               <adverseEvent name="Pruritus "/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="71" name="vildagliptin low-dose">
               <notes/>
            </arm>
            <arm size="72" name="vildagliptin mid-dose">
               <notes/>
            </arm>
            <arm size="76" name="vildagliptin high-dose">
               <notes/>
            </arm>
            <arm size="72" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.84" sampleSize="71" mean="6.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.85" sampleSize="72" mean="6.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.87" sampleSize="76" mean="6.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.85" sampleSize="72" mean="7.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.59" sampleSize="71" mean="-0.53"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.6" sampleSize="72" mean="-0.67"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.61" sampleSize="76" mean="-0.92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.6" sampleSize="72" mean="0.28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="1.5" sampleSize="71" mean="-0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="1.3" sampleSize="72" mean="0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="1.4" sampleSize="76" mean="0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.1" sampleSize="72" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="44"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="47"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="53"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="18"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood CPK increased"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood CPK increased"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood CPK increased"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood CPK increased"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood CPK-MB increased"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood CPK-MB increased"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood CPK-MB increased"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood CPK-MB increased"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Seasonal allergy"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Seasonal allergy"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Seasonal allergy"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Seasonal allergy"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-r-Glutamyl transferase increased"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-r-Glutamyl transferase increased"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-r-Glutamyl transferase increased"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-r-Glutamyl transferase increased"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract inflammation"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract inflammation"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract inflammation"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract inflammation"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pruritus "/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pruritus "/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pruritus "/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pruritus "/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="72" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="76" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="72" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="71" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="8.6" sampleSize="71" mean="58.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="8.5" sampleSize="72" mean="57.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="8.6" sampleSize="76" mean="58.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="8.1" sampleSize="72" mean="60.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="19" name="female"/>
                  <category rate="52" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin mid-dose"/>
               <categoricalMeasurement>
                  <category rate="26" name="female"/>
                  <category rate="46" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="25" name="female"/>
                  <category rate="51" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="26" name="female"/>
                  <category rate="46" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="10.4" sampleSize="71" mean="64.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="9.7" sampleSize="72" mean="63.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="9.3" sampleSize="76" mean="62.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="10.1" sampleSize="72" mean="63.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="2.7" sampleSize="71" mean="24.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="2.5" sampleSize="72" mean="24.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.8" sampleSize="76" mean="24.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.1" sampleSize="72" mean="24.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.8" sampleSize="71" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="72" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.8" sampleSize="76" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.8" sampleSize="72" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="1.9" sampleSize="71" mean="8.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="1.8" sampleSize="72" mean="9.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="1.8" sampleSize="76" mean="8.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.7" sampleSize="72" mean="9.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="4.2" sampleSize="71" mean="4.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.0" sampleSize="72" mean="4.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="4.3" sampleSize="76" mean="4.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.5" sampleSize="72" mean="7.1"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P84D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="vildagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin mid-dose" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <usedBy arm="vildagliptin high-dose" epoch="Placebo run-in"/>
               <usedBy arm="vildagliptin low-dose" epoch="Placebo run-in"/>
               <usedBy arm="vildagliptin mid-dose" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="10.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin mid">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="25.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin mid-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="madsbad04">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>Liraglutide is a long-acting glucagon-like peptide 1 analog designed for once daily injection. This study assessed the efficacy and safety of liraglutide after 12 weeks of treatment in type 2 diabetic patients.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Eligible patients were men and women age &gt;30 years who had a type 2 diabetes diagnosis (according to American Diabetes Association criteria) (20), had BMI &lt;40 kg/m2, were being treated with diet or an OHA, and had an HbA1c&lt; 9.5% (OHA) or 7.5–10.0% (diet). For patient safety, an upper limit for HbA1c was defined as a 4-week wash-out period and
a placebo arm was included in the trial.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if any of the following were present: liver or renal disease, heart failure (New York Heart Association class III and IV) (21), unstable angina pectoris, myocardial infarction within the previous 12 months, concomitant treatment with thiazolidinediones or other investigational drugs, or other significant conditions likely to affect a patient’s diabetes and/or ability to complete the trial. Women who were pregnant, breast-feeding, or not using an adequate method of contraception were also excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>15161785</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes>
                  <note source="MANUAL">SD is not reported</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Fructosamine">
               <populationCharacteristic name="Fructosamine"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FSG bas">
               <populationCharacteristic name="FSG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-C-peptide">
               <populationCharacteristic name="C-peptide"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Insulin">
               <populationCharacteristic name="Insulin"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Glucagon">
               <populationCharacteristic name="Glucagon"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-B-cell function index bas">
               <populationCharacteristic name="B-cell function index bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="29" name="placebo">
               <notes/>
            </arm>
            <arm size="26" name="liraglutide 45ug/day">
               <notes/>
            </arm>
            <arm size="25" name="liraglutide 225ug/day">
               <notes/>
            </arm>
            <arm size="27" name="liraglutide 450ug/day">
               <notes/>
            </arm>
            <arm size="30" name="liraglutide 600ug/day">
               <notes/>
            </arm>
            <arm size="29" name="liraglutide 750ug/day">
               <notes/>
            </arm>
            <arm size="27" name="glimepiride">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="29" mean="7.31"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="0.0" sampleSize="26" mean="7.91"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="0.0" sampleSize="25" mean="7.51"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="0.0" sampleSize="27" mean="7.31"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="0.0" sampleSize="30" mean="6.81"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="0.0" sampleSize="29" mean="6.81"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="0.0" sampleSize="27" mean="7.21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="29" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.4" sampleSize="29" mean="57.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="9.0" sampleSize="26" mean="53.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="7.5" sampleSize="25" mean="58.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="11.3" sampleSize="27" mean="57.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="7.7" sampleSize="30" mean="57.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="9.7" sampleSize="29" mean="58.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="9.2" sampleSize="27" mean="57.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="9" name="female"/>
                  <category rate="20" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide 45ug/day"/>
               <categoricalMeasurement>
                  <category rate="4" name="female"/>
                  <category rate="22" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide 225ug/day"/>
               <categoricalMeasurement>
                  <category rate="9" name="female"/>
                  <category rate="15" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide 450ug/day"/>
               <categoricalMeasurement>
                  <category rate="9" name="female"/>
                  <category rate="18" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide 600ug/day"/>
               <categoricalMeasurement>
                  <category rate="10" name="female"/>
                  <category rate="20" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide 750ug/day"/>
               <categoricalMeasurement>
                  <category rate="12" name="female"/>
                  <category rate="16" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="glimepiride"/>
               <categoricalMeasurement>
                  <category rate="10" name="female"/>
                  <category rate="16" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.2" sampleSize="29" mean="30.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="5.4" sampleSize="26" mean="30.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="5.3" sampleSize="25" mean="32.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="5.0" sampleSize="27" mean="30.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="4.8" sampleSize="30" mean="30.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="4.3" sampleSize="29" mean="31.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="4.6" sampleSize="27" mean="30.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.9" sampleSize="29" mean="3.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="3.7" sampleSize="26" mean="4.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="4.0" sampleSize="25" mean="4.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="4.6" sampleSize="27" mean="4.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="4.6" sampleSize="30" mean="4.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="7.9" sampleSize="29" mean="6.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="3.4" sampleSize="27" mean="3.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.2" sampleSize="29" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="0.8" sampleSize="26" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="0.8" sampleSize="25" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="1.0" sampleSize="27" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="1.2" sampleSize="30" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="0.9" sampleSize="29" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="0.9" sampleSize="27" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Fructosamine"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="72.5" sampleSize="29" mean="335.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Fructosamine"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="77.9" sampleSize="26" mean="344.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Fructosamine"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="57.7" sampleSize="25" mean="358.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Fructosamine"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="104.9" sampleSize="27" mean="374.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Fructosamine"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="74.2" sampleSize="30" mean="352.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Fructosamine"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="73.7" sampleSize="29" mean="344.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Fructosamine"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="69.5" sampleSize="27" mean="364.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FSG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.9" sampleSize="29" mean="9.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FSG bas"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="2.2" sampleSize="26" mean="10.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FSG bas"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="3.6" sampleSize="25" mean="10.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FSG bas"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="2.8" sampleSize="27" mean="11.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FSG bas"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="2.8" sampleSize="30" mean="10.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FSG bas"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="2.3" sampleSize="29" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FSG bas"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="2.4" sampleSize="27" mean="10.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-C-peptide"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.4" sampleSize="29" mean="1.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-C-peptide"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="0.5" sampleSize="26" mean="1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-C-peptide"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="0.5" sampleSize="25" mean="1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-C-peptide"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="0.5" sampleSize="27" mean="1.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-C-peptide"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="0.6" sampleSize="30" mean="1.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-C-peptide"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="0.4" sampleSize="29" mean="1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-C-peptide"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="0.5" sampleSize="27" mean="0.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Insulin"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="43.6" sampleSize="29" mean="84.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Insulin"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="40.1" sampleSize="26" mean="74.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Insulin"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="73.0" sampleSize="25" mean="81.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Insulin"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="51.0" sampleSize="27" mean="73.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Insulin"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="55.3" sampleSize="30" mean="72.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Insulin"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="42.0" sampleSize="29" mean="71.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Insulin"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="40.4" sampleSize="27" mean="64.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Glucagon"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="37.7" sampleSize="29" mean="110.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Glucagon"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="47.6" sampleSize="26" mean="111.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Glucagon"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="140.0" sampleSize="25" mean="131.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Glucagon"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="33.0" sampleSize="27" mean="110.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Glucagon"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="31.1" sampleSize="30" mean="99.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Glucagon"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="23.4" sampleSize="29" mean="91.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Glucagon"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="23.6" sampleSize="27" mean="101.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="26.3" sampleSize="29" mean="44.06"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="liraglutide 45ug/day"/>
               <continuousMeasurement stdDev="23.1" sampleSize="26" mean="34.65"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="liraglutide 225ug/day"/>
               <continuousMeasurement stdDev="22.6" sampleSize="25" mean="31.83"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="liraglutide 450ug/day"/>
               <continuousMeasurement stdDev="31.7" sampleSize="27" mean="31.95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="liraglutide 600ug/day"/>
               <continuousMeasurement stdDev="37.3" sampleSize="30" mean="34.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="liraglutide 750ug/day"/>
               <continuousMeasurement stdDev="21.7" sampleSize="29" mean="33.75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-B-cell function index bas"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="18.2" sampleSize="27" mean="26.78"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Washout">
               <duration>P28D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P84D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="glimepiride" epoch="Randomization"/>
               <usedBy arm="liraglutide 225ug/day" epoch="Randomization"/>
               <usedBy arm="liraglutide 450ug/day" epoch="Randomization"/>
               <usedBy arm="liraglutide 45ug/day" epoch="Randomization"/>
               <usedBy arm="liraglutide 600ug/day" epoch="Randomization"/>
               <usedBy arm="liraglutide 750ug/day" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="glimepiride" epoch="Screening"/>
               <usedBy arm="liraglutide 225ug/day" epoch="Screening"/>
               <usedBy arm="liraglutide 450ug/day" epoch="Screening"/>
               <usedBy arm="liraglutide 45ug/day" epoch="Screening"/>
               <usedBy arm="liraglutide 600ug/day" epoch="Screening"/>
               <usedBy arm="liraglutide 750ug/day" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="glimepiride" epoch="Washout"/>
               <usedBy arm="liraglutide 225ug/day" epoch="Washout"/>
               <usedBy arm="liraglutide 450ug/day" epoch="Washout"/>
               <usedBy arm="liraglutide 45ug/day" epoch="Washout"/>
               <usedBy arm="liraglutide 600ug/day" epoch="Washout"/>
               <usedBy arm="liraglutide 750ug/day" epoch="Washout"/>
               <usedBy arm="placebo" epoch="Washout"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 45ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.045"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide 45ug/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 225ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.225"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide 225ug/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 450ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.45"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide 450ug/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 600ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.6"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide 600ug/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 750ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.75"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide 750ug/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="glimepiride">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="glimepiride" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="marre09">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with
Type 2 diabetes (LEAD-1 SU)</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>116</value>
               <notes/>
            </centers>
            <objective>
               <value>To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥ 228) or placebo ( n = 114) with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>T2D treated with oral glucose-lowering agents (OGLAs) for ≥ 3 months; 18–80 years of age; HbA1c 7.0–11.0% (previous OGLA monotherapy) or 7.0–10.0% (previous OGLA combination therapy); body mass index (BMI) ≤ 45.0 kg/m.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>used insulin within 3 months, impaired liver or renal function, uncontrolled hypertension ( ≥ 180/100 mmHg), cancer or used any drugs apart from OGLAs likely to affect glucose concentrations. </value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>19317822</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="false" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B end">
               <endpoint name="HOMA-B end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-systolic blood pressure">
               <populationCharacteristic name="systolic blood pressure"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HOMA-B bas">
               <populationCharacteristic name="HOMA-B bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="233" name="liraglutide low-dose">
               <notes/>
            </arm>
            <arm size="228" name="liraglutide mid-dose">
               <notes/>
            </arm>
            <arm size="234" name="liraglutide high-dose">
               <notes/>
            </arm>
            <arm size="114" name="placebo">
               <notes/>
            </arm>
            <arm size="232" name="rosiglitazone">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="2.16" sampleSize="208" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="2.24" sampleSize="196" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="2.34" sampleSize="213" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.19" sampleSize="83" mean="8.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="0.0" sampleSize="194" mean="8.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="2.16" sampleSize="208" mean="-0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="1.54" sampleSize="196" mean="-1.08"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="2.48" sampleSize="213" mean="-1.13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.46" sampleSize="83" mean="0.23"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="0.0" sampleSize="194" mean="-0.44"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="5.8" sampleSize="208" mean="0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="4.2" sampleSize="196" mean="0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="5.84" sampleSize="213" mean="-0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.56" sampleSize="83" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="88.6" sampleSize="208" mean="70.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="184.3" sampleSize="196" mean="99.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="108.2" sampleSize="213" mean="91.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="107.3" sampleSize="83" mean="52.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="63.3" sampleSize="194" mean="59.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="liraglutide low-dose"/>
               <rateMeasurement sampleSize="233" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="liraglutide mid-dose"/>
               <rateMeasurement sampleSize="228" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="liraglutide high-dose"/>
               <rateMeasurement sampleSize="234" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="114" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="rosiglitazone"/>
               <rateMeasurement sampleSize="232" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="liraglutide low-dose"/>
               <rateMeasurement sampleSize="233" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="liraglutide mid-dose"/>
               <rateMeasurement sampleSize="228" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="liraglutide high-dose"/>
               <rateMeasurement sampleSize="234" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="114" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="rosiglitazone"/>
               <rateMeasurement sampleSize="232" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide low-dose"/>
               <categoricalMeasurement>
                  <category rate="107" name="female"/>
                  <category rate="126" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide mid-dose"/>
               <categoricalMeasurement>
                  <category rate="125" name="female"/>
                  <category rate="103" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide high-dose"/>
               <categoricalMeasurement>
                  <category rate="110" name="female"/>
                  <category rate="124" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="60" name="female"/>
                  <category rate="54" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="rosiglitazone"/>
               <categoricalMeasurement>
                  <category rate="123" name="female"/>
                  <category rate="109" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="9.9" sampleSize="233" mean="55.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="9.0" sampleSize="228" mean="57.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="10.0" sampleSize="234" mean="55.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="10.0" sampleSize="114" mean="54.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="9.8" sampleSize="232" mean="56.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="1.58" sampleSize="233" mean="6.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="1.7" sampleSize="228" mean="6.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="1.7" sampleSize="234" mean="6.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.56" sampleSize="114" mean="6.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="1.63" sampleSize="232" mean="6.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="233" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="2.7" sampleSize="228" mean="9.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="234" mean="9.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.0" sampleSize="114" mean="9.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="2.5" sampleSize="232" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="1.0" sampleSize="233" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="1.1" sampleSize="228" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="234" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.0" sampleSize="114" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="1.0" sampleSize="232" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="5.0" sampleSize="233" mean="30.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="5.1" sampleSize="228" mean="29.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="5.1" sampleSize="234" mean="30.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.4" sampleSize="114" mean="30.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="4.8" sampleSize="232" mean="29.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="16.0" sampleSize="233" mean="131.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="15.0" sampleSize="228" mean="133.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="16.0" sampleSize="234" mean="132.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="15.3" sampleSize="114" mean="131.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="15.0" sampleSize="232" mean="133.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HOMA-B bas"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="43.3" sampleSize="233" mean="51.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HOMA-B bas"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="254.3" sampleSize="228" mean="71.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HOMA-B bas"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="84.6" sampleSize="234" mean="56.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HOMA-B bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="103.3" sampleSize="114" mean="56.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HOMA-B bas"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="36.2" sampleSize="232" mean="46.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="17.7" sampleSize="233" mean="82.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="17.1" sampleSize="228" mean="80.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="18.1" sampleSize="234" mean="83.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="17.1" sampleSize="114" mean="81.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="rosiglitazone"/>
               <continuousMeasurement stdDev="17.0" sampleSize="232" mean="80.6"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Forced glimepiride titration">
               <duration>P28D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P182D</duration>
               <notes/>
            </epoch>
            <epoch name="Follow-up">
               <duration>P7D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="liraglutide high-dose" epoch="Randomization"/>
               <usedBy arm="liraglutide low-dose" epoch="Randomization"/>
               <usedBy arm="liraglutide mid-dose" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="rosiglitazone" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="rosiglitazone">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="4.0"/>
                        <drug name="rosiglitazone"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="rosiglitazone" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="liraglutide high-dose" epoch="Screening"/>
               <usedBy arm="liraglutide low-dose" epoch="Screening"/>
               <usedBy arm="liraglutide mid-dose" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <usedBy arm="rosiglitazone" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Follow up">
               <activity>
                  <predefined>FOLLOW_UP</predefined>
               </activity>
               <usedBy arm="liraglutide high-dose" epoch="Follow-up"/>
               <usedBy arm="liraglutide low-dose" epoch="Follow-up"/>
               <usedBy arm="liraglutide mid-dose" epoch="Follow-up"/>
               <usedBy arm="placebo" epoch="Follow-up"/>
               <usedBy arm="rosiglitazone" epoch="Follow-up"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 600ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.6"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 1200ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1.2"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide mid-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 1800ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1.8"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="liraglutide high-dose" epoch="Forced glimepiride titration"/>
               <usedBy arm="liraglutide low-dose" epoch="Forced glimepiride titration"/>
               <usedBy arm="liraglutide mid-dose" epoch="Forced glimepiride titration"/>
               <usedBy arm="placebo" epoch="Forced glimepiride titration"/>
               <usedBy arm="rosiglitazone" epoch="Forced glimepiride titration"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="mimori06">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>vildagliptin improves glucose control as evidenced by A1c therapy after 12 weeks therapy in Japanese patients with type 2 diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To assess the efficacy and tolerability of vildagliptin</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <notes/>
            </inclusion>
            <exclusion>
               <notes/>
            </exclusion>
            <references/>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="0" name="vildagliptin low-dose">
               <notes/>
            </arm>
            <arm size="0" name="vildagliptin mid-dose">
               <notes/>
            </arm>
            <arm size="0" name="vildagliptin high-dose">
               <notes/>
            </arm>
            <arm size="0" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.07" sampleSize="0" mean="0.53"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.07" sampleSize="0" mean="0.67"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.07" sampleSize="0" mean="0.92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.07" sampleSize="0" mean="0.28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="0" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.8" sampleSize="0" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="0" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.8" sampleSize="0" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.7" sampleSize="0" mean="7.4"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="vildagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin mid-dose" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="10.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin mid">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="25.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin mid-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="mohan09">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To evaluate the efficacy and safety of sitagliptin as monotherapy in Chinese, Indian and Korean patients with T2DM inadequately controlled by diet and exercise.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Eligible patients were at least 18 years of age and had been diagnosed with type 2 diabeteswithin the past 5 years.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients who had received a peroxisome proliferator-activated receptorg (PPARg) agonist (e.g., pioglitazone or rosiglitazone) or insulin within the prior 12 weeks, or who were pregnant or breastfeeding, were excluded. Patients with type 1 diabetes, unstable cardiac disease, or moderate to severe renal insufficiency were also excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>19097665</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-2-h PPG end">
               <endpoint name="2-h PPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related SAE">
               <adverseEvent name="Discontinuation due to drug-related SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Who died">
               <adverseEvent name="Who died"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Nationality">
               <populationCharacteristic name="Nationality"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="178" name="placebo">
               <notes/>
            </arm>
            <arm size="352" name="Sitagliptin">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.6" sampleSize="178" mean="9.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="1.3" sampleSize="352" mean="8.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.1" sampleSize="169" mean="0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.05" sampleSize="339" mean="-0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.2" sampleSize="133" mean="0.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.1" sampleSize="306" mean="0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.0" sampleSize="169" mean="10.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="2.4" sampleSize="339" mean="9.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.2" sampleSize="131" mean="15.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="3.8" sampleSize="297" mean="12.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="82"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="18"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="352" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.3" sampleSize="178" mean="50.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="9.3" sampleSize="352" mean="50.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="72" name="female"/>
                  <category rate="106" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="152" name="female"/>
                  <category rate="200" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Nationality"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="33" name="Korean"/>
                  <category rate="63" name="Indian"/>
                  <category rate="82" name="Chinese"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Nationality"/>
               <arm name="Sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="62" name="Korean"/>
                  <category rate="127" name="Indian"/>
                  <category rate="163" name="Chinese"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="11.4" sampleSize="178" mean="66.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="10.2" sampleSize="352" mean="66.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.4" sampleSize="178" mean="24.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="3.4" sampleSize="352" mean="25.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.6" sampleSize="178" mean="1.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="1.7" sampleSize="352" mean="2.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.1" sampleSize="178" mean="8.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="1.0" sampleSize="352" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.6" sampleSize="178" mean="10.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="2.4" sampleSize="352" mean="10.5"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Diet,exercise run-in">
               <duration>P42D</duration>
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P126D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Diet,exercise run-in"/>
               <usedBy arm="Sitagliptin" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Diet,exercise run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="moretto08">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and Tolerability of Exenatide Monotherapy Over 24 Weeks in Antidiabetic Drug-Naive Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>23</value>
               <notes/>
            </centers>
            <objective>
               <value>The aim of this study was to evaluate the efficacy and tolerability of exenatide monotherapy
in patients with type 2 diabetes naive to antidiabetic agents and whose disease was inadequately controlled with diet and exercise alone.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients were eligible for this study if they were &gt;18 years of age, had type 2 diabetes, and had a body mass index of 25 to 45 kg/m 2 (inclusive). Patients were required to have been managing their type 2 diabetes with diet and exercise consistent with the local standards of medical care, in the opinion of the investigator, but were required to have suboptimal glycemic control, as evidenced by an HbAI~ value at screening of between 6.5% and 10.0% (inclusive) despite treatment with diet and exercise.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if: they had ever been treated with an antidiabetic agent; had blood pressure &gt;160/&gt;110 mm Hg; had a history or presence of clinically significant cardiac disease within the year prior to inclusion in the study; had a history of renal transplant or active renal or hepatic disease; or had received any medication for weight loss within 12 weeks prior to screening. Female patients were eligible if they were postmenopausal or surgically sterile or had been using contraceptives for &gt;12 weeks before screening and continuing throughout the study.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>18803987</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Influenza">
               <adverseEvent name="Influenza"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Back pain">
               <adverseEvent name="Back pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Neck pain">
               <adverseEvent name="Neck pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pain">
               <adverseEvent name="Pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pain in extremity">
               <adverseEvent name="Pain in extremity"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race3">
               <populationCharacteristic name="race3"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-systolic blood pressure">
               <populationCharacteristic name="systolic blood pressure"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-diagstolic blood pressure bas">
               <populationCharacteristic name="diagstolic blood pressure bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="77" name="exenatide low-dose">
               <notes/>
            </arm>
            <arm size="78" name="exenatide high-dose">
               <notes/>
            </arm>
            <arm size="78" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="0.87" sampleSize="77" mean="-0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="0.88" sampleSize="78" mean="-0.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.87" sampleSize="77" mean="-0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="2.63" sampleSize="77" mean="-2.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="2.65" sampleSize="78" mean="-3.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.63" sampleSize="77" mean="-1.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Neck pain"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Neck pain"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Neck pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="exenatide high-dose"/>
               <rateMeasurement sampleSize="78" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="77" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="exenatide low-dose"/>
               <rateMeasurement sampleSize="77" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="10.0" sampleSize="77" mean="54.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="10.0" sampleSize="78" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.0" sampleSize="77" mean="53.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide low-dose"/>
               <categoricalMeasurement>
                  <category rate="37" name="female"/>
                  <category rate="40" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide high-dose"/>
               <categoricalMeasurement>
                  <category rate="30" name="female"/>
                  <category rate="48" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="35" name="female"/>
                  <category rate="42" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race3"/>
               <arm name="exenatide low-dose"/>
               <categoricalMeasurement>
                  <category rate="0" name="other"/>
                  <category rate="65" name="white"/>
                  <category rate="6" name="hispanic"/>
                  <category rate="0" name="black"/>
                  <category rate="29" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race3"/>
               <arm name="exenatide high-dose"/>
               <categoricalMeasurement>
                  <category rate="0" name="other"/>
                  <category rate="72" name="white"/>
                  <category rate="1" name="hispanic"/>
                  <category rate="4" name="black"/>
                  <category rate="23" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race3"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="0" name="other"/>
                  <category rate="66" name="white"/>
                  <category rate="3" name="hispanic"/>
                  <category rate="4" name="black"/>
                  <category rate="27" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="3.0" sampleSize="77" mean="2.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="3.0" sampleSize="78" mean="2.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.0" sampleSize="77" mean="1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="1.0" sampleSize="77" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="1.0" sampleSize="78" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.9" sampleSize="77" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="2.7" sampleSize="77" mean="9.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="2.2" sampleSize="78" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.6" sampleSize="77" mean="8.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="15.0" sampleSize="77" mean="85.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="16.0" sampleSize="78" mean="86.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="16.0" sampleSize="77" mean="86.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="5.0" sampleSize="77" mean="32.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="5.0" sampleSize="78" mean="31.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.0" sampleSize="77" mean="32.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="11.0" sampleSize="77" mean="129.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="12.0" sampleSize="78" mean="130.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="12.0" sampleSize="77" mean="129.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="exenatide low-dose"/>
               <continuousMeasurement stdDev="8.0" sampleSize="77" mean="78.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="exenatide high-dose"/>
               <continuousMeasurement stdDev="8.0" sampleSize="78" mean="79.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="7.0" sampleSize="77" mean="78.0"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase ">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Randomization"/>
               <usedBy arm="exenatide low-dose" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Screening"/>
               <usedBy arm="exenatide low-dose" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Placebo run-in"/>
               <usedBy arm="exenatide low-dose" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase "/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.005"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide low-dose" epoch="Main phase "/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.01"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide high-dose" epoch="Main phase "/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="nauck09">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>170</value>
               <notes/>
            </centers>
            <objective>
               <value>The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Adult subjects with type 2 diabetes were screened and enrolled if they were 18–80 years of age, had A1C between 7 and 11% (prestudy OADmonotherapy for&gt;3 months) or between
7 and 10% (prestudy combination OAD therapy for &gt;3 months), and had BMI &lt;40 kg/m2.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Subjects were excluded if they had used insulin during the previous 3 months (except short-term treatment).</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>18931095</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-one or more AE">
               <adverseEvent name="one or more AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race2">
               <populationCharacteristic name="race2"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-systolic blood pressure">
               <populationCharacteristic name="systolic blood pressure"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-diagstolic blood pressure bas">
               <populationCharacteristic name="diagstolic blood pressure bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="242" name="liraglutide low-dose">
               <notes/>
            </arm>
            <arm size="241" name="liraglutide mid-dose">
               <notes/>
            </arm>
            <arm size="242" name="liraglutide high-dose">
               <notes/>
            </arm>
            <arm size="244" name="glimepiride">
               <notes/>
            </arm>
            <arm size="122" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="0.1" sampleSize="208" mean="-0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="0.1" sampleSize="197" mean="-1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="0.1" sampleSize="191" mean="-1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="0.1" sampleSize="210" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.1" sampleSize="74" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="2.5" sampleSize="208" mean="9.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="2.6" sampleSize="197" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="191" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="2.5" sampleSize="210" mean="8.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.2" sampleSize="74" mean="10.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="0.2" sampleSize="208" mean="-1.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="0.2" sampleSize="197" mean="-2.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="0.2" sampleSize="191" mean="-2.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="0.2" sampleSize="210" mean="1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.3" sampleSize="74" mean="1.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-one or more AE"/>
               <arm name="liraglutide low-dose"/>
               <rateMeasurement sampleSize="242" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-one or more AE"/>
               <arm name="liraglutide mid-dose"/>
               <rateMeasurement sampleSize="241" rate="23"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-one or more AE"/>
               <arm name="liraglutide high-dose"/>
               <rateMeasurement sampleSize="242" rate="29"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-one or more AE"/>
               <arm name="glimepiride"/>
               <rateMeasurement sampleSize="244" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-one or more AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="liraglutide low-dose"/>
               <rateMeasurement sampleSize="242" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="liraglutide mid-dose"/>
               <rateMeasurement sampleSize="241" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="liraglutide high-dose"/>
               <rateMeasurement sampleSize="242" rate="20"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="glimepiride"/>
               <rateMeasurement sampleSize="244" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="liraglutide low-dose"/>
               <rateMeasurement sampleSize="242" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="liraglutide mid-dose"/>
               <rateMeasurement sampleSize="241" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="liraglutide high-dose"/>
               <rateMeasurement sampleSize="242" rate="20"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="glimepiride"/>
               <rateMeasurement sampleSize="244" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="liraglutide low-dose"/>
               <rateMeasurement sampleSize="242" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="liraglutide mid-dose"/>
               <rateMeasurement sampleSize="241" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="liraglutide high-dose"/>
               <rateMeasurement sampleSize="242" rate="20"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="glimepiride"/>
               <rateMeasurement sampleSize="244" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="122" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="liraglutide low-dose"/>
               <rateMeasurement sampleSize="242" rate="21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide low-dose"/>
               <categoricalMeasurement>
                  <category rate="92" name="female"/>
                  <category rate="150" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide mid-dose"/>
               <categoricalMeasurement>
                  <category rate="111" name="female"/>
                  <category rate="130" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="liraglutide high-dose"/>
               <categoricalMeasurement>
                  <category rate="99" name="female"/>
                  <category rate="143" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="glimepiride"/>
               <categoricalMeasurement>
                  <category rate="105" name="female"/>
                  <category rate="139" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="49" name="female"/>
                  <category rate="73" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="11.0" sampleSize="242" mean="56.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="9.0" sampleSize="241" mean="57.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="9.0" sampleSize="242" mean="57.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="9.0" sampleSize="244" mean="57.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.0" sampleSize="122" mean="56.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="liraglutide low-dose"/>
               <categoricalMeasurement>
                  <category rate="2" name="other"/>
                  <category rate="0" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="2" name="black"/>
                  <category rate="13" name="asian"/>
                  <category rate="84" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="liraglutide mid-dose"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="0" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="4" name="black"/>
                  <category rate="8" name="asian"/>
                  <category rate="88" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="liraglutide high-dose"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="0" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="2" name="black"/>
                  <category rate="9" name="asian"/>
                  <category rate="89" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="glimepiride"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="0" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="2" name="black"/>
                  <category rate="9" name="asian"/>
                  <category rate="89" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="3" name="other"/>
                  <category rate="0" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="3" name="black"/>
                  <category rate="7" name="asian"/>
                  <category rate="88" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="4.8" sampleSize="242" mean="30.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="4.8" sampleSize="241" mean="31.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="4.6" sampleSize="242" mean="31.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="4.6" sampleSize="244" mean="31.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.4" sampleSize="122" mean="31.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="5.0" sampleSize="242" mean="7.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="5.0" sampleSize="241" mean="7.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="5.0" sampleSize="242" mean="8.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="5.0" sampleSize="244" mean="8.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="6.0" sampleSize="122" mean="8.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="242" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="1.0" sampleSize="241" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="1.0" sampleSize="242" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="1.0" sampleSize="244" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.1" sampleSize="122" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="242" mean="10.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="2.3" sampleSize="241" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="2.6" sampleSize="242" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="2.6" sampleSize="244" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.3" sampleSize="122" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="14.0" sampleSize="242" mean="131.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="14.0" sampleSize="241" mean="132.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="16.0" sampleSize="242" mean="132.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="16.0" sampleSize="244" mean="132.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="16.0" sampleSize="122" mean="135.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="liraglutide low-dose"/>
               <continuousMeasurement stdDev="8.0" sampleSize="242" mean="80.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="liraglutide mid-dose"/>
               <continuousMeasurement stdDev="10.0" sampleSize="241" mean="80.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="liraglutide high-dose"/>
               <continuousMeasurement stdDev="8.0" sampleSize="242" mean="80.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="glimepiride"/>
               <continuousMeasurement stdDev="8.0" sampleSize="244" mean="80.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.0" sampleSize="122" mean="81.0"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Forced metformin titration">
               <duration>P21D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P182D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="glimepiride" epoch="Randomization"/>
               <usedBy arm="liraglutide high-dose" epoch="Randomization"/>
               <usedBy arm="liraglutide low-dose" epoch="Randomization"/>
               <usedBy arm="liraglutide mid-dose" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="glimepiride" epoch="Screening"/>
               <usedBy arm="liraglutide high-dose" epoch="Screening"/>
               <usedBy arm="liraglutide low-dose" epoch="Screening"/>
               <usedBy arm="liraglutide mid-dose" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="glimepiride" epoch="Forced metformin titration"/>
               <usedBy arm="liraglutide high-dose" epoch="Forced metformin titration"/>
               <usedBy arm="liraglutide low-dose" epoch="Forced metformin titration"/>
               <usedBy arm="liraglutide mid-dose" epoch="Forced metformin titration"/>
               <usedBy arm="placebo" epoch="Forced metformin titration"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.6"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide mid">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1.2"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide mid-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1.8"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="liraglutide high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="glimepiride ">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="4.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="glimepiride" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="nonaka08">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>Efficacy and tolerability of sitagliptin was assessed in Japanese patients with T2DM.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients with type 2 diabetes ages 20–69 years were eligible if they were either not on treatment with an oral antihyperglycemic agent (OHA) or only on a single OHA over the 8 weeks prior to screening. After a diet and exercise run-in period (and drug washout period for patients who had been on an OHA) of 8 weeks in duration (including a 2-week placebo lead-in period) prior to randomization, patients with an HbA1c of &gt;6.5% to &lt;10% and a fasting plasma glucose (FPG) of &gt;126 to &lt;240 mg/dL were eligible to participate.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Exclusion criteria included type 1 diabetes, any treatment with either insulin or pioglitazone in the 8 weeks prior to screening, unstable cardiac disease, elevated serum creatinine (&gt;1.3 mg/dL in men and &gt;1.2 mg/dL in women), and elevations &gt;2-fold the upper limit of normal (ULN) in either alanine aminotransferase (ALT), aspartate aminotransferase (AST), or creatine phosphokinase (CPK).</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17933414</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555
SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-nervous system disorders">
               <adverseEvent name="nervous system disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="76" name="Sitagliptin">
               <notes/>
            </arm>
            <arm size="76" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="1.0" sampleSize="75" mean="6.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.04" sampleSize="75" mean="8.09"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.08" sampleSize="75" mean="-0.65"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.08" sampleSize="75" mean="0.41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="1.56" sampleSize="75" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.33" sampleSize="75" mean="-0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="1.7" sampleSize="75" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.0" sampleSize="75" mean="9.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.16" sampleSize="75" mean="-1.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.16" sampleSize="75" mean="0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="76" rate="45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="76" rate="49"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="76" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="76" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="76" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="76" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="76" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="76" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-nervous system disorders"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="76" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-nervous system disorders"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="76" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="76" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="8.6" sampleSize="75" mean="55.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="8.0" sampleSize="76" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="30" name="female"/>
                  <category rate="45" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="26" name="female"/>
                  <category rate="50" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="3.5" sampleSize="75" mean="25.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.2" sampleSize="76" mean="25.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="4.1" sampleSize="75" mean="4.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.6" sampleSize="76" mean="4.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.9" sampleSize="75" mean="7.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.9" sampleSize="76" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="2.0" sampleSize="75" mean="9.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.7" sampleSize="76" mean="9.1"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Diet,exercise run-in">
               <duration>P42D</duration>
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P84D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Diet,exercise run-in"/>
               <usedBy arm="Sitagliptin" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Diet,exercise run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="pisunyer07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To assess the efficacy and tolerability of vildagliptin.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>The study enrolled patientswhowere diagnosed withT2DM and hadA1Cof 7.5–10.0% at the screening visit while receiving no pharmacologic treatment. Patients who had taken no oral
antidiabetic drug (OAD) for at least 12 weeks prior to screening and no OAD for &gt;3 consecutive months at any time in the past were considered to be representative of a drug-naive population. Male and female (non-fertile or of childbearing potential using a
medically approved birth-control method) patients aged 18–80 years, inclusive,with aBMIof 22–45 kg/m2, inclusive, and with FPG &lt;15 mmol/L were eligible to participate.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had a history of type 1 or secondary forms of diabetes, acute metabolic diabetic complications, myocardial infarction, unstable angina, or coronary artery bypass surgery within the previous 6 months. Congestive heart failure, NYHA Class III or IV, and liver disease such as cirrhosis or chronic active hepatitis also precluded participation.
Patients with any of the following laboratory abnormalities were also excluded: ALT or AST greater than three times the upper limit of normal (ULN), direct bilirubin &gt;1.3 times the ULN, serum creatinine levels &gt;220 mmol/L, clinically significant abnormal thyroid stimulating hormone, or fasting triglycerides (TG) &gt;7.9 mmol/L.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17223217</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight end">
               <endpoint name="weight end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypertension">
               <adverseEvent name="Hypertension"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pain in extremity">
               <adverseEvent name="Pain in extremity"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race5">
               <populationCharacteristic name="race5"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Height">
               <populationCharacteristic name="Height"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="88" name="vildagliptin low-dose">
               <notes/>
            </arm>
            <arm size="83" name="vildagliptin low-dose twice-perday">
               <notes/>
            </arm>
            <arm size="91" name="vildagliptin high-dose">
               <notes/>
            </arm>
            <arm size="92" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="1.83" sampleSize="84" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="1.8" sampleSize="79" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="89" mean="7.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.9" sampleSize="88" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.92" sampleSize="84" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="0.9" sampleSize="79" mean="-0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="89" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.9" sampleSize="88" mean="0.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="22.0" sampleSize="84" mean="90.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="18.7" sampleSize="79" mean="90.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="20.8" sampleSize="89" mean="90.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="22.5" sampleSize="88" mean="91.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="3.7" sampleSize="84" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="3.6" sampleSize="79" mean="0.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.8" sampleSize="89" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.75" sampleSize="88" mean="-1.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="3.7" sampleSize="84" mean="9.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="2.7" sampleSize="79" mean="9.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.8" sampleSize="89" mean="9.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.75" sampleSize="88" mean="10.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="2.7" sampleSize="84" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="2.7" sampleSize="79" mean="-1.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.8" sampleSize="89" mean="-1.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.8" sampleSize="88" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="86" rate="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="83" rate="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="91" rate="54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="92" rate="53"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="86" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="83" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="91" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="92" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="86" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="83" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="91" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="92" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="86" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="83" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="91" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="92" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="86" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="83" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="91" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="92" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="86" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="83" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="91" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="92" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="88" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="10.4" sampleSize="88" mean="50.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="12.7" sampleSize="83" mean="50.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="11.7" sampleSize="91" mean="52.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="12.0" sampleSize="92" mean="52.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="39" name="female"/>
                  <category rate="49" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <categoricalMeasurement>
                  <category rate="36" name="female"/>
                  <category rate="47" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="42" name="female"/>
                  <category rate="49" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="42" name="female"/>
                  <category rate="50" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race5"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="3" name="asian (non-indian subcontinent)"/>
                  <category rate="16" name="hispanic or latino"/>
                  <category rate="14" name="asian (indian subcontinent)"/>
                  <category rate="7" name="black"/>
                  <category rate="48" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race5"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <categoricalMeasurement>
                  <category rate="1" name="asian (non-indian subcontinent)"/>
                  <category rate="18" name="hispanic or latino"/>
                  <category rate="15" name="asian (indian subcontinent)"/>
                  <category rate="5" name="black"/>
                  <category rate="44" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race5"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="1" name="asian (non-indian subcontinent)"/>
                  <category rate="11" name="hispanic or latino"/>
                  <category rate="15" name="asian (indian subcontinent)"/>
                  <category rate="11" name="black"/>
                  <category rate="53" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race5"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="1" name="asian (non-indian subcontinent)"/>
                  <category rate="17" name="hispanic or latino"/>
                  <category rate="15" name="asian (indian subcontinent)"/>
                  <category rate="12" name="black"/>
                  <category rate="47" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Height"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="11.9" sampleSize="88" mean="167.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Height"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="9.2" sampleSize="83" mean="167.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Height"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="10.5" sampleSize="91" mean="168.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Height"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="10.8" sampleSize="92" mean="168.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="22.3" sampleSize="88" mean="90.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="18.5" sampleSize="83" mean="89.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="19.9" sampleSize="91" mean="90.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="23.2" sampleSize="92" mean="93.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="5.4" sampleSize="88" mean="31.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="6.0" sampleSize="83" mean="32.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="5.0" sampleSize="91" mean="31.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="6.4" sampleSize="92" mean="32.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="88" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="0.9" sampleSize="83" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.8" sampleSize="91" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.8" sampleSize="92" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="3.0" sampleSize="88" mean="10.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="3.1" sampleSize="83" mean="11.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.8" sampleSize="91" mean="10.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.7" sampleSize="92" mean="10.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="2.7" sampleSize="88" mean="1.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="3.2" sampleSize="83" mean="2.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.9" sampleSize="91" mean="2.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.7" sampleSize="92" mean="2.5"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="vildagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose twice-perday" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Screening"/>
               <usedBy arm="vildagliptin high-dose" epoch="Screening"/>
               <usedBy arm="vildagliptin low-dose" epoch="Screening"/>
               <usedBy arm="vildagliptin low-dose twice-perday" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin low-dose" epoch="Main phase"/>
               <usedBy arm="vildagliptin low-dose twice-perday" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="poon05">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Exenatide Improves Glycemic Control and Reduces Body Weight in Subjects with Type 2 Diabetes: A Dose-Ranging Study</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>TRIPLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>This study was designed to assess the dose dependencies of the glucoregulatory effects and tolerability of exenatide when added to diet and exercise or metformin monotherapy in patients with type 2 diabetes.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>General inclusion criteria at screening included HbA1c of 6.8–9.0% inclusive, FPG of &lt;240 mg/dL, and body mass index (BMI) in the range of 27–45 kg/m2 inclusive. In addition, subjects had a history of stable body weight (not varying by &gt;10% for at least 3 months prior to screening) and no clinically relevant abnormal laboratory test values (for a type 2 diabetes population). Female subjects were postmenopausal, surgically sterile, or using
contraceptives for at least 3 months prior to screening and continuing throughout the
study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Subjects were excluded if they had received exogenous insulin therapy, OADs other than
metformin, or prescription weight loss agents within 3 months prior to screening; lipid-lowering
agents that had not been stable for a minimum of 6 weeks prior to screening; or anti-hypertension agents that had not been stable for a minimum of 4 weeks prior to screening; or if they had evidence of clinically significant comorbid conditions. In addition, subjects receiving chronic systemic glucocorticoid therapy or that had participated within the prior 3 months in an interventional medical, surgical, or pharmaceutical study were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>15929678</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race2">
               <populationCharacteristic name="race2"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="33" name="placebo">
               <notes/>
            </arm>
            <arm size="30" name="exenatide 2.5ug/day">
               <notes/>
            </arm>
            <arm size="31" name="exenatide 5ug/day">
               <notes/>
            </arm>
            <arm size="31" name="exenatide 7.5ug/day">
               <notes/>
            </arm>
            <arm size="31" name="exenatide 10ug/day">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.1" sampleSize="32" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide 2.5ug/day"/>
               <continuousMeasurement stdDev="0.1" sampleSize="27" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide 5ug/day"/>
               <continuousMeasurement stdDev="0.1" sampleSize="30" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide 7.5ug/day"/>
               <continuousMeasurement stdDev="0.0" sampleSize="26" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="exenatide 10ug/day"/>
               <continuousMeasurement stdDev="0.1" sampleSize="26" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.3" sampleSize="32" mean="0.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide 2.5ug/day"/>
               <continuousMeasurement stdDev="0.3" sampleSize="27" mean="-0.07"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide 5ug/day"/>
               <continuousMeasurement stdDev="0.2" sampleSize="30" mean="-0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide 7.5ug/day"/>
               <continuousMeasurement stdDev="0.3" sampleSize="26" mean="-1.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="exenatide 10ug/day"/>
               <continuousMeasurement stdDev="0.3" sampleSize="26" mean="-1.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="exenatide 2.5ug/day"/>
               <rateMeasurement sampleSize="30" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="33" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide 2.5ug/day"/>
               <rateMeasurement sampleSize="30" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide 5ug/day"/>
               <rateMeasurement sampleSize="31" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide 7.5ug/day"/>
               <rateMeasurement sampleSize="31" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="exenatide 10ug/day"/>
               <rateMeasurement sampleSize="31" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.9" sampleSize="33" mean="51.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide 2.5ug/day"/>
               <continuousMeasurement stdDev="12.9" sampleSize="30" mean="53.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide 5ug/day"/>
               <continuousMeasurement stdDev="10.5" sampleSize="31" mean="50.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide 7.5ug/day"/>
               <continuousMeasurement stdDev="11.9" sampleSize="31" mean="55.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="exenatide 10ug/day"/>
               <continuousMeasurement stdDev="9.6" sampleSize="31" mean="54.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="20" name="female"/>
                  <category rate="13" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide 2.5ug/day"/>
               <categoricalMeasurement>
                  <category rate="19" name="female"/>
                  <category rate="11" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide 5ug/day"/>
               <categoricalMeasurement>
                  <category rate="18" name="female"/>
                  <category rate="13" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide 7.5ug/day"/>
               <categoricalMeasurement>
                  <category rate="18" name="female"/>
                  <category rate="13" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="exenatide 10ug/day"/>
               <categoricalMeasurement>
                  <category rate="14" name="female"/>
                  <category rate="17" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="2" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="5" name="black"/>
                  <category rate="24" name="caucasian"/>
                  <category rate="1" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="exenatide 2.5ug/day"/>
               <categoricalMeasurement>
                  <category rate="3" name="other"/>
                  <category rate="2" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="5" name="black"/>
                  <category rate="20" name="caucasian"/>
                  <category rate="0" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="exenatide 5ug/day"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="2" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="3" name="black"/>
                  <category rate="23" name="caucasian"/>
                  <category rate="2" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="exenatide 7.5ug/day"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="2" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="2" name="black"/>
                  <category rate="25" name="caucasian"/>
                  <category rate="1" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="exenatide 10ug/day"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="1" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="1" name="black"/>
                  <category rate="25" name="caucasian"/>
                  <category rate="2" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="19.9" sampleSize="33" mean="102.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide 2.5ug/day"/>
               <continuousMeasurement stdDev="22.6" sampleSize="30" mean="98.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide 5ug/day"/>
               <continuousMeasurement stdDev="15.4" sampleSize="31" mean="103.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide 7.5ug/day"/>
               <continuousMeasurement stdDev="21.0" sampleSize="31" mean="99.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="exenatide 10ug/day"/>
               <continuousMeasurement stdDev="15.1" sampleSize="31" mean="92.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.7" sampleSize="33" mean="35.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide 2.5ug/day"/>
               <continuousMeasurement stdDev="7.2" sampleSize="30" mean="35.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide 5ug/day"/>
               <continuousMeasurement stdDev="5.4" sampleSize="31" mean="36.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide 7.5ug/day"/>
               <continuousMeasurement stdDev="6.2" sampleSize="31" mean="35.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="exenatide 10ug/day"/>
               <continuousMeasurement stdDev="4.8" sampleSize="31" mean="32.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.0" sampleSize="33" mean="8.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide 2.5ug/day"/>
               <continuousMeasurement stdDev="2.7" sampleSize="30" mean="9.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide 5ug/day"/>
               <continuousMeasurement stdDev="1.8" sampleSize="31" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide 7.5ug/day"/>
               <continuousMeasurement stdDev="1.9" sampleSize="31" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="exenatide 10ug/day"/>
               <continuousMeasurement stdDev="1.5" sampleSize="31" mean="8.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.8" sampleSize="33" mean="7.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide 2.5ug/day"/>
               <continuousMeasurement stdDev="0.7" sampleSize="30" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide 5ug/day"/>
               <continuousMeasurement stdDev="0.7" sampleSize="31" mean="7.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide 7.5ug/day"/>
               <continuousMeasurement stdDev="0.7" sampleSize="31" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="exenatide 10ug/day"/>
               <continuousMeasurement stdDev="0.5" sampleSize="31" mean="7.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.2" sampleSize="33" mean="4.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide 2.5ug/day"/>
               <continuousMeasurement stdDev="5.0" sampleSize="30" mean="4.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide 5ug/day"/>
               <continuousMeasurement stdDev="2.5" sampleSize="31" mean="2.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide 7.5ug/day"/>
               <continuousMeasurement stdDev="5.6" sampleSize="31" mean="4.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="exenatide 10ug/day"/>
               <continuousMeasurement stdDev="2.6" sampleSize="31" mean="3.5"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P28D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="exenatide 10ug/day" epoch="Randomization"/>
               <usedBy arm="exenatide 2.5ug/day" epoch="Randomization"/>
               <usedBy arm="exenatide 5ug/day" epoch="Randomization"/>
               <usedBy arm="exenatide 7.5ug/day" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="exenatide 10ug/day" epoch="Placebo run-in"/>
               <usedBy arm="exenatide 2.5ug/day" epoch="Placebo run-in"/>
               <usedBy arm="exenatide 5ug/day" epoch="Placebo run-in"/>
               <usedBy arm="exenatide 7.5ug/day" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide 2.5ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0025"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide 2.5ug/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide 5ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.005"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide 5ug/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide 7.5ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0075"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide 7.5ug/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide 10ug/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.01"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="exenatide 10ug/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="raz06">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>The aim of this study was to assess the efficacy and safety of sitagliptin (MK-0431) as monotherapy in patients with type 2 diabetes mellitus and inadequate glycaemic control (HbA1c Q7% and e10%) on exercise and diet.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and women with type 2 diabetes mellitus, 18–75 years of age, were recruited. Patients not currently on oral antihyperglycaemic agent (OHA) therapy and patients on OHA monotherapy (or dual oral combination therapy in low doses) who could be taken off their OHA(s) during the run-in period, were eligible.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Key exclusion criteria included type 1 diabetes, insulin therapy, significant hepatic or renal disease, hepatic transaminase or creatine phosphokinase (CK) levels Q2 times the upper limit of normal, fasting plasma glucose (FPG) &gt;15 mmol/l (270 mg/dl) and BMI &lt;20 kg/m2 or &gt;43 kg/m2.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17001471</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-insulin end">
               <endpoint name="insulin end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-fasting proinsuline end">
               <endpoint name="fasting proinsuline end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-Fasting proinsulin level change">
               <endpoint name="Fasting proinsulin level change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B end">
               <endpoint name="HOMA-B end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B change">
               <endpoint name="HOMA-B change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related SAE">
               <adverseEvent name="Discontinuation due to drug-related SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="110" name="placebo">
               <notes/>
            </arm>
            <arm size="205" name="Sitagliptin low-dose">
               <notes/>
            </arm>
            <arm size="206" name="Sitagliptin high-dose">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.35" sampleSize="103" mean="8.21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="1.15" sampleSize="193" mean="7.58"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="1.31" sampleSize="199" mean="7.81"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.08" sampleSize="103" mean="0.12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.07" sampleSize="193" mean="-0.48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.06" sampleSize="199" mean="-0.36"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.3" sampleSize="107" mean="10.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="3.0" sampleSize="201" mean="9.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="3.2" sampleSize="202" mean="9.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.3" sampleSize="107" mean="0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.2" sampleSize="201" mean="-0.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.2" sampleSize="202" mean="-0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-insulin end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="103.2" sampleSize="81" mean="108.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-insulin end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="58.8" sampleSize="168" mean="90.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-insulin end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="105.6" sampleSize="173" mean="97.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting proinsuline end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="45.8" sampleSize="77" mean="44.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting proinsuline end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="31.6" sampleSize="167" mean="32.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting proinsuline end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="34.2" sampleSize="168" mean="34.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.7" sampleSize="77" mean="2.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="1.9" sampleSize="167" mean="-2.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-Fasting proinsulin level change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="1.9" sampleSize="168" mean="2.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="63.9" sampleSize="800" mean="69.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="45.5" sampleSize="168" mean="65.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="82.2" sampleSize="171" mean="69.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.6" sampleSize="80" mean="1.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="3.1" sampleSize="168" mean="12.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="3.1" sampleSize="171" mean="13.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="57"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="102"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="25"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="19"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="110" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin high-dose"/>
               <rateMeasurement sampleSize="206" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Sitagliptin low-dose"/>
               <rateMeasurement sampleSize="205" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.9" sampleSize="110" mean="8.05"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="0.82" sampleSize="205" mean="8.04"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="0.91" sampleSize="206" mean="8.14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="18.8" sampleSize="110" mean="92.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="19.1" sampleSize="205" mean="89.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="19.4" sampleSize="206" mean="89.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.7" sampleSize="110" mean="10.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin low-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="205" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin high-dose"/>
               <continuousMeasurement stdDev="2.5" sampleSize="206" mean="10.2"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="diet,exercise run-in">
               <duration>P84D</duration>
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P126D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Sitagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="Sitagliptin low-dose" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Sitagliptin high-dose" epoch="Screening"/>
               <usedBy arm="Sitagliptin low-dose" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Sitagliptin high-dose" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin high-dose" epoch="diet,exercise run-in"/>
               <usedBy arm="Sitagliptin low-dose" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin low-dose" epoch="diet,exercise run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="diet,exercise run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="200.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="raz08">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add-on
to metformin therapy in patients with moderately severe (hemoglobin A1c ≥ 8.0% and ≤ 11.0%) type 2 diabetes mellitus (T2DM)</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients with T2DM, 18–78 years of age, who were currently on metformin monotherapy or any other single OHA, or being treated with metformin in combination with another OHA, were eligible to enter the study if their HbA1c value met screening criteria.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded who had received treatment with insulin within 8 weeks prior to screening, treatment with a PPARγ agent (e.g., pioglitazone or rosiglitazone) or incretin mimetics (e.g., exenatide) within 12 weeks, had type 1 diabetes, a body mass index (BMI) &lt; 20 kg/m2 or &gt; 43 kg/m2, or a fasting plasma glucose (FPG) during run-in that was consistently &lt; 7.2 mmol/L or &gt; 15.6 mmol/L. Patients who were pregnant or breast-feeding were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>18194595</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-2-h PPG change">
               <endpoint name="2-h PPG change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Who died">
               <adverseEvent name="Who died"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Angina pectoris">
               <adverseEvent name="Angina pectoris"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastritis">
               <adverseEvent name="Gastritis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Influenza">
               <adverseEvent name="Influenza"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pharyngitis">
               <adverseEvent name="Pharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pharyngotonsillitis">
               <adverseEvent name="Pharyngotonsillitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Respiratory tract infection">
               <adverseEvent name="Respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Tinea pedis">
               <adverseEvent name="Tinea pedis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Urinary tract infection">
               <adverseEvent name="Urinary tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Blood glucose increased">
               <adverseEvent name="Blood glucose increased"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hyperglycaemia">
               <adverseEvent name="Hyperglycaemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pain in extremity">
               <adverseEvent name="Pain in extremity"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diabetic neuropathy">
               <adverseEvent name="Diabetic neuropathy"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypertension">
               <adverseEvent name="Hypertension"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race6">
               <populationCharacteristic name="race6"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="94" name="placebo">
               <notes/>
            </arm>
            <arm size="96" name="sitagliptin">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.13" sampleSize="92" mean="0.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="sitagliptin"/>
               <continuousMeasurement stdDev="0.1" sampleSize="95" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.2" sampleSize="92" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="sitagliptin"/>
               <continuousMeasurement stdDev="0.3" sampleSize="96" mean="-1.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.43" sampleSize="74" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG change"/>
               <arm name="sitagliptin"/>
               <continuousMeasurement stdDev="0.41" sampleSize="79" mean="-3.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="56"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="55"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Who died"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Angina pectoris"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Angina pectoris"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastritis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastritis"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pharyngitis"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pharyngotonsillitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pharyngotonsillitis"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Respiratory tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Respiratory tract infection"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tinea pedis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Tinea pedis"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Urinary tract infection"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Urinary tract infection"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood glucose increased"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Blood glucose increased"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperglycaemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hyperglycaemia"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diabetic neuropathy"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diabetic neuropathy"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="94" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="sitagliptin"/>
               <rateMeasurement sampleSize="96" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.5" sampleSize="94" mean="56.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="sitagliptin"/>
               <continuousMeasurement stdDev="9.5" sampleSize="96" mean="53.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="55" name="female"/>
                  <category rate="39" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="47" name="female"/>
                  <category rate="49" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race6"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="2" name="other"/>
                  <category rate="44" name="white"/>
                  <category rate="23" name="multiracial"/>
                  <category rate="24" name="hispanic"/>
                  <category rate="1" name="black"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race6"/>
               <arm name="sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="40" name="white"/>
                  <category rate="21" name="multiracial"/>
                  <category rate="31" name="hispanic"/>
                  <category rate="3" name="black"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="94" mean="19.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="sitagliptin"/>
               <continuousMeasurement stdDev="16.8" sampleSize="96" mean="81.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.3" sampleSize="94" mean="30.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="sitagliptin"/>
               <continuousMeasurement stdDev="4.4" sampleSize="96" mean="30.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.3" sampleSize="94" mean="7.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="sitagliptin"/>
               <continuousMeasurement stdDev="6.5" sampleSize="96" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.8" sampleSize="94" mean="9.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="sitagliptin"/>
               <continuousMeasurement stdDev="0.9" sampleSize="96" mean="9.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.4" sampleSize="94" mean="11.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="sitagliptin"/>
               <continuousMeasurement stdDev="2.6" sampleSize="96" mean="11.2"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Diet,exercise run-in">
               <duration>P42D</duration>
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P210D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="sitagliptin" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Screening"/>
               <usedBy arm="sitagliptin" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Diet,exercise run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <usedBy arm="sitagliptin" epoch="Diet,exercise run-in"/>
               <usedBy arm="sitagliptin" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo +metformin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="sitagliptin+metformin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="sitagliptin" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="ristic05">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>91</value>
               <notes/>
            </centers>
            <objective>
               <value>A novel treatment option for diabetic patients is the enhancement of incretin hormone activity by inhibition of the enzyme dipeptidyl peptidase-4 (DPP-4). This study was designed to establish a dose of the DPP-4-inhibitor vildagliptin (LAF237) that was effective in reducing HbA1c levels and was safe and well tolerated in patients with type 2 diabetes.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>During the run-in phase, inclusion criteria were evaluated for mean glycosylated haemoglobin (HbA1c) levels between 6.8 and 10.0%, FPG between 6.1 and 15 mmol/l, serum creatinine level less than 220 mmol/l, bilirubin less than 1.3*upper limit of normal (ULN), serum levels of liver enzymes less than 2*ULN and body mass index (BMI) of 20–42 kg/m2.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients with abnormal thyroid-stimulating hormone, type 1 diabetes, acute metabolic diabetic
complications such as ketoacidosis or hyperosmolar state, history of myocardial infarction,
clinically significant cardiovascular abnormalities, pancreatitis, parotitis, acromegaly, asthma or major skin allergies, liver disease or previous major gastrointestinal surgery were excluded. Additional exclusion criteria were treatment with oral antidiabetic drugs or sodium
channel blockers within the previous 12 weeks, combination oral antidiabetic therapy or insulin treatment within 6 months prior to study and treatment with systemic corticosteroids, thyroid hormone replacement, warfarin, dicoumarin or digoxin.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>16219012</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B change">
               <endpoint name="HOMA-B change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dizziness">
               <adverseEvent name="Dizziness"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Oedema peripheral">
               <adverseEvent name="Oedema peripheral"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Constipation">
               <adverseEvent name="Constipation"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Cough">
               <adverseEvent name="Cough"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Influenza">
               <adverseEvent name="Influenza"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Sinusitis">
               <adverseEvent name="Sinusitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race7">
               <populationCharacteristic name="race7"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="51" name="vildagliptin low-dose twice-perday">
               <notes/>
            </arm>
            <arm size="54" name="vildagliptin low-dose">
               <notes/>
            </arm>
            <arm size="53" name="vildagliptin mid-dose">
               <notes/>
            </arm>
            <arm size="63" name="vildagliptin high-dose">
               <notes/>
            </arm>
            <arm size="58" name="placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="0.11" sampleSize="51" mean="-0.31"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.1" sampleSize="54" mean="-0.27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.1" sampleSize="52" mean="-0.56"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.1" sampleSize="60" mean="-0.53"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.1" sampleSize="55" mean="-0.13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="2.3" sampleSize="51" mean="-0.55"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="54" mean="0.06"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="53" mean="0.04"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="2.5" sampleSize="63" mean="-0.07"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.5" sampleSize="58" mean="-0.73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="0.25" sampleSize="51" mean="-0.44"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.24" sampleSize="54" mean="-0.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.25" sampleSize="52" mean="-0.97"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.23" sampleSize="62" mean="-0.95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.24" sampleSize="55" mean="-0.41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="8.1" sampleSize="35" mean="816.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="6.9" sampleSize="39" mean="2.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="7.0" sampleSize="38" mean="6.41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="7.0" sampleSize="41" mean="22.54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.51" sampleSize="37" mean="-0.96"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="31"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="35"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Oedema peripheral"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Oedema peripheral"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Oedema peripheral"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Oedema peripheral"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Oedema peripheral"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Constipation"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Cough"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Cough"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Cough"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Cough"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Cough"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <rateMeasurement sampleSize="51" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="vildagliptin mid-dose"/>
               <rateMeasurement sampleSize="53" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="vildagliptin high-dose"/>
               <rateMeasurement sampleSize="63" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sinusitis"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="58" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="vildagliptin low-dose"/>
               <rateMeasurement sampleSize="54" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="10.9" sampleSize="51" mean="55.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="10.2" sampleSize="54" mean="57.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="10.2" sampleSize="53" mean="57.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="10.1" sampleSize="63" mean="56.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="10.6" sampleSize="58" mean="54.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <categoricalMeasurement>
                  <category rate="27" name="female"/>
                  <category rate="24" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="20" name="female"/>
                  <category rate="34" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin mid-dose"/>
               <categoricalMeasurement>
                  <category rate="27" name="female"/>
                  <category rate="26" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="28" name="female"/>
                  <category rate="35" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="25" name="female"/>
                  <category rate="33" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race7"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <categoricalMeasurement>
                  <category rate="10" name="other"/>
                  <category rate="41" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race7"/>
               <arm name="vildagliptin low-dose"/>
               <categoricalMeasurement>
                  <category rate="11" name="other"/>
                  <category rate="43" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race7"/>
               <arm name="vildagliptin mid-dose"/>
               <categoricalMeasurement>
                  <category rate="12" name="other"/>
                  <category rate="41" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race7"/>
               <arm name="vildagliptin high-dose"/>
               <categoricalMeasurement>
                  <category rate="16" name="other"/>
                  <category rate="47" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race7"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="7" name="other"/>
                  <category rate="51" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="5.23" sampleSize="51" mean="30.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="3.89" sampleSize="54" mean="31.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="3.9" sampleSize="53" mean="31.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="4.01" sampleSize="63" mean="31.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.41" sampleSize="58" mean="31.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="3.81" sampleSize="51" mean="3.28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="5.16" sampleSize="54" mean="3.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="3.24" sampleSize="53" mean="2.71"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="4.22" sampleSize="63" mean="3.03"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.99" sampleSize="58" mean="2.28"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="0.69" sampleSize="51" mean="7.64"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="0.8" sampleSize="54" mean="7.73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="0.82" sampleSize="53" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="0.75" sampleSize="63" mean="7.64"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.83" sampleSize="58" mean="7.76"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin low-dose twice-perday"/>
               <continuousMeasurement stdDev="2.07" sampleSize="51" mean="9.18"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin low-dose"/>
               <continuousMeasurement stdDev="2.29" sampleSize="54" mean="9.43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin mid-dose"/>
               <continuousMeasurement stdDev="2.09" sampleSize="53" mean="9.22"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="vildagliptin high-dose"/>
               <continuousMeasurement stdDev="1.85" sampleSize="63" mean="9.25"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.94" sampleSize="58" mean="9.23"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Placebo run-in">
               <duration>P28D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P84D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Randomization"/>
               <usedBy arm="vildagliptin high-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose" epoch="Randomization"/>
               <usedBy arm="vildagliptin low-dose twice-perday" epoch="Randomization"/>
               <usedBy arm="vildagliptin mid-dose" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <usedBy arm="vildagliptin high-dose" epoch="Placebo run-in"/>
               <usedBy arm="vildagliptin low-dose" epoch="Placebo run-in"/>
               <usedBy arm="vildagliptin low-dose twice-perday" epoch="Placebo run-in"/>
               <usedBy arm="vildagliptin mid-dose" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="25.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin low-dose" epoch="Main phase"/>
               <usedBy arm="vildagliptin low-dose twice-perday" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin mid">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin mid-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="vildagliptin high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="vildagliptin high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="rosenstock06">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Pioglitazone Therapy in Patients with Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>The efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing
pioglitazone therapy were assessed in patients with type 2 diabetes and inadequate glycemic control (glycosylated hemoglobin [HbA1c] &gt;7% and &lt;10%) while receiving a stable dose of pioglitazone.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and women, aged &gt;18 years, with type 2 diabetes were eligible for the study, whether they were already taking an oral antihyperglycemic agent (OHA) or not.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>patients were excluded if they had a history of type 1 diabetes or ketoacidosis; had been treated with insulin within 8 weeks of the screening visit; had moderate renal dysfunction
(creatinine clearance [CrCI] &lt;45 mL/min or age- and sex-adjusted serum creatinine levels consistent with this CrC1); or had a history of hypersensitivity, intolerance, or a contraindication to the use of TZDs.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17157112</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555
SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-fasting serum insuline end">
               <endpoint name="fasting serum insuline end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-fasting serum insulin change">
               <endpoint name="fasting serum insulin change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B end">
               <endpoint name="HOMA-B end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-B change">
               <endpoint name="HOMA-B change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-IR end">
               <endpoint name="HOMA-IR end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-HOMA-IR change">
               <endpoint name="HOMA-IR change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-QUICKI end">
               <endpoint name="QUICKI end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-QUICKI change">
               <endpoint name="QUICKI change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes>
                  <note source="MANUAL">SD is not reported</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related SAE">
               <adverseEvent name="Discontinuation due to drug-related SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Upper respiratory tract infection">
               <adverseEvent name="Upper respiratory tract infection"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Influenza">
               <adverseEvent name="Influenza"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-periphera oedema">
               <adverseEvent name="periphera oedema"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Arthralgia">
               <adverseEvent name="Arthralgia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-weight increase">
               <adverseEvent name="weight increase"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Depression">
               <adverseEvent name="Depression"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Pain in extremity">
               <adverseEvent name="Pain in extremity"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Back pain">
               <adverseEvent name="Back pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race3">
               <populationCharacteristic name="race3"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="175" name="Sitagliptin">
               <notes/>
            </arm>
            <arm size="178" name="Placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.91" sampleSize="163" mean="7.17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.1" sampleSize="174" mean="7.82"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.07" sampleSize="163" mean="-0.85"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.06" sampleSize="174" mean="-0.15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="2.1" sampleSize="163" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.5" sampleSize="174" mean="9.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.16" sampleSize="163" mean="-0.93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.14" sampleSize="174" mean="0.06"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insuline end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="6.0" sampleSize="134" mean="10.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insuline end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="7.0" sampleSize="143" mean="10.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insulin change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.5" sampleSize="134" mean="0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-fasting serum insulin change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.5" sampleSize="143" mean="0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="26.5" sampleSize="133" mean="480.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="42.0" sampleSize="142" mean="45.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="2.8" sampleSize="133" mean="11.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.6" sampleSize="142" mean="5.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="2.9" sampleSize="133" mean="3.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="3.0" sampleSize="142" mean="3.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.3" sampleSize="133" mean="-0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-IR change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.2" sampleSize="142" mean="0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI end"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.033" sampleSize="133" mean="0.327"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.031" sampleSize="142" mean="0.325"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.002" sampleSize="133" mean="0.003"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-QUICKI change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.002" sampleSize="142" mean="-0.001"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.0" sampleSize="175" mean="1.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="178" mean="1.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="84"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="24"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-periphera oedema"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-periphera oedema"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-weight increase"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-weight increase"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Depression"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Depression"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Pain in extremity"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="Sitagliptin"/>
               <rateMeasurement sampleSize="175" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="178" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="10.4" sampleSize="175" mean="55.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="11.1" sampleSize="178" mean="56.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="82" name="female"/>
                  <category rate="93" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="75" name="female"/>
                  <category rate="103" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race3"/>
               <arm name="Sitagliptin"/>
               <categoricalMeasurement>
                  <category rate="6" name="other"/>
                  <category rate="127" name="white"/>
                  <category rate="21" name="hispanic"/>
                  <category rate="11" name="black"/>
                  <category rate="10" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race3"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="10" name="other"/>
                  <category rate="129" name="white"/>
                  <category rate="22" name="hispanic"/>
                  <category rate="12" name="black"/>
                  <category rate="5" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="17.0" sampleSize="175" mean="90.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="17.4" sampleSize="178" mean="86.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="5.2" sampleSize="175" mean="32.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="5.0" sampleSize="178" mean="31.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="5.4" sampleSize="175" mean="6.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="5.7" sampleSize="178" mean="6.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="0.8" sampleSize="175" mean="8.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.8" sampleSize="178" mean="8.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin"/>
               <continuousMeasurement stdDev="38.9" sampleSize="175" mean="168.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="39.8" sampleSize="178" mean="165.3"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P168D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <usedBy arm="Sitagliptin" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Screening"/>
               <usedBy arm="Sitagliptin" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin+Pioglitazone">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="pioglitazone"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Placebo+Pioglitazone">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="pioglitazone"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="russelljones08">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Significantly better glycaemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin + sulphonylurea in type 2 diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To compare the efficacy and safety of liraglutide, liraglutide placebo and open-label insulin glargine</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <notes/>
            </inclusion>
            <exclusion>
               <notes/>
            </exclusion>
            <references/>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="228" name="Liraglutide">
               <notes/>
            </arm>
            <arm size="114" name="Placebo">
               <notes/>
            </arm>
            <arm size="228" name="Glargine">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Liraglutide"/>
               <continuousMeasurement stdDev="1.0" sampleSize="228" mean="7.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.3" sampleSize="114" mean="8.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Glargine"/>
               <continuousMeasurement stdDev="0.9" sampleSize="228" mean="7.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Liraglutide"/>
               <continuousMeasurement stdDev="0.09" sampleSize="228" mean="-1.33"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.11" sampleSize="114" mean="-0.24"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Glargine"/>
               <continuousMeasurement stdDev="0.09" sampleSize="228" mean="-1.09"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Liraglutide"/>
               <continuousMeasurement stdDev="0.33" sampleSize="228" mean="-1.81"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.39" sampleSize="114" mean="-0.42"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Glargine"/>
               <continuousMeasurement stdDev="0.33" sampleSize="228" mean="1.62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Liraglutide"/>
               <continuousMeasurement stdDev="2.2" sampleSize="228" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.9" sampleSize="114" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Glargine"/>
               <continuousMeasurement stdDev="2.1" sampleSize="228" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Liraglutide"/>
               <continuousMeasurement stdDev="0.0" sampleSize="228" mean="-1.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="114" mean="0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Glargine"/>
               <continuousMeasurement stdDev="0.0" sampleSize="228" mean="-1.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Liraglutide"/>
               <rateMeasurement sampleSize="228" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="114" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Glargine"/>
               <rateMeasurement sampleSize="228" rate="18"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Liraglutide"/>
               <rateMeasurement sampleSize="228" rate="32"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="114" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Glargine"/>
               <rateMeasurement sampleSize="228" rate="3"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Initial medication administration">
               <duration>P42D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P182D</duration>
               <notes/>
            </epoch>
            <epoch name="Follow-up">
               <duration>P7D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Glargine" epoch="Randomization"/>
               <usedBy arm="Liraglutide" epoch="Randomization"/>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Glargine" epoch="Screening"/>
               <usedBy arm="Liraglutide" epoch="Screening"/>
               <usedBy arm="Placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Follow up">
               <activity>
                  <predefined>FOLLOW_UP</predefined>
               </activity>
               <usedBy arm="Glargine" epoch="Follow-up"/>
               <usedBy arm="Liraglutide" epoch="Follow-up"/>
               <usedBy arm="Placebo" epoch="Follow-up"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Glargine" epoch="Initial medication administration"/>
               <usedBy arm="Liraglutide" epoch="Initial medication administration"/>
               <usedBy arm="Placebo" epoch="Initial medication administration"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Placebo+Metformin+Glimepiride">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Liraglutide+Metformin+Glimepiride">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1.8"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Glargine+Metformin+Glimepiride">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="Insulin glargine"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="metformin"/>
                     </drugTreatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="glimepiride"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Glargine" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="scherbaum08">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To assess the 2-year efficacy and tolerability of vildagliptin (50 mg once daily) in patients with type 2 diabetes (T2DM) and mild hyperglycaemia.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>The core study enrolled drug-naive patients &gt;18 years of age who were diagnosed with T2DM at least 8 weeks previously and who had HbA1c in the range of 6.2–7.5% at the screening visit (upper limit of 7.0% for centres in Finland and Spain). Patients who had taken no oral antidiabetic drug (OAD) for at least 12 weeks prior to screening and no OAD for &gt;3 months consecutively at any time in the past were considered to be representative of a drug-naive population.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>18355325</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Back pain">
               <adverseEvent name="Back pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Arthralgia">
               <adverseEvent name="Arthralgia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Osteoarthritis">
               <adverseEvent name="Osteoarthritis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Bronchitis">
               <adverseEvent name="Bronchitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Depression">
               <adverseEvent name="Depression"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypertension">
               <adverseEvent name="Hypertension"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Eczema">
               <adverseEvent name="Eczema"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastritis">
               <adverseEvent name="Gastritis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Cervicobrachial syndrome">
               <adverseEvent name="Cervicobrachial syndrome"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Influenza">
               <adverseEvent name="Influenza"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Joint sprain">
               <adverseEvent name="Joint sprain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Musculoskeletal pain">
               <adverseEvent name="Musculoskeletal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Sciatica">
               <adverseEvent name="Sciatica"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-cough">
               <adverseEvent name="cough"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastroenteritis">
               <adverseEvent name="Gastroenteritis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race7">
               <populationCharacteristic name="race7"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="68" name="Vildagliptin ">
               <notes/>
            </arm>
            <arm size="63" name="Placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Vildagliptin "/>
               <continuousMeasurement stdDev="0.1" sampleSize="68" mean="-0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.1" sampleSize="63" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Vildagliptin "/>
               <continuousMeasurement stdDev="0.3" sampleSize="68" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.3" sampleSize="63" mean="-0.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="57"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="56"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Back pain"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Arthralgia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Osteoarthritis"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Osteoarthritis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bronchitis"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Bronchitis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Depression"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Depression"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypertension"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Eczema"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Eczema"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastritis"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastritis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Cervicobrachial syndrome"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Cervicobrachial syndrome"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Joint sprain"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Joint sprain"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Musculoskeletal pain"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Musculoskeletal pain"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sciatica"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Sciatica"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-cough"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-cough"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastroenteritis"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastroenteritis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="63" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Vildagliptin "/>
               <rateMeasurement sampleSize="68" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Vildagliptin "/>
               <continuousMeasurement stdDev="9.6" sampleSize="68" mean="63.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="10.0" sampleSize="63" mean="63.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Vildagliptin "/>
               <categoricalMeasurement>
                  <category rate="27" name="female"/>
                  <category rate="41" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="26" name="female"/>
                  <category rate="37" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race7"/>
               <arm name="Vildagliptin "/>
               <categoricalMeasurement>
                  <category rate="0" name="other"/>
                  <category rate="68" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race7"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="0" name="other"/>
                  <category rate="63" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Vildagliptin "/>
               <continuousMeasurement stdDev="4.7" sampleSize="68" mean="30.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="4.5" sampleSize="63" mean="30.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Vildagliptin "/>
               <continuousMeasurement stdDev="0.4" sampleSize="68" mean="6.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.4" sampleSize="63" mean="6.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Vildagliptin "/>
               <continuousMeasurement stdDev="1.0" sampleSize="68" mean="6.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.0" sampleSize="63" mean="7.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Vildagliptin "/>
               <continuousMeasurement stdDev="2.1" sampleSize="68" mean="2.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.6" sampleSize="63" mean="2.5"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="treatment free washout">
               <duration>P28D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P364D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <usedBy arm="Vildagliptin " epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Screening"/>
               <usedBy arm="Vildagliptin " epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="treatment free washout"/>
               <usedBy arm="Vildagliptin " epoch="treatment free washout"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Vildagliptin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="vildagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Vildagliptin " epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="scott07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in
patients with type 2 diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>The aim of this study was to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes who have inadequate glycaemic control on diet and exercise.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Male and female patients 21–75 years of age with type 2 diabetes, either currently on OHA monotherapy (except thiazolidinediones) with HbA1c &gt;6% and &lt;9% or not currently on an OHA with HbA1c &gt;6.5% and &lt;10%, were eligible to participate if they met screening criteria.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients with type 1 diabetes, unstable cardiac disease, active liver or gallbladder disease, creatinine clearance &lt;60 ml/min, or elevated (&gt;2-fold the upper limit of normal) alanine aminotransferase (ALT), aspartate aminotransferase (AST) or creatine phosphokinase (CK) were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17156104</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HOMA-B end">
               <endpoint name="HOMA-B end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HOMA-B change">
               <endpoint name="HOMA-B change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related SAE">
               <adverseEvent name="Discontinuation due to drug-related SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race8">
               <populationCharacteristic name="race8"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="125" name="placebo">
               <notes/>
            </arm>
            <arm size="125" name="Sitagliptin 5mg/day">
               <notes/>
            </arm>
            <arm size="123" name="Sitagliptin 12.5mg/day">
               <notes/>
            </arm>
            <arm size="123" name="Sitagliptin 25mg/day">
               <notes/>
            </arm>
            <arm size="124" name="Sitagliptin 50mg/day">
               <notes/>
            </arm>
            <arm size="123" name="Glipizide">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.23" sampleSize="121" mean="8.14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="1.22" sampleSize="122" mean="7.77"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="0.98" sampleSize="122" mean="7.48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="1.14" sampleSize="120" mean="7.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="1.01" sampleSize="121" mean="7.34"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="0.91" sampleSize="119" mean="7.11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.07" sampleSize="121" mean="0.23"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="0.07" sampleSize="122" mean="-0.15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="0.07" sampleSize="122" mean="-0.41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="0.07" sampleSize="120" mean="-0.43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="0.07" sampleSize="121" mean="-0.54"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="0.07" sampleSize="119" mean="-0.76"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.88" sampleSize="123" mean="10.04"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="3.15" sampleSize="124" mean="9.52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="2.0" sampleSize="123" mean="8.76"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="2.53" sampleSize="121" mean="8.89"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="2.03" sampleSize="122" mean="8.48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="1.71" sampleSize="121" mean="8.18"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="0.18" sampleSize="123" mean="0.27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="0.18" sampleSize="124" mean="-0.04"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="0.18" sampleSize="123" mean="-0.72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="0.18" sampleSize="121" mean="-0.72"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="0.18" sampleSize="122" mean="-1.01"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="0.18" sampleSize="121" mean="-1.38"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="58.9" sampleSize="112" mean="58.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="51.9" sampleSize="115" mean="60.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="40.1" sampleSize="118" mean="58.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="48.5" sampleSize="114" mean="63.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="54.9" sampleSize="115" mean="67.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B end"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="69.1" sampleSize="105" mean="78.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="3.8" sampleSize="112" mean="-0.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="3.8" sampleSize="115" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="3.7" sampleSize="118" mean="8.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="3.8" sampleSize="114" mean="6.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="3.8" sampleSize="115" mean="17.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HOMA-B change"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="4.0" sampleSize="105" mean="25.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="125" rate="67"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="68"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <rateMeasurement sampleSize="123" rate="67"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin 25mg/day"/>
               <rateMeasurement sampleSize="123" rate="76"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin 50mg/day"/>
               <rateMeasurement sampleSize="124" rate="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Glipizide"/>
               <rateMeasurement sampleSize="123" rate="77"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="125" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <rateMeasurement sampleSize="123" rate="20"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin 25mg/day"/>
               <rateMeasurement sampleSize="123" rate="17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin 50mg/day"/>
               <rateMeasurement sampleSize="124" rate="15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Glipizide"/>
               <rateMeasurement sampleSize="123" rate="34"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="125" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <rateMeasurement sampleSize="123" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin 25mg/day"/>
               <rateMeasurement sampleSize="123" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin 50mg/day"/>
               <rateMeasurement sampleSize="124" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Glipizide"/>
               <rateMeasurement sampleSize="123" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <rateMeasurement sampleSize="123" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin 25mg/day"/>
               <rateMeasurement sampleSize="123" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin 50mg/day"/>
               <rateMeasurement sampleSize="124" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Glipizide"/>
               <rateMeasurement sampleSize="123" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <rateMeasurement sampleSize="123" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin 25mg/day"/>
               <rateMeasurement sampleSize="123" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin 50mg/day"/>
               <rateMeasurement sampleSize="124" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Glipizide"/>
               <rateMeasurement sampleSize="123" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <rateMeasurement sampleSize="123" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin 25mg/day"/>
               <rateMeasurement sampleSize="123" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin 50mg/day"/>
               <rateMeasurement sampleSize="124" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Glipizide"/>
               <rateMeasurement sampleSize="123" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <rateMeasurement sampleSize="123" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin 25mg/day"/>
               <rateMeasurement sampleSize="123" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin 50mg/day"/>
               <rateMeasurement sampleSize="124" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Glipizide"/>
               <rateMeasurement sampleSize="123" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <rateMeasurement sampleSize="123" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin 25mg/day"/>
               <rateMeasurement sampleSize="123" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin 50mg/day"/>
               <rateMeasurement sampleSize="124" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Glipizide"/>
               <rateMeasurement sampleSize="123" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="placebo"/>
               <rateMeasurement sampleSize="125" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <rateMeasurement sampleSize="123" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin 25mg/day"/>
               <rateMeasurement sampleSize="123" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin 50mg/day"/>
               <rateMeasurement sampleSize="124" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Glipizide"/>
               <rateMeasurement sampleSize="123" rate="21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Sitagliptin 5mg/day"/>
               <rateMeasurement sampleSize="125" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="9.7" sampleSize="125" mean="55.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="9.5" sampleSize="125" mean="55.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="9.0" sampleSize="123" mean="56.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="9.0" sampleSize="123" mean="55.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="9.8" sampleSize="124" mean="55.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="10.7" sampleSize="123" mean="54.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="47" name="female"/>
                  <category rate="78" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin 5mg/day"/>
               <categoricalMeasurement>
                  <category rate="63" name="female"/>
                  <category rate="62" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <categoricalMeasurement>
                  <category rate="64" name="female"/>
                  <category rate="59" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin 25mg/day"/>
               <categoricalMeasurement>
                  <category rate="52" name="female"/>
                  <category rate="71" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin 50mg/day"/>
               <categoricalMeasurement>
                  <category rate="59" name="female"/>
                  <category rate="65" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Glipizide"/>
               <categoricalMeasurement>
                  <category rate="53" name="female"/>
                  <category rate="70" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race8"/>
               <arm name="placebo"/>
               <categoricalMeasurement>
                  <category rate="20" name="other"/>
                  <category rate="83" name="white"/>
                  <category rate="9" name="multiracial"/>
                  <category rate="10" name="black"/>
                  <category rate="3" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race8"/>
               <arm name="Sitagliptin 5mg/day"/>
               <categoricalMeasurement>
                  <category rate="16" name="other"/>
                  <category rate="86" name="white"/>
                  <category rate="8" name="multiracial"/>
                  <category rate="8" name="black"/>
                  <category rate="7" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race8"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <categoricalMeasurement>
                  <category rate="26" name="other"/>
                  <category rate="78" name="white"/>
                  <category rate="7" name="multiracial"/>
                  <category rate="6" name="black"/>
                  <category rate="6" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race8"/>
               <arm name="Sitagliptin 25mg/day"/>
               <categoricalMeasurement>
                  <category rate="23" name="other"/>
                  <category rate="75" name="white"/>
                  <category rate="8" name="multiracial"/>
                  <category rate="11" name="black"/>
                  <category rate="6" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race8"/>
               <arm name="Sitagliptin 50mg/day"/>
               <categoricalMeasurement>
                  <category rate="20" name="other"/>
                  <category rate="86" name="white"/>
                  <category rate="9" name="multiracial"/>
                  <category rate="6" name="black"/>
                  <category rate="3" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race8"/>
               <arm name="Glipizide"/>
               <categoricalMeasurement>
                  <category rate="30" name="other"/>
                  <category rate="75" name="white"/>
                  <category rate="8" name="multiracial"/>
                  <category rate="4" name="black"/>
                  <category rate="6" name="asian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="5.8" sampleSize="125" mean="31.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="5.1" sampleSize="125" mean="30.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="5.0" sampleSize="123" mean="30.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="6.9" sampleSize="123" mean="31.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="4.9" sampleSize="124" mean="30.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="5.3" sampleSize="123" mean="30.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="4.7" sampleSize="125" mean="4.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="4.1" sampleSize="125" mean="4.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="5.0" sampleSize="123" mean="4.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="5.2" sampleSize="123" mean="5.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="4.0" sampleSize="124" mean="4.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="4.2" sampleSize="123" mean="4.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="1.0" sampleSize="125" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="1.0" sampleSize="125" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="0.9" sampleSize="123" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="0.9" sampleSize="123" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="1.0" sampleSize="124" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="1.0" sampleSize="123" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="placebo"/>
               <continuousMeasurement stdDev="2.5" sampleSize="125" mean="9.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin 5mg/day"/>
               <continuousMeasurement stdDev="2.2" sampleSize="125" mean="9.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin 12.5mg/day"/>
               <continuousMeasurement stdDev="2.0" sampleSize="123" mean="9.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin 25mg/day"/>
               <continuousMeasurement stdDev="2.2" sampleSize="123" mean="9.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin 50mg/day"/>
               <continuousMeasurement stdDev="2.2" sampleSize="124" mean="9.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Glipizide"/>
               <continuousMeasurement stdDev="2.2" sampleSize="123" mean="9.5"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Diet,exercise run-in">
               <duration>P42D</duration>
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P84D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Glipizide" epoch="Randomization"/>
               <usedBy arm="Sitagliptin 12.5mg/day" epoch="Randomization"/>
               <usedBy arm="Sitagliptin 25mg/day" epoch="Randomization"/>
               <usedBy arm="Sitagliptin 50mg/day" epoch="Randomization"/>
               <usedBy arm="Sitagliptin 5mg/day" epoch="Randomization"/>
               <usedBy arm="placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Glipizide" epoch="Screening"/>
               <usedBy arm="Sitagliptin 12.5mg/day" epoch="Screening"/>
               <usedBy arm="Sitagliptin 25mg/day" epoch="Screening"/>
               <usedBy arm="Sitagliptin 50mg/day" epoch="Screening"/>
               <usedBy arm="Sitagliptin 5mg/day" epoch="Screening"/>
               <usedBy arm="placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Glipizide" epoch="Diet,exercise run-in"/>
               <usedBy arm="Glipizide" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin 12.5mg/day" epoch="Diet,exercise run-in"/>
               <usedBy arm="Sitagliptin 12.5mg/day" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin 25mg/day" epoch="Diet,exercise run-in"/>
               <usedBy arm="Sitagliptin 25mg/day" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin 50mg/day" epoch="Diet,exercise run-in"/>
               <usedBy arm="Sitagliptin 50mg/day" epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin 5mg/day" epoch="Diet,exercise run-in"/>
               <usedBy arm="Sitagliptin 5mg/day" epoch="Placebo run-in"/>
               <usedBy arm="placebo" epoch="Diet,exercise run-in"/>
               <usedBy arm="placebo" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin 5mg/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="5.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin 5mg/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin 12.5mg/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="12.5"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin 12.5mg/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin 25mg/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="25.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin 25mg/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin 50mg/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="50.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin 50mg/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Glipizide">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="Glipizide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Glipizide" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="scott08">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To assess the addition of sitagliptin to ongoing metformin therapy in patients with type 2 diabetes who were inadequately controlled [haemoglobin A1c (HbA1c) 7–11%] on metformin monotherapy.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Men and women with type 2 diabetes (18–75 years of age) who were taking metformin monotherapy at a stable dose of &gt;1500 mg/day for at least 10 weeks prior to the screening
visit and had inadequate glycaemic control [defined by a haemoglobin A1c (HbA1c) level &gt;7 and &lt;11%] were recruited for the study.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients were excluded if they had type 1 diabetes, insulin use within 8 weeks of the screening visit, any contraindications for use of TZDs or metformin, impaired renal function (creatinine clearance &lt;60 ml/min), alanine aminotransferase (ALT) or aspartate aminotransferase levels more than twofold the upper limit of normal or a fasting glucose value
&gt;270 mg/dl prior to randomization.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>18201203</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555
SD is calculated according to 95%CI</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical AE">
               <adverseEvent name="Drug-related clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Drug-related clinical SAE">
               <adverseEvent name="Drug-related clinical SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to AE">
               <adverseEvent name="Discontinuation due to AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related AE">
               <adverseEvent name="Discontinuation due to drug-related AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to SAE">
               <adverseEvent name="Discontinuation due to SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Discontinuation due to drug-related SAE">
               <adverseEvent name="Discontinuation due to drug-related SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Oedema peripheral">
               <adverseEvent name="Oedema peripheral"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Abdominal pain">
               <adverseEvent name="Abdominal pain"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race2">
               <populationCharacteristic name="race2"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes>
                  <note source="MANUAL">unit change from mg/dl to mmol/l, calculated by * 0.0555</note>
               </notes>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="92" name="Placebo">
               <notes/>
            </arm>
            <arm size="94" name="Sitagliptin ">
               <notes/>
            </arm>
            <arm size="87" name="Rosiglitazone ">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.05" sampleSize="88" mean="7.74"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="0.86" sampleSize="91" mean="7.01"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="0.75" sampleSize="87" mean="6.94"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.07" sampleSize="88" mean="-0.22"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="0.07" sampleSize="91" mean="-0.73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="0.07" sampleSize="87" mean="-0.79"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.8" sampleSize="89" mean="9.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="2.0" sampleSize="92" mean="8.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="1.7" sampleSize="87" mean="7.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.2" sampleSize="89" mean="0.34"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="0.2" sampleSize="92" mean="-0.65"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="0.2" sampleSize="87" mean="-1.36"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.2" sampleSize="92" mean="-0.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="0.2" sampleSize="94" mean="-0.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="0.23" sampleSize="87" mean="1.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="27"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="37"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="38"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="10"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical AE"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Drug-related clinical SAE"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to AE"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="92" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related AE"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="92" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to SAE"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="92" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Discontinuation due to drug-related SAE"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Oedema peripheral"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Oedema peripheral"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Oedema peripheral"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Abdominal pain"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="91" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Rosiglitazone "/>
               <rateMeasurement sampleSize="87" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Sitagliptin "/>
               <rateMeasurement sampleSize="94" rate="12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="9.3" sampleSize="92" mean="55.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="9.8" sampleSize="94" mean="55.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="10.5" sampleSize="87" mean="54.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="38" name="female"/>
                  <category rate="54" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Sitagliptin "/>
               <categoricalMeasurement>
                  <category rate="42" name="female"/>
                  <category rate="52" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Rosiglitazone "/>
               <categoricalMeasurement>
                  <category rate="32" name="female"/>
                  <category rate="55" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="0" name="other"/>
                  <category rate="0" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="0" name="black"/>
                  <category rate="36" name="asian"/>
                  <category rate="56" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="Sitagliptin "/>
               <categoricalMeasurement>
                  <category rate="1" name="other"/>
                  <category rate="0" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="0" name="black"/>
                  <category rate="36" name="asian"/>
                  <category rate="57" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race2"/>
               <arm name="Rosiglitazone "/>
               <categoricalMeasurement>
                  <category rate="3" name="other"/>
                  <category rate="0" name="hispanic or latino"/>
                  <category rate="0" name="pacific islander"/>
                  <category rate="0" name="black"/>
                  <category rate="33" name="asian"/>
                  <category rate="51" name="caucasian"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="16.5" sampleSize="92" mean="84.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="17.1" sampleSize="94" mean="83.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="18.5" sampleSize="87" mean="84.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="4.5" sampleSize="92" mean="30.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="4.7" sampleSize="94" mean="30.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="5.5" sampleSize="87" mean="30.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="3.7" sampleSize="92" mean="5.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="3.5" sampleSize="94" mean="4.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="4.0" sampleSize="87" mean="4.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.9" sampleSize="92" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="1.0" sampleSize="94" mean="7.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="0.8" sampleSize="87" mean="7.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.1" sampleSize="92" mean="8.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Sitagliptin "/>
               <continuousMeasurement stdDev="1.7" sampleSize="94" mean="8.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Rosiglitazone "/>
               <continuousMeasurement stdDev="1.8" sampleSize="87" mean="8.7"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P126D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <usedBy arm="Rosiglitazone " epoch="Randomization"/>
               <usedBy arm="Sitagliptin " epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Screening"/>
               <usedBy arm="Rosiglitazone " epoch="Screening"/>
               <usedBy arm="Sitagliptin " epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Placebo" epoch="Placebo run-in"/>
               <usedBy arm="Rosiglitazone " epoch="Placebo run-in"/>
               <usedBy arm="Sitagliptin " epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="rosiglitazone">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="8.0"/>
                        <drug name="rosiglitazone"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Rosiglitazone " epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Sitagliptin">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="100.0"/>
                        <drug name="Sitagliptin"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Sitagliptin " epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="seino08">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain:
A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To evaluate dose–response efficacy and safety of once-daily human GLP-1 analog liraglutide in Japanese subjects with type 2 diabetes.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Patients included were to have type 2 diabetes treated with diet therapy with or without oral antidiabetic drug (OAD) monotherapy, HbA1c &gt;7.0% and &lt;10.0%, to be aged between 20 and 75 years and to have BMI &lt;30 kg/m2.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Patients treated with insulin or insulin sensitizer within 16 weeks, or receiving or expected to receive systemic corticosteroids, were excluded, as were those with impaired hepatic or renal
function (serum glutamic oxaloacetic transaminase or serum glutamic pyruvic transaminase &gt;80 IU/L, or serum creatinine &gt;1.7 mg/dL), congestive heart failure (New York Heart Association class III or IV), unstable angina pectoris or myocardial infarction within 12 months, uncontrolled hypertension (SBP &gt; 160 mmHg or diastolic blood pressure &gt;100 mmHg), non-stabilised proliferative retinopathy or maculopathy.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>18495285</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight end">
               <endpoint name="weight end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FPG end">
               <endpoint name="FPG end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-2-h PPG change">
               <endpoint name="2-h PPG change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-2-h PPG bas">
               <populationCharacteristic name="2-h PPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="46" name="Placebo">
               <notes/>
            </arm>
            <arm size="45" name="Liraglutide 0.1mg/day">
               <notes/>
            </arm>
            <arm size="46" name="Liraglutide 0.3mg/day">
               <notes/>
            </arm>
            <arm size="45" name="Liraglutide 0.6mg/day">
               <notes/>
            </arm>
            <arm size="44" name="Liraglutide 0.9mg/day">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.23" sampleSize="46" mean="8.52"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="0.91" sampleSize="45" mean="7.78"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="1.01" sampleSize="46" mean="7.17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="0.92" sampleSize="45" mean="6.71"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="0.77" sampleSize="44" mean="6.45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="10.89" sampleSize="46" mean="61.05"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="10.67" sampleSize="45" mean="64.21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="11.39" sampleSize="46" mean="61.67"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="9.68" sampleSize="45" mean="61.42"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="11.07" sampleSize="44" mean="61.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.47" sampleSize="46" mean="9.77"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="1.76" sampleSize="45" mean="9.03"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="1.96" sampleSize="46" mean="8.42"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="1.23" sampleSize="45" mean="7.41"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG end"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="1.22" sampleSize="44" mean="6.91"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="3.49" sampleSize="46" mean="14.95"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG change"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="3.15" sampleSize="45" mean="13.57"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG change"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="2.89" sampleSize="46" mean="11.48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG change"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="2.94" sampleSize="45" mean="10.74"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-2-h PPG change"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="3.16" sampleSize="44" mean="8.89"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="46" rate="11"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <rateMeasurement sampleSize="45" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <rateMeasurement sampleSize="46" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <rateMeasurement sampleSize="45" rate="14"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <rateMeasurement sampleSize="44" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="8.7" sampleSize="46" mean="57.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="8.4" sampleSize="45" mean="56.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="8.8" sampleSize="46" mean="56.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="7.0" sampleSize="45" mean="60.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="7.6" sampleSize="44" mean="55.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="17" name="female"/>
                  <category rate="29" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <categoricalMeasurement>
                  <category rate="14" name="female"/>
                  <category rate="31" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <categoricalMeasurement>
                  <category rate="14" name="female"/>
                  <category rate="32" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <categoricalMeasurement>
                  <category rate="17" name="female"/>
                  <category rate="28" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <categoricalMeasurement>
                  <category rate="13" name="female"/>
                  <category rate="31" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="10.88" sampleSize="46" mean="62.78"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="10.29" sampleSize="45" mean="64.82"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="11.18" sampleSize="46" mean="62.42"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="9.4" sampleSize="45" mean="61.97"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="10.65" sampleSize="44" mean="62.36"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.63" sampleSize="46" mean="23.77"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="2.77" sampleSize="45" mean="24.26"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="3.09" sampleSize="46" mean="23.93"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="2.78" sampleSize="45" mean="23.74"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="3.04" sampleSize="44" mean="23.59"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="5.65" sampleSize="46" mean="7.48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="5.14" sampleSize="45" mean="7.15"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="4.69" sampleSize="46" mean="6.78"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="6.77" sampleSize="45" mean="8.87"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="4.92" sampleSize="44" mean="7.62"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.02" sampleSize="46" mean="8.43"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="0.84" sampleSize="45" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="0.92" sampleSize="46" mean="8.24"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="0.83" sampleSize="45" mean="8.21"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="0.98" sampleSize="44" mean="8.12"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.71" sampleSize="46" mean="9.99"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="1.73" sampleSize="45" mean="10.03"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="1.73" sampleSize="46" mean="9.84"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="1.23" sampleSize="45" mean="9.84"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="1.36" sampleSize="44" mean="9.34"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-2-h PPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.92" sampleSize="46" mean="15.98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-2-h PPG bas"/>
               <arm name="Liraglutide 0.1mg/day"/>
               <continuousMeasurement stdDev="3.04" sampleSize="45" mean="16.05"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-2-h PPG bas"/>
               <arm name="Liraglutide 0.3mg/day"/>
               <continuousMeasurement stdDev="2.74" sampleSize="46" mean="14.77"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-2-h PPG bas"/>
               <arm name="Liraglutide 0.6mg/day"/>
               <continuousMeasurement stdDev="3.78" sampleSize="45" mean="16.01"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-2-h PPG bas"/>
               <arm name="Liraglutide 0.9mg/day"/>
               <continuousMeasurement stdDev="3.44" sampleSize="44" mean="14.42"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Run-in">
               <duration>P56D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P98D</duration>
               <notes>
                  <note source="MANUAL">Titration at week 2</note>
               </notes>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Liraglutide 0.1mg/day" epoch="Randomization"/>
               <usedBy arm="Liraglutide 0.3mg/day" epoch="Randomization"/>
               <usedBy arm="Liraglutide 0.6mg/day" epoch="Randomization"/>
               <usedBy arm="Liraglutide 0.9mg/day" epoch="Randomization"/>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Liraglutide 0.1mg/day" epoch="Screening"/>
               <usedBy arm="Liraglutide 0.3mg/day" epoch="Screening"/>
               <usedBy arm="Liraglutide 0.6mg/day" epoch="Screening"/>
               <usedBy arm="Liraglutide 0.9mg/day" epoch="Screening"/>
               <usedBy arm="Placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Liraglutide 0.1mg/day" epoch="Run-in"/>
               <usedBy arm="Liraglutide 0.3mg/day" epoch="Run-in"/>
               <usedBy arm="Liraglutide 0.6mg/day" epoch="Run-in"/>
               <usedBy arm="Liraglutide 0.9mg/day" epoch="Run-in"/>
               <usedBy arm="Placebo" epoch="Run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 0.1mg/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.1"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide 0.1mg/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 0.3mg/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.3"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide 0.3mg/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 0.6mg/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.6"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide 0.6mg/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide 0.9mg/day">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.9"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide 0.9mg/day" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="vilsboll07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To evaluate the efficacy and safety of liraglutide in patients with T2DM</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Main inclusion criteria were patients aged &gt;18 years with type 2 diabetes and A1C &gt;7.5 and &lt;10.0% (diet) or &gt;7.0 and &lt;9.5% (mono–oral antidiabetes drug); previous therapy was discontinued. Fasting plasma glucose (FPG) at randomization was 7–13 mmol/l.</value>
               <notes/>
            </inclusion>
            <exclusion>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17372153</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL">SD is not reported</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="41" name="Liraglutide high-dose">
               <notes/>
            </arm>
            <arm size="42" name="Liraglutide mid-dose">
               <notes/>
            </arm>
            <arm size="40" name="Liraglutide low-dose">
               <notes/>
            </arm>
            <arm size="40" name="Placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="0.0" sampleSize="41" mean="-1.45"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Liraglutide mid-dose"/>
               <continuousMeasurement stdDev="0.0" sampleSize="42" mean="-1.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="0.0" sampleSize="40" mean="-0.98"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="40" mean="0.29"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="11.4" sampleSize="41" mean="55.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Liraglutide mid-dose"/>
               <continuousMeasurement stdDev="10.7" sampleSize="42" mean="53.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="9.3" sampleSize="40" mean="56.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="8.2" sampleSize="40" mean="57.7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Liraglutide high-dose"/>
               <categoricalMeasurement>
                  <category rate="11" name="female"/>
                  <category rate="30" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Liraglutide mid-dose"/>
               <categoricalMeasurement>
                  <category rate="19" name="female"/>
                  <category rate="23" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Liraglutide low-dose"/>
               <categoricalMeasurement>
                  <category rate="0" name="female"/>
                  <category rate="27" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="21" name="female"/>
                  <category rate="19" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="4.2" sampleSize="41" mean="29.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Liraglutide mid-dose"/>
               <continuousMeasurement stdDev="4.7" sampleSize="42" mean="31.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="3.9" sampleSize="40" mean="28.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="4.0" sampleSize="40" mean="30.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="0.9" sampleSize="41" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Liraglutide mid-dose"/>
               <continuousMeasurement stdDev="0.8" sampleSize="42" mean="8.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="0.6" sampleSize="40" mean="8.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.7" sampleSize="40" mean="8.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="0.0" sampleSize="41" mean="4.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Liraglutide mid-dose"/>
               <continuousMeasurement stdDev="0.0" sampleSize="42" mean="7.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="0.0" sampleSize="40" mean="6.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="40" mean="5.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="3.1" sampleSize="41" mean="12.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Liraglutide mid-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="42" mean="11.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="2.7" sampleSize="40" mean="11.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.2" sampleSize="40" mean="11.3"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P98D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Liraglutide high-dose" epoch="Randomization"/>
               <usedBy arm="Liraglutide low-dose" epoch="Randomization"/>
               <usedBy arm="Liraglutide mid-dose" epoch="Randomization"/>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1.9"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide mid">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1.25"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide mid-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.65"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="zinman07">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <value>49</value>
               <notes/>
            </centers>
            <objective>
               <value>To compare the effects of exenatide versus placebo on glycemic control.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <notes/>
            </inclusion>
            <exclusion>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>17404349</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight end">
               <endpoint name="weight end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-FPG change">
               <endpoint name="FPG change"/>
               <notes>
                  <note source="MANUAL">SD is not reported</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-One or more clinical AE">
               <adverseEvent name="One or more clinical AE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-SAE">
               <adverseEvent name="SAE"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nausea">
               <adverseEvent name="Nausea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Nasopharyngitis">
               <adverseEvent name="Nasopharyngitis"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Vomiting">
               <adverseEvent name="Vomiting"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Hypoglycemia">
               <adverseEvent name="Hypoglycemia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Dyspepsia">
               <adverseEvent name="Dyspepsia"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Edema">
               <adverseEvent name="Edema"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Headache">
               <adverseEvent name="Headache"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Diarrhea">
               <adverseEvent name="Diarrhea"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Influenza">
               <adverseEvent name="Influenza"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Number of hypeoglycemic episodes">
               <adverseEvent name="Number of hypeoglycemic episodes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-race9">
               <populationCharacteristic name="race9"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-baseline mean weight">
               <populationCharacteristic name="baseline mean weight"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="121" name="Exenatide ">
               <notes/>
            </arm>
            <arm size="112" name="Placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="1.1" sampleSize="121" mean="0.09"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.95" sampleSize="112" mean="-0.89"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="2.86" sampleSize="121" mean="96.89"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.65" sampleSize="112" mean="95.38"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="2.75" sampleSize="121" mean="-1.75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.75" sampleSize="112" mean="-0.24"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="0.0" sampleSize="121" mean="-1.59"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-FPG change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="112" mean="0.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="92"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-One or more clinical AE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="73"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-SAE"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="48"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nausea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="17"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="16"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Hypoglycemia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Dyspepsia"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Edema"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Edema"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Headache"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="7"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Diarrhea"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Influenza"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="112" rate="5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Number of hypeoglycemic episodes"/>
               <arm name="Exenatide "/>
               <rateMeasurement sampleSize="121" rate="13"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Exenatide "/>
               <categoricalMeasurement>
                  <category rate="56" name="female"/>
                  <category rate="65" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="48" name="female"/>
                  <category rate="64" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race9"/>
               <arm name="Exenatide "/>
               <categoricalMeasurement>
                  <category rate="18" name="other"/>
                  <category rate="103" name="white"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-race9"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="20" name="other"/>
                  <category rate="92" name="white"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="10.8" sampleSize="121" mean="55.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="10.2" sampleSize="112" mean="56.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="18.8" sampleSize="121" mean="97.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-baseline mean weight"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="19.0" sampleSize="112" mean="96.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="5.1" sampleSize="121" mean="34.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="5.0" sampleSize="112" mean="34.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="2.6" sampleSize="121" mean="9.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.9" sampleSize="112" mean="8.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="0.9" sampleSize="121" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.8" sampleSize="112" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Exenatide "/>
               <continuousMeasurement stdDev="4.9" sampleSize="121" mean="7.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="5.8" sampleSize="112" mean="8.2"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Placebo run-in">
               <duration>P14D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P112D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Exenatide " epoch="Randomization"/>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Exenatide " epoch="Placebo run-in"/>
               <usedBy arm="Placebo" epoch="Placebo run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="exenatide">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <flexibleDose unit="MILLIGRAMS_A_DAY" maxDose="0.01" minDose="0.005"/>
                        <drug name="exenatide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Exenatide " epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
      <study name="zinman09">
         <indication name="Type II diabetes mellitus ">
            <notes/>
         </indication>
         <characteristics>
            <title>
               <value>Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin
and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)</value>
               <notes/>
            </title>
            <allocation>
               <value>RANDOMIZED</value>
               <notes/>
            </allocation>
            <blinding>
               <value>DOUBLE_BLIND</value>
               <notes/>
            </blinding>
            <centers>
               <notes/>
            </centers>
            <objective>
               <value>To determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to metformin and rosiglitazone in type 2 diabetes.</value>
               <notes/>
            </objective>
            <study_start>
               <notes/>
            </study_start>
            <study_end>
               <notes/>
            </study_end>
            <status>
               <value>COMPLETED</value>
               <notes/>
            </status>
            <inclusion>
               <value>Subjects with type 2 diabetes were screened and enrolled if they were aged 18–80 years, had A1C between 7 and 11% (prestudy OAD monotherapy for &gt;3 months) or 7–10%
(prestudy combination OAD therapy for &gt;3 months), and had BMI &lt;45 kg/m2.
</value>
               <notes/>
            </inclusion>
            <exclusion>
               <value>Subjects who used insulin during the previous 3 months (except short-term treatment) were excluded.</value>
               <notes/>
            </exclusion>
            <references>
               <pubMedId>19289857</pubMedId>
            </references>
            <source>
               <value>MANUAL</value>
               <notes/>
            </source>
            <creation_date>
               <notes/>
            </creation_date>
         </characteristics>
         <studyOutcomeMeasures>
            <studyOutcomeMeasure primary="false" id="endpoint-HbA1c end">
               <endpoint name="HbA1c end"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="true" id="endpoint-HbA1c change">
               <endpoint name="HbA1c change"/>
               <notes>
                  <note source="MANUAL"> some sd is not reported</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="endpoint-weight change">
               <endpoint name="weight change"/>
               <notes>
                  <note source="MANUAL">some result is not reported</note>
               </notes>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="adverseEvent-Gastrointestinal disorders">
               <adverseEvent name="Gastrointestinal disorders"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Sex">
               <populationCharacteristic name="Sex"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Age">
               <populationCharacteristic name="Age"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-BMI">
               <populationCharacteristic name="BMI"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-Duration of diabetes">
               <populationCharacteristic name="Duration of diabetes"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-HbA1c bas">
               <populationCharacteristic name="HbA1c bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-FPG bas">
               <populationCharacteristic name="FPG bas"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-systolic blood pressure">
               <populationCharacteristic name="systolic blood pressure"/>
               <notes/>
            </studyOutcomeMeasure>
            <studyOutcomeMeasure primary="false" id="popChar-diagstolic blood pressure bas">
               <populationCharacteristic name="diagstolic blood pressure bas"/>
               <notes/>
            </studyOutcomeMeasure>
         </studyOutcomeMeasures>
         <arms>
            <arm size="178" name="Liraglutide low-dose">
               <notes/>
            </arm>
            <arm size="178" name="Liraglutide high-dose">
               <notes/>
            </arm>
            <arm size="177" name="Placebo">
               <notes/>
            </arm>
         </arms>
         <measurements>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="0.0" sampleSize="153" mean="7.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="0.0" sampleSize="133" mean="7.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c end"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.0" sampleSize="121" mean="7.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="1.23" sampleSize="153" mean="-1.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="1.15" sampleSize="133" mean="-1.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-HbA1c change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.1" sampleSize="121" mean="-0.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="2.75" sampleSize="133" mean="-1.75"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="endpoint-weight change"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.75" sampleSize="121" mean="-0.24"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Liraglutide low-dose"/>
               <rateMeasurement sampleSize="178" rate="80"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Liraglutide high-dose"/>
               <rateMeasurement sampleSize="178" rate="100"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="adverseEvent-Gastrointestinal disorders"/>
               <arm name="Placebo"/>
               <rateMeasurement sampleSize="177" rate="34"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Liraglutide low-dose"/>
               <categoricalMeasurement>
                  <category rate="43" name="female"/>
                  <category rate="57" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Liraglutide high-dose"/>
               <categoricalMeasurement>
                  <category rate="49" name="female"/>
                  <category rate="51" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Sex"/>
               <arm name="Placebo"/>
               <categoricalMeasurement>
                  <category rate="38" name="female"/>
                  <category rate="62" name="male"/>
               </categoricalMeasurement>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="10.0" sampleSize="178" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="11.0" sampleSize="178" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Age"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="10.0" sampleSize="177" mean="55.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="5.4" sampleSize="178" mean="33.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="5.1" sampleSize="178" mean="33.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-BMI"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="5.2" sampleSize="177" mean="33.9"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="6.0" sampleSize="178" mean="9.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="6.0" sampleSize="178" mean="9.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-Duration of diabetes"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="6.0" sampleSize="177" mean="9.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="1.2" sampleSize="178" mean="8.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="1.2" sampleSize="178" mean="8.6"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-HbA1c bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="1.2" sampleSize="177" mean="8.4"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="178" mean="10.1"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="2.4" sampleSize="178" mean="10.3"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-FPG bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="2.6" sampleSize="177" mean="10.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="14.8" sampleSize="178" mean="129.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="14.2" sampleSize="178" mean="126.0"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-systolic blood pressure"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="0.0" sampleSize="177" mean="14.5"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="Liraglutide low-dose"/>
               <continuousMeasurement stdDev="9.0" sampleSize="178" mean="75.8"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="Liraglutide high-dose"/>
               <continuousMeasurement stdDev="8.4" sampleSize="178" mean="75.2"/>
            </measurement>
            <measurement>
               <studyOutcomeMeasure id="popChar-diagstolic blood pressure bas"/>
               <arm name="Placebo"/>
               <continuousMeasurement stdDev="9.2" sampleSize="177" mean="76.2"/>
            </measurement>
         </measurements>
         <epochs>
            <epoch name="Screening">
               <notes/>
            </epoch>
            <epoch name="Run-in">
               <duration>P63D</duration>
               <notes/>
            </epoch>
            <epoch name="Randomization">
               <notes/>
            </epoch>
            <epoch name="Main phase">
               <duration>P182D</duration>
               <notes/>
            </epoch>
         </epochs>
         <activities>
            <studyActivity name="Randomization">
               <activity>
                  <predefined>RANDOMIZATION</predefined>
               </activity>
               <usedBy arm="Liraglutide high-dose" epoch="Randomization"/>
               <usedBy arm="Liraglutide low-dose" epoch="Randomization"/>
               <usedBy arm="Placebo" epoch="Randomization"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Screening">
               <activity>
                  <predefined>SCREENING</predefined>
               </activity>
               <usedBy arm="Liraglutide high-dose" epoch="Screening"/>
               <usedBy arm="Liraglutide low-dose" epoch="Screening"/>
               <usedBy arm="Placebo" epoch="Screening"/>
               <notes/>
            </studyActivity>
            <studyActivity name="Wash out">
               <activity>
                  <predefined>WASH_OUT</predefined>
               </activity>
               <usedBy arm="Liraglutide high-dose" epoch="Run-in"/>
               <usedBy arm="Liraglutide low-dose" epoch="Run-in"/>
               <usedBy arm="Placebo" epoch="Run-in"/>
               <notes/>
            </studyActivity>
            <studyActivity name="placebo">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="0.0"/>
                        <drug name="placebo"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Placebo" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide low">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1.2"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide low-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
            <studyActivity name="liraglutide high">
               <activity>
                  <treatment>
                     <drugTreatment>
                        <fixedDose unit="MILLIGRAMS_A_DAY" quantity="1.8"/>
                        <drug name="liraglutide"/>
                     </drugTreatment>
                  </treatment>
               </activity>
               <usedBy arm="Liraglutide high-dose" epoch="Main phase"/>
               <notes/>
            </studyActivity>
         </activities>
         <notes/>
      </study>
   </studies>
   <metaAnalyses>
      <pairwiseMetaAnalysis name="fgasdf">
         <indication name="Type II diabetes mellitus "/>
         <endpoint name="HbA1c change"/>
         <alternative>
            <drugs>
               <drug name="Sitagliptin"/>
               <drug name="glimepiride"/>
            </drugs>
            <arms>
               <arm study="hermansen07" name="sitagliptin+glimepiride"/>
            </arms>
         </alternative>
         <alternative>
            <drugs>
               <drug name="Sitagliptin"/>
               <drug name="glimepiride"/>
               <drug name="metformin"/>
            </drugs>
            <arms>
               <arm study="hermansen07" name="sitagliptin+glimepiride+metformin"/>
            </arms>
         </alternative>
      </pairwiseMetaAnalysis>
      <pairwiseMetaAnalysis name="hyerdf">
         <indication name="Type II diabetes mellitus "/>
         <adverseEvent name="Abdominal pain"/>
         <alternative>
            <drugs>
               <drug name="Sitagliptin"/>
               <drug name="glimepiride"/>
            </drugs>
            <arms>
               <arm study="hermansen07" name="sitagliptin+glimepiride"/>
            </arms>
         </alternative>
         <alternative>
            <drugs>
               <drug name="Sitagliptin"/>
               <drug name="glimepiride"/>
               <drug name="metformin"/>
            </drugs>
            <arms>
               <arm study="hermansen07" name="sitagliptin+glimepiride+metformin"/>
            </arms>
         </alternative>
      </pairwiseMetaAnalysis>
   </metaAnalyses>
   <benefitRiskAnalyses>
      <studyBenefitRiskAnalysis analysisType="LyndOBrien" name="dfsasdf">
         <indication name="Type II diabetes mellitus "/>
         <study name="ahren04"/>
         <arms>
            <arm study="ahren04" name="Placebo"/>
            <arm study="ahren04" name="Vildagliptin"/>
         </arms>
         <outcomeMeasures>
            <adverseEvent name="Bursitis"/>
            <endpoint name="HbA1c change"/>
         </outcomeMeasures>
      </studyBenefitRiskAnalysis>
      <metaBenefitRiskAnalysis analysisType="LyndOBrien" name="ggjk">
         <indication name="Type II diabetes mellitus "/>
         <baseline>
            <drug name="Sitagliptin"/>
            <drug name="glimepiride"/>
         </baseline>
         <alternatives>
            <alternative>
               <drug name="Sitagliptin"/>
               <drug name="glimepiride"/>
               <drug name="metformin"/>
            </alternative>
            <alternative>
               <drug name="Sitagliptin"/>
               <drug name="glimepiride"/>
            </alternative>
         </alternatives>
         <metaAnalyses>
            <metaAnalysis name="fgasdf"/>
            <metaAnalysis name="hyerdf"/>
         </metaAnalyses>
      </metaBenefitRiskAnalysis>
      <studyBenefitRiskAnalysis analysisType="SMAA" name="klbn">
         <indication name="Type II diabetes mellitus "/>
         <study name="ahren04"/>
         <arms>
            <arm study="ahren04" name="Placebo"/>
            <arm study="ahren04" name="Vildagliptin"/>
         </arms>
         <outcomeMeasures>
            <adverseEvent name="Worsening hypertension"/>
            <endpoint name="HbA1c change"/>
         </outcomeMeasures>
      </studyBenefitRiskAnalysis>
      <metaBenefitRiskAnalysis analysisType="SMAA" name="uopi">
         <indication name="Type II diabetes mellitus "/>
         <baseline>
            <drug name="Sitagliptin"/>
            <drug name="glimepiride"/>
         </baseline>
         <alternatives>
            <alternative>
               <drug name="Sitagliptin"/>
               <drug name="glimepiride"/>
               <drug name="metformin"/>
            </alternative>
            <alternative>
               <drug name="Sitagliptin"/>
               <drug name="glimepiride"/>
            </alternative>
         </alternatives>
         <metaAnalyses>
            <metaAnalysis name="fgasdf"/>
            <metaAnalysis name="hyerdf"/>
         </metaAnalyses>
      </metaBenefitRiskAnalysis>
   </benefitRiskAnalyses>
</addis-data>